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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that although primarily 
affecting the joints is recognised as a systemic disease with a variety of co-morbidities. 
One such co-morbidity is cardiovascular disease (CVD) and patients with RA are at a two-
fold increased risk of developing CVD compared to the general population.  Indeed, CVD, 
principally as a result of atherosclerosis, is recognised as the leading cause of death in RA 
patients. In this study the vascular adventitia and serum samples from patients with co-
existing RA and CVD were investigated to identify factors that could explain the 
increased CVD morbidity observed in RA patients.  This involved culture-independent 
identification of bacterial signatures and histological evaluation for pro-inflammatory 
molecules and potential RA-associated autoantigens in the aortic adventitia.  Additionally, 
serum samples from healthy controls, patients with RA or CVD alone, and patients with 
co-existing RA and CVD, were screened for a broad range of cytokines, chemokines and 
growth factors.  These data provided the basis for further studies into the effect of 
cytokines on foam cell formation.  
Histological evaluation of the aortic adventitia revealed that pronounced inflammatory 
infiltrates were detectable in all patients with CVD, regardless of rheumatic disease. To 
assess whether or not the inflammatory composition of the aortic adventitia differed 
between patients with or without RA, sections were examined using 
immunohistochemistry for a markers including TNFα, CD21 and heat shock proteins 
(HSP) 47 and 60, both of which have been implicated in the pathogenesis of RA and 
CVD.  TNFα and HSP47 were confirmed in the aortic adventitia; however, neither CD21 
nor HSP60 were detected.  The expression of total TNFα was significantly elevated in 
RA+CVD compared to non-RA CVD patients.  These data demonstrate that the aortic 
adventitia is a site of considerable immunological function and suggest a possible role for 
TNFα overexpression in the pathogenesis of CVD in RA. 
Bacterial infection has been implicated as a causative agent for both RA and CVD.  The 
present study used culture-independent methods to identify bacteria in the aortic adventitia 
of RA+CVD and non-RA CVD patients.  The presence of bacterial DNA was confirmed in 
three of 11 RA+CVD and four of 11 non-RA CVD patients.  The bacterial flora of 
RA+CVD patients was significantly less heterogeneous compared to non-RA CVD 
patients.  Methylobacterium oryzae was detected in every RA+CVD patient positive for the 
presence of bacterial DNA.  Subsequent in vitro characterisation demonstrated that M. 
 
 
 
 
oryzae stimulates mild Toll-like receptor 2 (TLR2), but not TLR4, signalling and, upon 
challenge of primary human macrophages, produces a robust pro-inflammatory response.  
Importantly, these findings implicate M. oryzae infection as playing a potential role in the 
pathogenesis of CVD in RA patients.  
Previous studies have argued that the persistently high levels of systemic inflammation 
exhibited by RA patients are critical to elevated CVD risk.  In the current study it was 
demonstrated that RA patients exhibit an altered systemic immune profile compared to 
non-RA CVD patients and healthy controls.  The pro-inflammatory phenotype in co-
morbind CVD and RA is suggestive of an environment that may promote atherosclerosis.  
Furthermore, RA+CVD patients were shown to possess an altered systemic immune 
phenotype compared to both RA and CVD patients. Notably, IL-1β, IL-2, IL-5, IL-8, IL-
13, IL-17, Monokine induced by gamma interferon (MIG), Granulocyte colony-stimulating 
factor (G-CSF) and Granulocyte macrophage colony stimulating factor (GM-CSF) 
expression was greater in the serum of RA+CVD patients compared to the additive values 
of the RA and CVD patients.   
The formation of lipid-rich foam cells is a major feature of atherosclerosis pathogenesis 
and is partially dependent on the inflammatory environment.  The present study 
demonstrated that GM-CSF stimulation significantly decreased the rate at which human 
primary macrophages could endocytose oxLDL and form foam cells.  The effect of dextran 
sulphate, a known competitive inhibitor of scavenger receptors, on the ability of GM-CSF 
stimulated macrophages to differentiate into foam cells revealed that GM-CSF decreases 
the concentration of dextran sulphate required to successfully inhibit scavenger receptor-
mediated ox-LDL uptake; suggesting that GM-CSF-stimulated macrophages express less 
scavenger receptors on the cell surface.  However, subsequent investigation demonstrated 
that GM-CSF stimulation did not decrease expression of the currently recognised 
scavenger receptors that are capable of oxLDL recognition (SR-A1, SR-B1, CD36 and 
MARCO).  These data imply that the overexpression of GM-CSF observed in RA and 
RA+CVD patients may provide some atheroprotective benefit.  This has clinical 
implications for future anti-RA drugs which target GM-CSF function. 
In summary, the data presented in this thesis demonstrate that RA+CVD patients exhibit 
immunological and pathological alterations both in the aortic adventitia and systemically.  
Further research will, over time, provide insight into the mechanisms underlying increased 
CVD burden in RA. 
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1.1  Overview 
 
The term atherosclerosis describes a chronic inflammatory disorder of the arterial blood 
vessel wall in which immune cell activation and inflammation leads to fibrotic plaque 
formation, followed by destabilisation and rupture (Hansson, 2001).   Risk of 
cardiovascular disease (CVD), as a result of atherosclerosis, is increased in patients 
diagnosed with inflammatory rheumatic disease such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) (van Leuven et al., 2006).  Indeed, CVD is the leading 
cause of mortality in both RA and SLE patients.   
The research undertaken for this thesis explores the hypothesis that the association between 
CVD and inflammatory rheumatic disease may be explained by the chronic inflammatory 
state itself.  Furthermore, several alternative hypotheses are explored in an effort to 
improve our understanding of why the association between CVD and RA arises.  Enhanced 
understanding will enable the design and implementation of specific therapeutic 
approaches for patients with these diseases. 
The following introduction will initially provide a brief overview of immunity before 
focusing in detail on RA, CVD and reviewing current popular thinking of why the 
association between these diseases exists.   
 
1.2  Introduction to immunity 
We are constantly exposed to pathogenic microbes that are swallowed, inhaled or inhabit 
mucous membranes or the skin.  Whether these microbes cause disease or not is a result of 
both the microbes’ pathogenicity and the integrity of the host defence mechanisms.  The 
immune system comprises an interactive network of lymphoid organs, cells, growth 
factors, chemokines and cytokines (Parkin and Cohen, 2001).  An effective immune 
system is essential to human health; however, in both RA and CVD the immune system 
attacks the body (self) leading to joint destruction and blood vessel inflammation. 
Host immunity can be divided into two functionally distinct but related systems, termed the 
innate and the adaptive immune responses.  These two systems have evolved to protect the 
host from the invasion of microbes (bacteria, viruses, protozoa and fungi), harmful 
substances and to eliminate modified or altered self. 
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The term innate immunity is occasionally used to describe physical barriers, but more 
commonly encompasses the elements of the immune system (macrophages, monocytes, 
neutrophils, cytokines, complement and acute phase proteins) that provide an immediate 
first line of defence against pathogenic challenge (Kumar et al., 2011).  Although not 
antigen specific, the innate immune system is effectively able to discriminate foreign 
molecules from self (self tolerance). 
The highly conserved nature of the innate immune response, which is present in even the 
simplest of animals, demonstrates its importance to host survival (Janeway and Medzhitov, 
2002).  The innate immune system initially exhibits effector mechanisms over invading 
pathogens through immediate activation of phagocytic antigen-presenting cells (APCs) and 
the complement pathway, and secretion of antimicrobial peptides.  The simultaneous 
secretion of down-regulatory mediators, for example the anti-inflammatory cytokine IL-10, 
alleviates the risk of host tissue destruction arising from an exaggerated rapid 
inflammatory response.   
Activation of the innate immune system is dependent upon recruitment and activation of 
phagocytes bearing pattern-recognition receptors (PRRs) (Section 1.2.2), with lectin-like 
activity.  PRRs recognise foreign structures termed pathogen-associated molecular patterns 
(PAMPs) (Section 1.2.1) present on microbes, but not self cells (Medzhitov and Janeway, 
2000).  PRRs support recognition, uptake and phagocytosis by antigen-presenting cells.  
Furthermore, the innate immune system also utilises the complement system during 
recognition and removal of pathogens (Section 1.2.3).  
The innate and acquired immune systems are not isolated systems but, through the 
secretion of soluble mediators and cellular contacts, are constantly interacting with each 
other.  The cytokine and chemokine profile established during the innate immune response 
initiates the migration of antigen-specific T cells to the lymph nodes where they come into 
contact with APCs.  Acquired immunity is dependent upon the innate system providing 
effective antigen presentation through class I and class II MHC antigens, which are 
predominantly located on the surface of macrophages and dendritic cells.  Additionally,  T 
helper (TH) cells bind to MHC antigens and stimulate B cells to generate immunity by 
undergoing immunoglobulin (Ig) class switching and somatic hypermutation, resulting in 
the production of antigen specific antibodies. 
Unlike the innate immune response, which is rapid and lacks specificity, the acquired 
immune response is highly precise but takes days to weeks to develop.  The acquired 
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immune response exhibits memory so that subsequent exposure results in a more rapid and 
vigorous response. 
The following sections will consider the immune system in more detail.  In keeping with 
the research outlined in this thesis, particular attention will be paid to PRRs, their 
corresponding PAMPs and inflammation. 
  
1.2.1  Pathogen-associated molecular patterns 
Pathogen associated molecular patterns (PAMPs) are molecules associated with groups of 
microbes that are recognised and targeted by the innate immune system.  Recent studies 
have suggested that chronic bacterial and viral infections may play a pivotal role in the 
pathogenesis of both CVD and RA (Haraszthy et al., 2000, Jacob et al., 1992, Alvarez-
Lafuente et al., 2005).  In chapter 4 of this thesis we investigate the potential role bacteria 
may play in the vasculature of RA and CVD patients. 
PAMPs are classically defined as evolutionarily conserved pathogen-derived molecules 
that distinguish hosts from pathogens (Ausubel, 2005).  PAMPs include lipopolysaccahride 
(LPS), bacterial flagellin, peptidoglycan and mannans.  It is worth noting that non-
pathogens also synthesise PAMPs and the term ‘pathogen-associated’ is a misnomer.  A 
more accurate term would be ‘microbe-associated molecular pattern’ (Ausubel, 2005).   
LPS is an essential constituent of the outer membrane of Gram-negative bacteria, and is 
often considered the prototypical PAMP (Holst et al., 1996, Rietschel et al., 1994).  LPS 
typically consists of a hydrophobic domain known as lipid A (endotoxin), a nonrepeating 
core oligosaccharide and a distal polysaccharide (O-antigen) (Raetz and Whitfield, 2002).  
Lipid A, the hydrophobic anchor of LPS, makes up the outermost monolayer of most 
Gram-negative bacteria.  The lipid A domain is highly conserved throughout Gram-
negative bacteria and is essential to their viability (Brabetz et al., 1997).  In humans, LPS is 
primarily targeted by phagocytic cells of the innate immune system (macrophages, 
monocytes, neutrophils, dendritic cells).  TLR4 in association with MD-2 is responsible for 
the physiological recognition of LPS (see Section 1.2.2) (Medzhitov et al., 1997, Shimazu 
et al., 1999). 
Lipid A activation of TLR4 triggers the biosynthesis of pro-inflammatory cytokines such 
as TNFα and IL-1β (Beutler and Cerami, 1988, Dinarello, 1991), and activates the 
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expression of co-stimulatory molecules required for the adaptive immune response 
(Medzhitov and Janeway, 2000).  LPS presence also induces an elevated expression of 
IFNγ by macrophages which acts to further enhance the sensitivity and magnitude of 
monocytes immune response to LPS (Fultz et al., 1993).  Furthermore, IFNγ induces 
increased TLR4 expression in human monocytes and several pro-inflammatory cytokines 
(Muzio et al., 2000).  LPS injections in apolipoprotein E (apoE)-deficient mice (a model of 
atherosclerosis) increased atherosclerotic lesion size and increased adventitial infiltrate of 
activated lymphocytes (Ostos et al., 2002).  This finding suggests that LPS derived from 
invading pathogens may accelerate or trigger atherosclerosis.  Gram-positive bacteria do 
not posses LPS. however, these bacterial populations posses several alternative PAMPs 
including peptidoglycans, lipopeptides, lipoteichoic acid, unmethylated DNA fragments 
(specifically, oligomer containing CpG dinoucleotides in the correct sequence context) and 
double-stranded RNA (Karlsson et al., 2002).  Although somewhat weaker than LPS in 
their immune potency, each of these molecules elicits an innate immune response 
(Muhlradt et al., 1997, Weidemann et al., 1997, Morath et al., 2001, Wagner, 2002). 
Viruses possess four classes of PAMPs including double-stranded RNA (dsRNA), single 
strandad RNA (ssRNA), unmethylated CpG DNA and envelope glycoproteins.  There are 
many common elements in the cellular responses to Gram-negative, Gram-positive and 
viral PAMPs, including the recruitment of leukocytes and the release of chemokines and 
cytokines, such as TNFα.  However, our understanding of how PAMPs and the resulting 
immune activation affect CVD and RA pathophysiology remains largely limited. 
 
1.2.2  Pattern recognition receptors 
Initiation of an effective immune response is reliant upon first recognising the pathogenic 
article.  The initial sensing of infection is mediated by germline-encoded pattern 
recognition receptors (PRRs) of the innate immune system (Takeuchi and Akira, 2010).   
Several classes of PRRs exist, including Toll-like receptors (TLRs), NOD-like receptors, 
RIG-I-like receptors and C-type lectin receptors.  This limited repertoire of PRRs is in 
contrast to the huge repertoire of rearranged receptors utilised by the acquired immune 
system.  The innate immune system is the principal contributor to the acute immune 
reaction triggered by infection (Akira et al., 2006).  Intracellular signalling cascades 
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triggered by PRRs leads to the expression of immune and inflammatory mediators that 
coordinate the effective removal of pathogens. 
PRRs share several common characteristics: (1) PRRs recognise microbial components 
known as PAMPs that are essential for survival and replication of the microbe;  (2) PRRs 
are constitutively expressed in the host and detect microbes regardless of their lifecycle; 
(3) PRRs are germline encoded, nonclonal and posses no immunologic memory (Akira et 
al., 2006). 
The remainder of this section will briefly review the mechanisms by which TLRs and 
NOD-like-receptors (NLRs) detect the presence of microbial insults, and how the resulting 
PRR signals stimulate an immune response.  A brief outline of which PAMPs the principal 
PRRs are capable of detecting is provided in table 1.1. 
The TLR family is evolutionarily conserved and is responsible for sensing microbial 
components outside of the cell and in intracellular lysosomes and endosomes (Chaturvedi 
and Pierce, 2009).  Twelve members of the TLR family have been identified in humans.  
TLRs are characterised by extracellular domains containing leucine rich repeat (LRR) 
motifs and a transmembrane signalling domain termed the Toll/IL-1R homology (TIR) 
domain (Bowie and O'Neill, 2000).  LRR is composed of 20 to 30 amino acid stretches that 
are rich in the hydrophobic amino acid leucine.  Typically each repeat unit is composed of 
a β-strand α-helix structure and the assembled domain, composed of many repeats, has a 
horseshoe like conformation (Kobe and Deisenhofer, 1994).  It has been widely considered 
that ligands would bind to the concave structure of the horseshoe structure (Kobe and 
Kajava, 2001).  However, following characterisation of the three-dimensional structure of 
the human TLR3 LRR motif it has been suggested that negatively charged dsRNA (a 
PAMP recognised by TLR3) is likely to bind to the outer convex surface of the horseshoe-
like conformation (Choe et al., 2005).  It is currently unknown if this observation can be 
applied to the other members of the TLR family. 
The TLR family can be divided into subfamilies based on their primary sequences.  Each 
subfamily detects related PAMPs.  The highly related subfamily consisting of TLR7, TLR8 
and TLR9 recognises nucleic acids, whereas the subfamily consisting of TLR1, TLR2 and 
TLR6 recognises lipids (table 1.1).   
The signalling pathway used by the TLR family is highly homologous to that used by the 
IL-1R ( IL-1 receptor) family (Akira and Takeda, 2004).  TLRs and IL-1R interact with 
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MyD88 (myeloid differentiation factor 88) through the TIR (Toll/IL-1R) domain.  
Following TLR stimulation, MyD88 binds the cytoplasmic TIR domain, where it facilitates 
the association of TRAF6 (TNF receptor-associated factor 6) and IRAKs (IL-1R associated 
kinases) (Vallejo, 2011).  TRAF6 association activates TAKs (transforming growth factor 
β-activated kinases), which initiates a kinase cascade resulting in the phosphorylation of 
inhibitory protein IkB (Hacker and Karin, 2006).  Phosphorylated IkB dissociates from the 
complex and is rapidly targeted for degradation, resulting in the activation of the 
transcription factor NF-kB, which translocates to the nucleus and initiates the expression of 
several inflammatory cytokines.  Although MyD88 has been suggested to be involved in 
all TLR signalling, TLR3 appears to transduce signals mainly using a MyD88-independent 
pathway, as the activation of NF-kB by dsRNA can occur in the absence of MyD88 
(Alexopoulou et al., 2001).  Furthermore, subtle differences to the signalling pathway of 
each TLR exist, thus supporting slightly different gene expression patterns for each TLR. 
As well as PAMPs, the PRRs are able to recognise certain endogenous self molecules.  For 
example, β-defensins (Biragyn et al., 2002), heatshock proteins (Ohashi et al., 2000) and a 
number of extracellular matrix proteins (Okamura et al., 2001) have been reported to 
activate TLR4 and stimulate inflammation.  It has been speculated that these endogenous 
molecules act as danger signals released from stressed or dead cells to trigger a pro-
inflammatory response (Matzinger, 2002). 
In addition to being expressed by immune cells, TLRs are also expressed by tissues of the 
cardiovascular system.  There is accumulating evidence that TLRs, notably TLR2 and 
TLR4, are involved in atherosclerotic development and progression (Lin et al., 2009).  
TLR2 was shown to be over-expressed in arterial endothelial cells in atherosclerosis prone 
LDLr-/- mice, and diet-induced hyperlipidaemia further increased this expression (Mullick 
et al., 2008).  TLR4-expressing macrophages have been identified in human atherosclerotic 
lesions and at sites of plaque rupture (Ishikawa et al., 2008).  However, the specific role of 
individual TLRs in initiating and maintaining pathological responses in the cardiovascular 
system remains to be defined. 
While TLRs constitute the main sensors for detection of extracellular microbes, recent 
findings suggest that NLRs act as intracellular surveillance molecules (Meylan et al., 2006, 
Fritz et al., 2006).  Several proteins of the highly conserved NLR family have been 
demonstrated to act as PRRs for the initiation of innate immune responses upon pattern 
specific microbial sensing (Inohara and Nunez, 2003).   Two members of the NOD family 
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(NOD1 and NOD2) recognise specific bacterial components D-glutamyl-meso-
diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP) respectively (table 1.1).  
NOD proteins are members of a family that includes the apoptosis regulator APAF1 
(apoptotic protease activating factor 1), mammalian NOD-LRR proteins and plant-disease-
resistance gene products.  Similar to TLRs, several NOD proteins have been implicated in 
the induction of NF-kB.  In addition, a role for NOD proteins in regulation of caspase 
activation and apoptosis has been indicated (Warren et al., 2008).  Interestingly, genetic 
variation in the genes encoding NOD proteins in humans is associated with inflammatory 
disease and increases susceptibility to bacterial infection (Hampe et al., 2001, Hoffman et 
al., 2001).  
 
PRR Localisation Ligand Origin of ligand 
TLR    
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein Bacteria, virus, 
parasites, self 
TLR3 Endolysosome dsRNA Virus 
TLR4 Plasma membrane LPS Bacteria, virus, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, virus 
TLR8 Endolysosome ssRNA Virus, bacteria, self 
TLR9 Endolysosome CpG-DNA Virus, bacteria, 
protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
NLR    
NOD1 Cytoplasm iE-DAP Bacteria 
NOD2 Cytoplasm MDP Bacteria 
Table 1.1  PRRs and their ligands 
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1.2.3  Inflammation  
 
As will become apparent in later sections, RA is a prototypical inflammatory disease 
(section 1.3.1).  Furthermore, understanding of atherosclerosis has evolved from a passive 
process resulting in narrowing of the lumen to a dynamic inflammatory process (Chung et 
al., 2007) (section 1.4.4).  Inflammation plays a pivotal role in an orchestrated immune 
response and can be activated by several mechanisms.  But what exactly is inflammation, 
and how does it function? 
The inflammatory process is the characteristic response of tissue to infection or cellular 
injury.  Inflammation functions to destroy, dilute or isolate the damaging agents and limit 
damage to the tissue.  Furthermore, inflammation is necessary for the mediation of immune 
responses and the maintenance of homeostasis.  At the clinical level, the inflammatory 
response is usually accompanied by tenderness, oedema, erythema and pain.  These 
associated symptoms occur due to increased blood flow to the site of inflammation, 
recruitment of activated leukocytes and fluid leakage into surrounding tissue.  The actions 
of inflammatory mediators and cytotoxic lymphocytes function to remove damaged tissue 
and pathogens, supporting healing, restoration of function and homeostasis.   
Inflammation is characterised by (1) vasodilation of local blood vessels with subsequent 
excess blood flow; (2) accumulation of fluid in interstitial space due to increased 
permeability of surrounding capillaries; (3) migration of monocytes and granulocytes into 
the affected tissue; (4) swelling of the cells within the tissue.  Some of the key pro-
inflammatory molecules include serotonin, histamine, bradykinin, blood clotting factors, 
the complement cascade and lymphokines secreted by sensitised cells. 
 
1.2.4  The acquired immune system 
The innate immune system is not an isolated response.  Instead, several components of the 
innate immune system cooperate with the acquired immune system, resulting in a highly 
integrated immune response. 
The acquired immune response involves the proliferation of antigen-specific B and T cells.  
Activation of these cells is dependent upon antigen-presenting cells of the innate immune 
system effectively presenting class I and class II MHC antigens.  This is predominantly 
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performed through the action of macrophages and dendritic cells.  Class I and class II 
MHC presenting antigen will activate cytotoxic CD8+ and CD4+ helper T cells respectively 
(Harding et al., 2003).   
MHC class I molecules are expressed on all nucleated cells.  The presentation of foreign 
antigen and MHC molecule allows infected cells to establish intercellular contacts with 
cytotoxic CD8+ T cells.  When exposed to such cells effector CD8+ T cells release 
cytotoxins that form pores in the target cell membrane, resulting in lysis. 
CD4+ T cells, or helper T cells, are immune-response mediators.  Unlike CD8+ T cells 
these cells have no phagocytic or cytotoxic capabilities.  Upon recognition and binding of 
class II MHC expressing foreign antigen, CD4+ T cells release specific cytokines which 
influence the activity of an array of immune cells.   
The principle function of B cells is to produce antibodies.  Antibodies serve several 
functions including, preventing microbes adhering to host cells, neutralising toxins, 
opsonising microbes, activating complement, and sensitising infected cells for antibody-
dependent attack by natural killer cells (NK cells).  Similar to the innate and acquired 
immune system, T and B cells interact with each other.  Antigen recognised by B cells is 
internalised and processed for MHC class II expression on the B cell surface.  This antigen 
is then presented to a primed specific T cell.  The T cell then produces B cell growth 
factors which stimulate B cell division and maturation, resulting in the formation of 
antibody-secreting cells.  Following an immune response, two types of differentiated B 
cells persist in a B cell memory pool: plasma cells, which confer immediate protection by 
the secretion of specific antibodies and memory B cells, which confer a rapid and 
enhanced response to secondary challenge (Lanzavecchia and Sallusto, 2009). 
B cells play several roles in the pathogenesis of RA.  They are a source of rheumatoid 
factors and anti-citrullinated protein antibodies, which activate complement and contribute 
to the formation of immune complexes in the joints (Silverman and Carson, 2003).  B cells 
both produce and respond to cytokines and chemokines that promote leukocyte infiltration 
into the joints.  Furthermore, germinal-like structures consisting of T and B cells clustered 
in aggregates around interdigitating dendritic cells are observed in the synovium of about 
60% of RA patients (Silverman and Carson, 2003).  Generally speaking, the presence of 
lymphoid infiltration correlates with clinical disease in RA (Weyand and Goronzy, 2003).  
Furthermore, evidence suggests that the mechanisms of immune-mediated tissue damage 
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are shared between the synovium and the atherosclerotic lesion, predisposing RA patients 
to CVD (Weyand et al., 2001). 
 
1.3. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most prevalent inflammatory arthritis and is characterised 
by systemic inflammation, persistent synovitis and autoantibodies leading to severe 
disability and premature mortality (Scott et al., 2010, Pincus et al., 1984).  RA principally 
affects the peripheral joints, which can lead to cartilage damage, bone erosion, and can 
subsequently disrupt bone integrity.   
In industrialised countries, RA affects 0.5-1% of the adult population and is a major cause 
of disability.  The incidence of RA is three times greater in women than men.  Rarely will 
RA occur in individuals under 15 years of age, but following this age the risk of RA 
increases until 80 years of age (Majithia and Geraci, 2007).   Severity of disease can vary 
enormously depending on the number of joints affected, the extent of inflammation and the 
rate of progression. 
Despite RA being considered an autoimmune disease the exact initiating stimulus remains 
unknown (Resch, 2008).  However, it is likely that RA results from a complex interaction 
between environmental and genetic factors.  An initial trigger, possibly infectious or 
autoimmune, initiates joint inflammation, with subsequent interactions between cells of the 
immune system, their cytokines, growth factors and proteinases leading to joint destruction 
(Majithia and Geraci, 2007) (Section 1.3.1). 
There is no single test to confirm the diagnosis of RA.  Instead, classification criteria 
devised by the American College of Rheumatology (ACR) and the European League 
Against Rheumatology (EULAR) (Aletaha et al., 2010) aim to distinguish individuals with 
RA from those with other types of established joint disease (table 1.2).  These criteria 
replace previous long-standing ACR diagnosis criteria (Arnett et al., 1988).  The updated 
criteria require measurement of the acute phase respondents, namely C-reactive protein 
(CRP) and the erythrocyte sedimentation rate (ESR).  Furthermore, measurement of anti-
citrullinated protein antibody (ACPA), an autoantibody against citrulline which can 
precede physical RA manifestation by several years (Nielen et al., 2004, Rantapaa-
Dahlqvist et al., 2003), is required.  Together these updates support earlier diagnosis of RA 
and will undoubtedly result in improved clinical outcomes over the long term. 
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 Score 
A.  Joint involvement * 
   1 large joint 
   2-10 large joints 
   1-3 small joints (with or without involvement of large joints) 
   4-10 small joints (with or without involvement of large joints) 
   >10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
B.  Serology (at least one test result is needed for classification) 
   Negative RF and negative ACPA 
   Low-positive RF or low-positive ACPA 
   High-positive RF or high-positive ACPA 
 
0 
2 
3 
C.  Acute-phase reactants (at least one test is needed for classification) 
   Normal CRP and normal ESR 
   Abnormal CRP or abnormal ESR 
 
0 
1 
D.  Duration of symptoms 
   <6 weeks 
   ≥6 weeks 
 
 
0 
1 
Table 1.2 ACR-EULAR classification criteria for rheumatoid arthritis (Aletaha et 
al., 2010).                     
The scores from categories A-D are added; a score of  ≥6 is needed to diagnose a patient 
as having definite RA.  Patients are recommended to undergo these tests if they have at 
least one joint with definite clinical synovitis and if the observed synovitis cannot be better 
explained by an alternative disease. 
*’Large joints’ refer to knees, hips, ankles, shoulders and elbows. ‘Small joints’ refers to 
the proximal interphalangeal joints, metacarpophalangeal joints, second through fifth 
metatarsophalangeal joints, thumb interphalangeal joints and wrists. 
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1.3.1 Pathogenesis of rheumatoid arthritis  
Despite intensive research the cause of RA remains unknown.  However, understanding of 
the pathogenesis of RA has advanced significantly in recent years.  RA is best regarded as 
a clinical syndrome involving several different inflammatory pathways that ultimately 
converge, resulting in persistent synovial inflammation and associated bone and cartilage 
damage (Scott et al., 2010, van der Helm-van Mil and Huizinga, 2008). 
 
1.3.1.1  Inflammation in RA 
Inflammation is typically a tightly regulated process involving both pro-inflammatory 
mediators and anti-inflammatory mediators.  In RA an imbalance exists between these two 
mediator systems, leading to cellular damage and tissue destruction (Choy and Panayi, 
2001). 
The synovial membrane in patients with RA is characterised by an infiltrate of 
inflammatory cells, principally CD4+ T cells, which orchestrate cell-mediated immune 
responses.  Antigen-activated CD4+ T cells stimulate monocytes, macrophages and 
synovial-like fibroblasts to produce pro-inflammatory cytokines such as IL-1, IL-6 and 
TNFα (Aggarwal, 2003). 
The overproduction of tumour necrosis factor (TNFα) has been identified as a key 
contributor to the inflammatory and tissue-destructive pathways in RA (Feldmann and 
Maini, 2003).  TNFα is overexpressed in the synovial fluid as well as the synovial 
membrane of RA patients (Digiovine et al., 1988).  Furthermore, expression of the TNFα 
receptor is also up-regulated in the synovial membrane of RA patients and appears to co-
localise with areas of bone erosion (Alsalameh et al., 1999).  Further evidence to support 
the direct role of TNFα in RA comes from transgenic mice, where overexpression of TNFα 
alone resulted in inflammation and rheumatoid-like lesions in the joints (Keffer et al., 
1991).  Importantly, inhibiting the biological activity of TNFα has revolutionised the 
treatment of RA and substantially improved clinical outcomes. 
Furthermore, TNFα and IL-1 stimulate mesenchymal cells (synovial fibroblasts, 
chondrocytes and osteoclasts) to release tissue degrading matrix metalloproteinases 
(Shingu et al., 1993). 
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Whereas IL-1, IL-6 and TNFα initiate and maintain inflammation, other cytokines such as 
IL-10 and IL-4 dampen it (vanRoon et al., 1996).  Both IL-10 and IL-4 attenuate the 
production of TNFα and IL-1 and have been shown to inhibit cartilage damage (Vanroon 
et al., 1995, Sugiyama et al., 1995).  Although both IL-10 and IL-4 have been found in the 
synovial fluid of RA patients, the amount is thought to be insufficient to protect from 
inflammation (Katsikis et al., 1994, Taki et al., 2000). 
 
1.3.1.2  Autoantibodies in RA 
Rheumatoid factor (RF) is the classic autoantibody in RA.  IgM and IgA rheumatoid 
factors are key pathogenic markers directed against the Fc fragment of immunoglobulin 
(IgG).  RF titre has been demonstrated to correlate with synovitis, joint damage and 
disability (Shmerling and Delbanco, 1991).  However, experimental studies have so far 
failed to attribute a pathogenic role to RF in RA.  Additional types of antibodies are those 
directed against citrullinated peptides (ACPA).  Although most ACPA-positive patients are 
also positive for RF, ACPA seems more specific and sensitive for diagnosis than RF and 
provides superior predictive information on joint destruction and disease activity (van der 
Linden et al., 2009, Fathi et al., 2008).  Autoantibodies are discussed further in section 
1.5.4. 
 
1.3.1.3  Genetics 
Although not a feature of the research carried out for this thesis, it must be highlighted that 
there is extensive evidence for a genetic component in the aetiology of RA.  A study of 91 
monozygotic (MZ) and 112 dizygotic (DZ) twins revealed that 15.4% of the MZ and 3.6% 
of the DZ pairs were disease concordant (Silman et al., 1993).  Furthermore, familial 
clustering tests demonstrated that there is an increased risk of RA in first- and second-
degree relatives of patients (Grant et al., 2001).  Owing to such studies, genetic factors are 
estimated to account for ~60% of the variation in liability to disease (MacGregor et al., 
2000). 
The HLA-DRB1 gene, which contributes to the major histocompatability complex (MHC),  
is the best understood genetic risk marker in RA (Williams et al., 1995).  Indeed, genome-
wide searches using micro-satellite loci have confirmed a linkage between RA and the 
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HLA-DR allele polymorphisms (Cornelis et al., 1998, Delgado-Vega and Anaya, 2007).  
Several non-HLA loci have also been demonstrated to exhibit genetic linkage to RA, 
including the 18q21 region of the TNFRSF11A gene, which encodes the receptor activator 
of nuclear factor kappaB (RANK), a membrane protein involved in bone resorption in RA 
(Jawaheer et al., 2003).  
 
1.3.2 Co-morbidities in RA 
The pathophysiology of RA is fairly well characterised, but less understood are the co-
morbid conditions that are associated with RA.  Physicians and researchers are interested 
in RA co-morbidity because of the potential effect on the quality of life (QOL) and the RA 
prognosis and outcome (Michaud and Wolfe, 2007).  It is customary to think of the 
functional status of RA patients as being directly related to RA pathophysiology; however, 
functional status is also strongly influenced by co-morbid conditions.   
RA patients have, on average, a 10 to 15 year decreased life expectancy compared to the 
general population (Pincus and Callahan, 1986, Wolfe et al., 1994).  CVD is the leading 
cause of mortality in RA, with over half of all reported mortalities in RA cohorts being 
explained by CVD events (Goodson, 2002).  Enhancing our understanding of why CVD 
burden is elevated in RA is fundamental to improve clinical outcomes and forms the basis 
of the research outlined in this thesis.  Atherogenesis in rheumatology is discussed in 
greater detail in section 1.5. 
In cohorts of RA patients, infection is considered the second greatest contributor to 
mortality (Franklin et al., 2007, Goodson et al., 2002) and the rate of infection-related 
mortality is typically 4 to 6 times greater than that of the general population (Sihvonen, 
2006, Au et al., 2011).  This association has implications for the research described in 
chapter 4, which characterises bacterial species present in the aortic adventitia of patients 
with RA. 
Although not the subject of the research presented in this thesis, epidemiological studies 
have also demonstrated that RA is associated with pathologies such as osteoporosis, 
gastrointestinal disease, cataracts, psoriasis and certain cancers.  Despite mortality rates 
resulting from these associated conditions being slight in comparison to CVD, future 
research into these co-morbidities could lead to development of therapeutics that 
significantly increase the quality of life experienced by RA patients. 
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Direct evidence to support CVD as a major pathology in RA comes from stress myocardial 
perfusion imaging.  This relatively simple technique allows clinicians to quantify blood 
flow to the myocardium. These studies demonstrated that 50% of RA patients aged 40 to 
70 years exhibited definitive signs of cardiac ischemia (principally caused by 
atherosclerosis), whereas only 27% of controls matched for age, sex and all classical 
cardiovascular risk factors exhibited similar signs of cardiac ischemia (Banks et al., 1998).  
This clinical observation occurred roughly 10 years earlier in the RA cohort indicating that 
RA itself (or the pathogenic mechanism) is an independent risk factor for CVD, 
attributable to accelerated atherosclerosis.   
Inflammation is known to play a role in the pathophysiology of atherosclerosis (Ross, 
1999, Alexander, 1994, Pasceri and Yeh, 1999).  In animal models engineered to over-
express inflammatory mediators, atherosclerosis severity is increased (Huber et al., 1999) 
and inflammatory cells and mediators have been found in human atherosclerotic plaque 
(Naruko et al., 2002).  Furthermore, elevated serum concentration of inflammatory markers 
such as IL-6 (Ridker et al., 2000)  and CRP (Ridker, 2005) can predict atherosclerosis.  
Consequently, elevated atherosclerosis risk could result from the chronic inflammation that 
accompanies RA.  
In order to conceptualise current thinking on elevated atherosclerosis risk in RA, and to 
introduce new hypotheses, it is important first to understand the pathogenesis of 
atherosclerosis.  The following section (section 1.4) will provide inter alia an overview of 
CVD before describing the physiology of atherosclerosis in more detail.   
 
1.4  Cardiovascular disease   
 
1.4.1  The global burden of cardiovascular disease 
 
Cardiovascular disease (CVD) is a broad-spectrum disease that most commonly refers to 
atherosclerosis, but also includes conditions such as angina and stroke.  CVD results from 
an accumulation of atherosclerotic plaques within the walls of the arteries that supply the 
myocardium.  In 2008 the World Health Organization (WHO) ranked CVD as the premier 
cause of global death, accounting for 12.2% of all recorded deaths (WHO, 2011).  This 
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trend is expected to continue indefinitely (Murray and Lopez, 1997a, Murray and Lopez, 
1997b).  Every 25 seconds an American citizen will experience a coronary event and every 
60 seconds someone will die as a result of such an event (Roger et al., 2011). 
CVD is causally linked to lifestyle.  Poor diet, lack of exercise and smoking have been 
popularised in the media and established in the literature to be major cardiovascular risk 
factors (Karasek et al., 2010, Gordon et al., 1974, Wildman et al., 2011).  The last few 
decades of urbanisation has led to changes in behavioural patterns towards activities that 
increase CVD burden.  Reduction in manual labour and greater reliance on motorised 
transportation coupled with the global uptake of an unhealthy western diet (low fruit and 
vegetable, high salt and saturated fat) have led to a pandemic of obesity in the developed 
nations. The WHO estimates that in 2006 66.7% of US adults were overweight (BMI ≥ 25 
kg/m²) and that 33.3% were obese (BMI ≥ 30 kg/m²).    Data from the 2009 United States 
Behavioural Risk Factor Surveillance System (BRFSS) of the Centers for Disease Control 
and Prevention (CDC) (Sherry et al., 2010) documented a 1.1% increase in US obesity 
between 2007 and 2009.  This has led some researchers to infer that by 2050 a vast 
proportion (approaching 100%) of American citizens will be overweight (Yanovski and 
Yanovski, 2011). 
There has been an epidemiological shift in the developing world which has seen a decrease 
in deaths due to communicable disease and malnutrition, coupled with an increased burden 
of degenerative disease – the major contributor being atherothrombotic CVD.  This 
epidemiological shift can be categorised into general stages.  The first stage encompasses 
the least developed countries (e.g. sub-Saharan Africa) where the predominant circulatory 
diseases are nutritional related disorders of the cardiac muscle and rheumatic heart disease 
(Yusuf et al., 2001).  Second-stage countries (e.g. China) are experiencing a decrease in 
communicable disease and improvements in nutrition.  In China, for example, 
hypertension-related diseases such as hypertensive heart disease and haemorrhagic stroke 
are the major contributors to CVD (Chiu et al., 2010).  Countries in the third stage of the 
epidemiological shift (e.g. Latin America, urban India) are experiencing improved life 
expectancy.  Here, sedentary lifestyles are being increasingly adopted, smoking and high 
fat diets are increasing, and as a result noncommunicable diseases predominate, with the 
greatest contributor to mortality being atherosclerotic CVD (Reddy, 1999).  For the 
majority of developing nations the increased prevalence of CVD accompanies the 
continuing burden from nutritional and infectious disease.  This has been aptly termed the 
“double burden”.  The fourth stage, applicable to highly developed nations, is in all senses 
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similar to the third stage, however increased investment in diagnosis and treatment has led 
to a delay of symptoms until a later age (Yusuf et al., 2001).  
Prevention and treatment of CVD is therefore a critical clinical and social issue.  However, 
as well as human costs, CVD has major economic consequences.  In the United Kingdom 
in 2006, CVD alone cost the NHS £14.4 billion, representing £250 per capita.  72% of this 
sum was accounted for by direct hospital care of CVD sufferers and 20% of the cost was 
due to medication (figure 1.1).  Accordingly there has been a recent burst of research 
focusing on identifying individuals at risk of CVD, educating them on the necessary 
lifestyle changes required and administering suitable prophylaxis such as aspirins and 
statins.  This approach has undoubtedly led to progression in the field, however more 
research is necessary to enhance our understanding of the molecular mechanisms that 
trigger and potentiate CVD.   
 
 
Figure 1.1 Breakdown of NHS spending for diagnosis and treatment of CVD in 2006.  
Figure generated using data from the British Heart Foundation Statistics Database.  
 
1.4.2  Blood vessel structure 
In order to understand the pathogenesis of atherosclerosis, it is important to be familiar 
with the basic structure of a healthy blood vessel. All blood vessels, with the exception of 
the very smallest, are composed of three distinct layers or tunics that surround the central 
Inpatient care 72% 
Medications 20% 
Primary care 6% 
Outpatient care 2% 
Accident and emergency 
care 0.5% 
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blood-containing lumen (figure 1.2).  The intima forms the innermost layer, which is 
composed of a single layer of endothelial cells arranged on a thin membrane of laminin, 
type IV collagen and proteoglycans.  An internal elastic lamina separates the tunica intima 
from the tunica media.  The media forms the middle layer of the vessel and comprises 
vascular smooth muscle cells with a basement membrane of elastic tissue.  The tunica 
adventitia forms the outermost layer of the vessel.  The adventitia is principally composed 
of loose connective tissue comprised of fat cells and a few smooth muscle cells. Nerves 
and capillaries (vasa vasorum), which provide the vessel wall with nutrients, are also 
present within the adventitia. 
It is widely accepted that atherosclerosis is initiated at the endothelial lining of the tunica 
intima  (Kharbanda and MacAllister, 2005, Ross, 1999).  The following sections (section 
1.4.3 – section 1.4.3.2) will describe current understanding of endothelial cells and how 
these may contribute to atherosclerosis.  However, as will become apparent later (section 
1.4.4.2 - the outside in phenomenon) there is a growing body of evidence to suggest that 
atherosclerosis may originate in the adventitia. 
 
1.4.3  Vascular endothelium  
 
The vascular endothelium is a single-celled layer that lines the interior surface of all blood 
vessels and forms the interface between the vessel wall and circulating blood in the lumen 
(figure 1.2) (Michiels, 2003).  For many years the endothelium was considered a relatively 
inert container for blood.  However, the last two decades have seen research reveal a 
wealth of endothelial functionality.  
Under normal physiological conditions the vascular endothelium allows nutrient exchange 
but limits the passage of blood and protein.  The endothelium also plays vital roles in the 
maintenance of vascular tone by releasing vasoactive substances such as nitric oxide (NO) 
as well as contributing to angiogenesis, humoral coagulation and inflammation 
(Stenvinkel, 2001). 
Vascular endothelial cells have threefold functionality in the interaction with leukocytes: 
(1) they dictate the passage of leukocytes to inflammatory foci; (2) they modulate 
leukocyte activation; (3) they possess receptors that recognise leukocyte derived 
molecules, which can result in endothelial cell activation or death (Biedermann, 2001). 
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Upon recognition of damaged cells or pathogens, neutrophils, macrophages and mast cells 
become activated.  These cells then secrete cytokines such as IL-6, IL-1, TNFα and a range 
of other pro-inflammatory mediators. These molecules stimulate blood vessels at the site of 
damage to vasodilate, increase vascular permeability and activate endothelial cells to 
express adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) and 
inter-cellular adhesion molecule-1 (ICAM-1) (Woodfin et al., 2009).  Adhesion molecules 
recognise and bind to circulating lymphocytes, supporting migration from the vascular 
lumen to the site of infection and/or injury (Yadav et al., 2003).   
 
 
Figure 1.2. Location of endothelial cells in the vessel wall                                               
A single layer of endothelial cells confined to the intimae line the surface of blood vessels, 
forming an interface between circulating blood and the rest of the vessel.  The media 
makes up the thickest layer of the vessel and is composed principally of smooth muscle 
cells.  The adventitia is composed primarily of connective tissue and also contains nerves 
and capillaries (vasa vasorum) that serve the vessel wall. Figure adapted from 
Micheles,2003. 
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1.4.3.1  Endothelial-dependent leukocyte recruitment  
Evidence suggests that the progression of atherosclerosis resembles a chronic 
inflammatory disease (Hansson, 2005).  Several different leukocyte subsets have been 
identified in the early lesion, including B cells, T cells, monocytes and macrophages, 
natural killer (NK) cells, dendritic cells (DCs), activated smooth muscle cells (SMCs), 
mast cells and a range of products secreted from these cells (Charo and Ransohoff, 2006). 
A key event in the atherogenic inflammatory response is the endothelial-dependent 
recruitment of leukocytes to the site of tissue damage and/or infection.  The vascular 
endothelium is responsible for orchestrating the cellular and regulatory mechanisms of 
leukocyte recruitment to the vessel wall (Rao et al., 2007).  Endothelial cell activation by a 
variety of proinflammatory cytokines (e.g. TNFα, IL-1β, IFNγ), thrombin, haemodynamic 
factors, bacterial endotoxin and viruses can lead to loss of endothelial function, local 
thrombosis and rapid leukocyte recruitment (Gimbrone, 1999).  These inflammatory 
mediators lead to small blood vessel dilation, resulting in increased blood flow and a 
slowed course of circulating leukocytes, thus allowing them opportunity to contact the 
endothelial lining.  If unrestricted, these alterations can lead to vascular inflammation and 
contribute to atherosclerosis (Meredith et al., 1993) and RA (Foster et al., 2010).  
A key stage in leukocyte recruitment is the secure adhesion of leukocytes to the surface of 
the endothelium, allowing migration into the vessel wall.  The specificity of leukocyte 
recruitment to the vascular wall is most probably dictated by the expression of different 
combinations of adhesion molecules and locally expressed chemoattractants, cytokines and 
chemokines.  Furthermore, only subsets of leukocytes which posses the ability to disrupt 
endothelial cell junctions including components such as tight junctions (claudins, 
occludins) and adherens junctions, will be free to pass across the endothelial lining. 
 
1.4.3.2  Endothelial dysfunction 
Endothelial dysfunction is an important early event in atherosclerosis, contributing to 
plaque formation.  Accumulating evidence indicates that endothelial dysfunction can be 
detected before physical changes to the vascular wall (Davignon and Ganz, 2004).  
Endothelial dysfunction is characterised by a shift in endothelial homeostasis towards a 
prothrombotic and proinflammatory state with reduced vasodilation (Endemann and 
Schiffrin, 2004).  Mechanisms that contribute to reduced vasodilation include reduced 
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production of nitric oxide (NO), diminished generation of hyperpolarising factor and 
oxidative excess (Chen et al., 2001).  Production of chemokines such as macrophage 
chemoattractant peptide-1 and upregulation of endothelial adhesion molecules supports a 
prothrombotic and proinflammatory response (Griendling and FitzGerald, 2003, Khan et 
al., 1996). 
The diminished production of NO by the endothelium appears paramount in the 
pathophysiology of endothelial dysfunction.  In addition to its vasodilatory effect, NO 
produced by the endothelium stimulates neovascularisation and angiogenesis (Aicher et al., 
2004), promotes endothelial growth and survival (Kawasaki et al., 2003), limits leukocyte 
adherence to the endothelium (Gauthier et al., 1995), and restricts platelet aggregation and 
reduces risk of thrombosis (De Graaf et al., 1992).  Interestingly, CRP (an established 
biomarker for CVD and RA) significantly downregulates endothelial nitric oxide synthase 
(eNOS) and disrupts eNOS mRNA expression, resulting in reduced NO and increased 
inflammatory cell adhesion (Verma et al., 2002, Venugopal et al., 2002). 
 
1.4.4  Formation of the atherosclerotic lesion  
Atherosclerosis is a chronic inflammatory disorder resulting from interaction between 
modified lipoproteins, monocytes and T cells as well as resident cells of the vessel wall 
(Glass and Witztum, 2001).  Chronic inflammation ultimately leads to development of the 
atheromatous lesion.  However, the site of atherosclerosis initiation has been the subject of 
debate in recent years.  The following two sections (Sections 1.4.4.1 and 1.4.4.2) will 
summarise the two conflicting hypotheses.  This is followed by an overview of the 
macroscopic stages of atherosclerosis progression, which is applicable to both models of 
disease initiation. 
 
1.4.4.1  From intima to adventitia 
The theory that atherosclerosis is initiated at the intima is the most widely accepted 
mechanism to explain atherosclerosis pathogenesis.  Owing to the direction of 
pathogenesis, this theory is commonly referred to as ‘inside-out’.  Accumulation of LDL in 
the subendothelial matrix has been described as a primary initiator of atherosclerosis 
(Steinbrecher et al., 1990).  Elevated lipid accumulation within large arteries allows low-
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density lipoprotein (LDL) to diffuse freely through endothelial cell junctions.  Retention of 
LDL at the site of atherosclerosis involves interaction between apolipoprotein B (ApoB) 
and matrix proteoglycans within the intima of the vessel wall.  While resident in the tunica 
intima, LDL will undergo modification by oxygen radicals and enzymes, forming oxidised 
LDL (oxLDL).  Upon exposure to oxLDL, endothelial cells express a variety of surface 
molecules, including intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion 
molecule 1 (VCAM1) and P-selectin, which recruit leukocytes into the intima (Hansson 
and Libby, 2006). 
Monocytes recruited to the activated endothelium are exposed to arterial M-CSF (Qiao et 
al., 1997) and differentiate into macrophages.  Macrophages will bind oxLDL through an 
array of scavenger receptors, principally CD36, SRA-1, SRB-1 and MARCO (Collot-
Teixeira et al., 2007, Naito et al., 1992, Sakaguchi et al., 1998).  Lipid particles are then 
taken up via a range of endocytic pathways (Kruth, 2001) to form foam cells.  Innate 
immune recognition of oxLDL epitopes prompts cytokine-mediated recruitment of 
lymphocytes that subsequently promote an adaptive immune response responsible for the 
chronic inflammation observed in atherosclerosis (Keaney, 2011).  The establishment of 
persistent arterial inflammation underpins the progression of atherosclerosis, resulting in 
the formation of a lipid-rich necrotic core and a fibrous cap.  These later stages in 
atherosclerosis development are discussed in more detail in Section 1.4.4.3. 
 
1.4.4.2  From adventitia to intima 
A growing body of research supports a novel ‘outside-in’ hypothesis (first proposed by 
Maiellaro & Taylor, 2007) in which vascular inflammation is initiated in the tunica 
adventitia and progresses inwards to the luminal surface (Maiellaro and Taylor, 2007).  
During CVD pathogenesis different immune cells, including monocytes, macrophages and 
T cells, are resident in the adventitia (Wick et al., 1997, Capers et al., 1997).  The 
accumulation of these cell populations in the adventitia results in the local expression of 
growth factors, chemokines and inflammatory cytokines similar to that observed in the 
inside-out mechanism (Jabs et al., 2007).  According to the ‘outside-in’ hypothesis (figure 
1.3) expression of inflammatory mediators signal adventitial fibroblasts, which are 
responsible for the synthesis of extracellular matrix and collagen, to undergo a phenotypic 
switch into migratory myofibroblasts.  The myofibroblasts transform into a contractile 
myofibroblast which secrete chemokines such as ccl-2, to recruit further monocytes, before 
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finally undergoing apoptosis in the media.  The fibroblasts that remain in the adventitia 
will secrete a range of cytokines and chemokines, resulting in pronounced leukocyte 
infiltrate.  Inflammatory infiltration into the adventitia has been suggested to occur through 
the vasa vasorum.  Upon exposure to inflammatory mediators the vasa vasorum will 
upregulate expression of adhesion molecules such as VCAM-1 and P-selectin. 
Following pronounced inflammatory infiltration, germinal centres are formed.   Antigen 
presenting cells interact with these lymphoid organ-like clusters of lymphocytes supporting 
the generation of antibodies against inflammatory antigens.  Antigen presenting cells also 
interact with T cells, transforming them into pro-inflammatory Th1 cells.  The cytokines 
and chemokines secreted by activated lymphocytes recruit leukocytes from the lumen into 
the intima and subsequent transformation into macrophages.  At this point, both the intima-
adventitia and adventitia-intima directional models share the same sequence of events.  
Macrophages uptake oxLDL, forming foam cells.  These cells then form apoptotic bodies 
and further release pro-inflammatory molecules, at which point the early atheromatous 
lesion becomes visible followed by the fibrous plaque. 
It is apparent that this theory provides no clear indication as to why immune cells initially 
present in the adventitia surmount an aggressive proinflammatory response.  This theory 
does however support a hypothesis where by autoantigens and/or microbial pathogens may 
reside in the adventitia and trigger a localised inflammatory response.  This concept will be 
reviewed further in sections 1.5.4 and 1.5.5 and is the subject of some of the research 
outlined in this thesis (chapters 3 and 4). 
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Figure 1.3 Atherosclerosis initiated in the adventitia                                                     
The expression of inflammatory molecules leads to a phenotypic switch in fibroblasts to 
migratory myofibroblasts.  Leukocyte recruitment to the adventitia supports a humoral 
response and allows further influx of leukocytes from the endothelium.  Macrophages 
present in the intima and media then uptake oxLDL and form foam cells, resulting in the 
early atherosclerotic lesion.  Figure from (Maiellaro and Taylor, 2007)                                        
 
1.4.4.3  Clinical manifestations of atherosclerosis 
The previous two sections outlined two alternative hypotheses of the mechanism behind 
atherosclerosis initiation.  At the point of initiation, atherosclerosis remains asymptomatic.  
It is only after several years that chronic inflammation of the vessel wall results in clinical 
manifestations (Ross, 1993). 
During atherosclerosis progression the structure of the vessel wall is altered.  SMCs from 
the media migrate to the intima.  The proliferation of both migratory and resident intimal 
SMCs coupled to the synthesis of extracellular matrix molecules such as elastin, collagen 
and proteoglycans forms the foundation of the atherosclerotic plaque (Libby et al., 2011).  
Foam cells and SMCs undergo apoptosis in advancing lesions releasing lipid into the 
extracellular matrix.  The accumulation of apoptotic foam cells and SMCs under the intima 
forms a plaque visible as a fibrous cap covering the surface of the lesion.  Extracellular 
lipid accumulates at the central region of the plaque to form a necrotic core, which, if large 
enough, can occlude blood flow through the vessel (figure 1.4). 
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Owing to the structure of the plaque and the haemodynamic stress experienced during 
systolic expansion and diastolic contraction, the fibrous plaque is prone to rupture.  Plaque 
rupture exposes tissue factors in the plaque interior to blood coagulation factors in the 
lumen resulting in thrombus formation (Didangelos et al., 2009).  Thrombi can extend into 
the lumen and are capable of completely occluding arteries resulting in myocardial 
infarction.  Alternatively, thrombi can detach and occlude smaller downstream branches of 
the circulatory system, causing thromboembolism (i.e. stroke). 
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Figure 1.4 The stages of atherosclerosis 
The earliest lesion consists of subendothelial accumulation of lipid-laden macrophages 
(foam cells). Such lesions are not clinically significant, but form the precursor for a more 
advanced lesion characterised by the accumulations of SMCs and necrotic debris.  The 
necrotic core of advanced lesions is typically enclosed by a fibrous cap consisting of 
extracellular matrix and SMCs.  Advanced lesions can grow sufficiently large to block 
blood vessels.  More commonly, advanced lesions become unstable resulting in rupture 
followed by thrombus.  Such clinical complication can result in myocardial infarction or 
stroke.  Figure adapted from (Lusis et al., 2004). 
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1.5 Atherogenesis in RA 
1.5.1 Exploring the link 
It is widely documented that RA patients die prematurely (Wolfe et al., 1994, 
WallbergJonsson et al., 1997).  The gap in mortality between RA patients and the general 
population is widening because RA patients have not experienced the improvements in 
survival evident in the general population over the past four decades (Gonzalez et al., 
2007).  A recent meta-analysis of observational studies indicates that increased CVD 
burden is the principle contributor to elevated mortality rates in RA patients (Avina-
Zubieta et al., 2008).  Importantly, despite the obvious clinical importance of CVD in RA, 
understanding why these diseases are associated remains elusive. 
The following sections will briefly review the potential contribution of traditional and non-
traditional risk factors to the excess CVD burden observed in RA.  Particular attention has 
been paid to areas that are relevant to the research outlined in this thesis.  As well as 
exploring current popular thinking, several novel hypotheses are suggested. 
 
1.5.2 Traditional risk factors shared between RA and CVD patients  
CVD risk factors provide strong predictors of cardiovascular outcomes that contribute to 
CVD in the general population (Kannel and Schatzkin, 1985).  The prevalence of 
traditional CVD risk factors in RA patients compared to controls has been well described 
and their relative contribution to excess CVD in RA is continuously being assessed 
(Solomon et al., 2004, Semb et al., 2010).  However, epidemiological work often shows 
unexpected or paradoxical results and associations, some of which may be explained by 
biological phenomena peculiar to the RA population (Gonzalez et al., 2008). 
The most striking of these unexpected epidemiological observations comes when 
considering body mass index (BMI).  BMI is a well established risk factor for CVD and in 
the general population mortality as a result of CVD reaches its highest among people in the 
top BMI categories  (>30kg/m2) (Fontaine et al., 2003).  However, within RA patients an 
inverse association between BMI and mortality has been observed (Escalante et al., 2005) 
with low BMI resulting in a threefold increased risk of CVD mortality (Kremers et al., 
2004).    
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Emerging information suggests a relationship between obesity and systemic inflammation 
(Lehrke and Lazar, 2004).  High BMI principally results from increases in both the number 
and size of adipocytes.  Adipose tissue was previously considered to act as a simple fuel 
store, but is now viewed as a complex endocrine system capable of secreting pro-
inflammatory and pro-atherosclerotic cytokines such as IL-6 and TNFα (Ahima and Flier, 
2000).  Macrophages have also been demonstrated to infiltrate adipose tissue in states of 
obesity (Weisberg et al., 2003), further perpetuating a pro-inflammatory state.  This 
apparent immunogenicity within adipose tissue may play a role in the ‘outside-in’ theory 
of atherosclerosis progression (section 1.4.4.2), as the majority of adipocytes reside in the 
adventia, the outer most layer of the vessel wall.  Although these observations may help to 
explain why elevated BMI increases the risk of CVD in the general population, the 
protective effect of adiposity in RA patients remains paradoxical.  In order to abet 
understanding of why this anomaly occurs it would be useful to correlate adventitial 
inflammation with BMI in both RA patients and the general population. 
The relative contribution of other traditional CVD risk factors, including smoking, 
hypertension, hyperlipidaemia, family history of CVD, diabetes mellitus and the male 
gender appears to be less in RA patients compared to the general population (Gabriel, 
2010) (figure 1.5). 
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Figure 1.5 Impact of traditional risk factors on endpoint CVD in RA compared to the 
general population                  
Figure reproduced from Gabriel (2010); original data from Gonzalez et al (2008). 
 
Undoubtedly, the anomaly in CVD risk factors between RA patients and the general 
population would benefit from further research in order to enhance understanding of the 
mechanisms underlying these relationships.  Kitas and Gabriel (2010) postulated that the 
chronic high-grade systemic inflammation may impart significant CVD risk in RA but not 
non-RA subjects.  They further suggested that such high-grade inflammation could have a 
dilution effect, resulting in the relative contribution of traditional risk factors appearing 
small in RA patients (Kitas and Gabriel, 2010). 
 
1.5.3 Systemic inflammation   
Accumulating evidence suggests that atherosclerosis is an inflammatory condition with a 
pathophysiology similar to that observed in RA (Ross, 1999, Pasceri and Yeh, 1999).  It 
has been proposed that RA-driven systemic inflammation could predispose an individual to 
atherosclerosis (Sattar et al., 2003).  During RA pathogenesis, the primary site of 
inflammation in is the synovial tissue, from which cytokines are released into the systemic 
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circulation.  CVD burden in RA has been found to correlate with the number of inflamed 
joints (Pincus et al., 1984).     
The concept of inflammatory-driven atherogenesis is supported by the composition of the 
atherosclerotic lesion, which exhibits an abundance of immune cells and inflammatory 
markers.  Pro-inflammatory cytokines have also been shown to play a predominant role in 
both RA and CVD (Park and Pillinger, 2007).  However the levels of pro-inflammatory 
cytokines detected in CVD patients are significantly lower than those observed in the 
serum of RA patients (Sattar et al., 2003).  Several other features are common in the two 
diseases, including T cell activation (increased Th1:Th2 cell ratio), elevated serum 
concentration of acute phase reactants (including CRP and fibrinogen) and the local 
expression of leukocyte adhesion molecules and endothelin (Snow and Mikuls, 2005).   
Endothelial dysfunction is considered to be one of the earliest events in CVD pathogenesis 
(section 1.4.3.2) and leads to increased inflammatory cell adhesion, reduced dilator 
function and increased coagulation activity (Davignon and Ganz, 2004).  Pro-inflammatory 
cytokines have been shown to impair endothelial function both in dissected human veins 
and in animal models (Clapp et al., 2004, Aicher et al., 2004). 
If systemic inflammation were a causative agent in CVD pathogenesis, it would seem 
likely that the use of anti-inflammatory RA therapeutics would decrease CVD burden.  In a 
small study involving 25 RA patients, disease-modifying anti-rheumatic drugs (DMARDs) 
were found to significantly improve coronary microcirculation (Turiel et al., 2010).  
Similarly, treatment of RA with infliximab, a monoclonal antibody targeting TNFα, has 
been shown to improve endothelial function in RA patients (Gonzalez-Juanatey et al., 
2008, Hurlimann et al., 2002). 
These observational studies support the hypothesis that elevation of pro-inflammatory 
cytokines promotes atherosclerosis; however, they do not explain how cytokines that are 
elevated as a result of RA promote atherogenesis at a molecular level.  One suggestion, by 
Sattar et al (2003), is that the mechanism may involve the pleiotropic functions of 
cytokines, since they mediate numerous metabolic effects in addition to their role in 
regulating immune responses and inflammation.  Importantly, such metabolic effects 
include transient alterations in lipids and peripheral insulin resistance (Feingold and 
Grunfeld, 1992).  In healthy individuals these responses are necessary, forming part of an 
effective short-term response to infection and inflammation.  However, the chronic 
elevation of certain cytokines observed during RA can have severe deleterious effects and 
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are capable of activating several physiological features known to increase the risk of 
developing atherosclerosis, including insulin resistance, dyslipidaemia and pro-oxidative 
stress (Feingold and Grunfeld, 1992, Guest et al., 2008, Prawan et al., 2009). 
Pro-inflammatory cytokines (e.g. TNFα and IL-6) and chemokines (e.g. IL-8 and 
monocyte chemoattractant protein-1 (MCP-1)) are significantly elevated in RA patients 
(Ellingsen et al., 2001, Endo et al., 1991).  Not only do these cytokines and chemokines 
play key roles in driving the synovial cell proliferation and chronic inflammation observed 
in RA, but they have also been demonstrated to play important roles in CVD pathogenesis.  
For example, IL-8 and MCP-1 have been suggested to play a pivotal role in atherosclerosis 
initiation by recruiting monocytes/macrophages to the vessel wall.  Furthermore, plasma 
concentrations of IL-6 have been suggested to reflect the intensity of plaque inflammation 
and the vulnerability to rupture (Ito and Ikeda, 2003). 
That systemic inflammation promotes CVD in RA is a hypothesis that has featured heavily 
in the literature on this subject (Sattar et al., 2003, Abou-Raya and Abou-Raya, 2006, 
Foster et al., 2010).  However, despite several mechanisms having been proposed, our 
understanding of the exact pathomechanisms that link these diseases remains incomplete.  
It is unknown whether the immune profile of patients with RA that go on to develop 
premature CVD differs from that of other RA patients; that certain RA patients have an 
altered immune profile which renders them at high risk of CVD is one possibility.  
 
1.5.4 Autoantigens and heat-shock proteins (HSPs) 
Autoantibodies against self-antigens have long been associated with RA (see section 
1.3.1.2).  Accordingly, a wide range of autoantigens have been described by the reactivity 
of antibodies present in the serum of RA patients.  The majority of suggested RA 
autoantigens fall into two distinct groups (Corrigall and Panayi, 2002).  The first group 
encompasses autoantigens associated with the joint, such as collagen type II, human 
chondrocyte glycoprotein 39 and proteoglycans.  The second group includes those proteins 
that are not associated with the joint.  Such proteins are made up of (1) post-translationally 
altered proteins, such as citrullinated filaggrin; (2) highly conserved antigens with foreign 
(bacterial, viral) homologues, such as heat shock proteins (HSPs), in which the initiating 
antigenic stimulus may be through infection; (3) ubiquitous proteins, such as glucose-6-
phosphate isomerase and HSPs released during times of stress. 
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It is well established that, within RA cohorts, traditional and non-traditional cardiovascular 
risk factors do not explain the observed increased CVD burden (Gonzalez et al., 2008), 
suggesting that alternative pathological processes may be responsible.  One potential 
explanation is that autoantigens and autoantibodies previously considered as specific to the 
pathology of RA are also contributing to the development and progression of CVD. 
In a study of 672 RA patients, it was determined that those positive for anti-cyclic 
citrullinated peptide (anti-CCP), a highly specific marker for RA, experienced more 
frequent ischaemic heart disease and had higher mortality rates.  Furthermore, there was no 
association between anti-CCP and established CVD risk factors (Javier Lopez-Longo et al., 
2009).  However, whether citrullinated proteins, peptidyl arginine deiminase (the enzyme 
responsible for citrullination) or antibodies against citrullinated proteins play a role in the 
development of CVD in RA patients remains unknown. 
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with many 
similarities to RA and for which the risk of fatal or debilitating CVD events is increased 
10-fold  (Hahn et al., 2007).  Accordingly this disease may provide a valuable insight into 
RA pathogenesis.  It has been shown that IgG autoantibodies which recognise high-density 
lipoproteins (HDLs), the major apolipoprotein constituent (Apo A-I) and also CRP exist in 
the sera of ~45% of SLE patients with high disease activity (O'Neill et al., 2010).  As all 
three of these molecules play roles in the pathogenesis of CVD, the clinical implications of 
such autoantibodies must be considered.  Several potential mechanisms by which these 
antibodies might contribute to CVD burden have been suggested (Hahn, 2010): (1) the 
binding of autoantibodies to HDL epitopes may remove the atheroprotective function of 
HDL; (2) soluble antibody-antigen complexes may attach to vascular tissue, fix 
complement, and trigger local inflammation; (3) antigen-antibody complexes are 
proinflammatory as immune recognition activates Fc expressing phagocytic cells; (4) 
antibody recognition is likely to interfere with normal metabolism of CRP, HDL and Apo 
A-I. 
It should also be noted that HSPs have been implicated as potential autoantigens in both 
RA and CVD (Pockley, 2002, Bodman-Smith et al., 2003).  In addition to being molecular 
chaperones, a significant element of the immune response to pathogens is directed towards 
HSP peptides (Kaufmann, 1990).  Furthermore, as the name would suggest, increased 
synthesis of HSPs occurs when cells are exposed to stress.  By increasing cellular HSP 
content, cells protect themselves from the uncontrolled protein unfolding that often 
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accompanies stress (Zuegel and Kaufmann, 1999).  As a result of the chronic inflammatory 
nature of RA, cells are constantly under the influence of pro-inflammatory signals, so it is 
not surprising that several members of the HSP family have been reported to be elevated in 
the serum and synovium of RA patients (Huang et al., 2009, Schett et al., 1998). 
Although the precise influence of HSPs on atherosclerosis remains unclear, an association 
between HSP expression and the induction of the inflammatory response that characterises 
the development of atherosclerosis has been demonstrated.  In one particular study 
intensity of HSP expression was found positively to correlate with atherosclerosis severity.  
At the same time a localised enrichment of T cells, with an ability to recognise HSPs, was 
detected in the lesion (Kleindienst et al., 1993).  Furthermore, immunisation of 
normocholesterolemic rabbits (Xu et al., 1992) and atherosclerosis model mice (Afek et al., 
2000) with mycobacterial HSP65 was found to induce atherosclerosis. 
Such studies raise the possibility that elevation of HSPs as a result of RA may lead to HSP 
overexpression at arterial sites vulnerable to atherosclerosis.  Such expression may further 
promote a localised arterial inflammatory response, resulting in recruitment of immune 
cells to the vessel wall.  This hypothesis is explored further in chapter 3. 
 
1.5.5 Bacterial triggers 
Despite conventional risk factors for CVD being well established, they can only account 
for 50 to 70% of CVD events within the general population (Haynes and Stanford, 2003), 
and even less in RA subjects (figure 1.5) (Gabriel, 2010).  Recently, infection has been 
proposed as playing an aetiological role in CVD.  In particular research efforts have 
concentrated on oral infection as an independent risk factor for CVD (Amar et al., 2003).  
Several epidemiological studies have supported a link between periodontal disease (PD) 
and CVD (Hung et al., 2003, Destefano et al., 1993).  CVD and PD are both major 
contributors to morbidity and mortality in developing and developed countries (Abou-Raya 
et al., 2007),  therefore quantification of their association may provide significant 
improvements to public health (Slots, 1998).  Furthermore, clinical studies support a 
significant association between RA and periodontal bacteria, with RA patients 
demonstrating a substantially higher incidence of PD when compared to age- and sex-
matched controls (Mercado et al., 2001) (Rosenstein et al., 2004).  Several anaerobic 
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periodontal pathogens have also been detected in both the synovial fluid and serum of 
patients with RA (Moen et al., 2006).   
Periodontal diseases, including gingivitis and periodontitis, are serious infections that when 
left untreated lead to inflammation and tooth loss.   
Two hypotheses to explain the link between infection and CVD and RA have been widely 
documented.  Firstly, inflammation as a result of local or systemic bacterial infection may 
stimulate a systemic inflammatory response that, in turn, could potentiate the onset of 
atherosclerosis and/or RA (the systemic inflammation hypothesis).  Alternatively, infection 
may lead to bacteraemia, with the potential for bacterial proliferation per se leading to 
atherosclerosis and/or RA (the bacteraemia hypothesis).   The following two sections will 
consider these two hypotheses (sections 1.5.5.1 and 1.5.5.2).  This is followed by 
suggestions as to how bacterial infection may help explain the link between RA and CVD 
(section 1.5.5.3).  
 
1.5.5.1 Systemic inflammation hypothesis 
Systemic inflammation as a result of either localised or systemic infection may contribute 
to both the development and maintenance of atherosclerosis through the activation of the 
immune and inflammatory cascade (Seymour et al., 2009).   
As previously discussed, endothelial dysfunction has been popularised as the first step in 
atherosclerosis development (section 1.4.3.2) (Higashi et al., 2008) (Cai and Harrison, 
2000).  There is a well-established link between inflammation and endothelial dysfunction.  
Several studies have established that chronic bacterial infection impairs vasodilation in 
otherwise healthy subjects (Charakida et al., 2005).  For example, Oshima et al (2005) 
demonstrated that PD impairs endothelium-dependent vasodilation but has no effect on 
endothelium independent vasodilation in hypertensive patients and subjects negative for all 
known cardiovascular risk (Oshima et al., 2005).   
Another way in which bacteria can potentially up-regulate immune responses remotely is 
by inducing autoimmunity against host vasculature cells.  Bacteria contain certain 
components that closely resemble host molecules.  Thus, an immune response triggered by 
bacterial infection may lead to production of autoaggressive T cells or cross-reacting 
autoantibodies (Leinonen and Saikku, 2002).  Heat shock proteins (Hsp) are an example of 
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autoimmunity-stimulating molecules, as they are widely conserved between both 
prokaryotes and eukaryotes.  Bacterial Hsp60 shares much sequence and structural 
homology with human Hsp60 and may be a candidate for triggering an autoimmune 
response which could lead to, or maintain, atherosclerosis.  
Other studies have implicated Porphyromonas gingivalis, the major periodontal pathogen, 
in playing a role in atherogenesis.  Pollreisz et al. in an attempt to reveal the effect this 
pathogen has on systemic inflammation, infected murine monocytes and macrophages with 
P. gingivalis (Pollreisz et al., 2009).  Infection with P. gingivalis significantly increased 
secretion of the pro-inflammatory cytokines IL-6 and TNF-α and stimulated monocyte 
migration.  Since both recruitment of monocytes/macrophages and the secretion of pro-
inflammatory cytokines are vital in the development of atherosclerosis, it is possible that P. 
gingivalis could be involved in the atherogenesis process. 
Furthermore, fibrinogen, a co-factor in platelet aggregation expressed during the acute 
phase response (Leinonen and Saikku, 2002), could help explain why infection may 
contribute to atherosclerosis.  Raised fibrinogen levels have been associated with 
atherosclerosis due to their effect upon platelet aggregation, leucocyte chemotaxis and 
vascular permeability (Levenson et al., 1995).  Equally, it has recently been demonstrated 
that periodontal infections are associated with increased fibrinogen concentrations in 
patients with CVD (Buhlin et al., 2009). Taken together, these findings imply that raised 
fibrinogen levels, as a result of infection, could increase the risk of CVD development.    
Bacteria may potentially alter host lipid metabolism, providing further support for the 
association between infection and CVD. Invasive bacteria are capable of altering host lipid 
metabolism in two ways.  Firstly, the LPS from Gram-negative pathogens have been 
demonstrated to reduce high density lipoprotein (HDL) cholesterol (Grunfeld and 
Feingold, 1992).  Secondly, during the acute phase response to infection, IL-1, IL-6 and 
TNFα release will increase triglyceride and cholesterol concentrations (Leinonen and 
Saikku, 2002).  Thus, it is possible that chronic infection leads to an expression of 
cytokines which can create a pro-atherogenic lipid profile.  
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1.5.5.2 Bacteraemia hypothesis 
If CVD development is found to be definitively associated with bacterial infection, a major 
hurdle to overcome will be in deciphering whether systemic inflammation or systemic 
infection is the causative link.   
The hypothesis that a local or systemic infection may be capable of triggering a systemic 
inflammatory response which could potentiate the onset of atherosclerosis has been 
discussed previously (section 1.5.5.1).  A similarly and equally plausible hypothesis is that 
subsequent to bacteraemia certain pathogens will be retained in the arterial vessel wall and 
trigger a localised inflammatory response associated with proteolytic and oxidative 
processes, eventually leading to atherosclerosis. 
Definitive proof that bacteria can potentiate atherosclerosis requires experimental 
modelling.  Murine models, following intravenous administration with the putative 
periodontal pathogen Porphyromonas gingivalis, have been found to go on to develop 
atherosclerosis (Li et al., 2002).   
A significant body of literature has established elevated concentrations of CRP as a risk 
factor for CVD (de Ferranti and Rifai, 2002).  Interestingly, elevated pathogen presence 
(either individually or as a cumulative pathogen burden) at the site of atherosclerosis has 
also been associated with an elevated concentration of CRP (Zhu et al., 2001a). This 
further implicates bacterial infection in the development of atherosclerosis.  
Several pathogens in particular have been associated with the development of 
atherosclerosis.  Viable Chlamydia pneumoniae (the human respiratory pathogen) has been 
commonly isolated from atherosclerotic plaques (Leinonen and Saikku, 2002).  However, 
of the periodontal bacteria (Porphyromonas gingivalis, Prevotella intermedia, 
Campylobacter rectus, Actinobacillus actinomycetemcomitans), association with 
atherosclerotic plaques has almost exclusively been determined by the presence of 
bacterial DNA, and not by culture dependent techniques.  A study conducted by Fiehn et al 
(2005) demonstrated that although DNA originating from periodontal pathogens could be 
isolated from atheromatous plaques, no viable oral bacteria could be isolated (Fiehn et al., 
2005).  These results could infer that if periodontal pathogens are in fact associated with 
CVD, it is either mediated by systemic inflammation or transient exposure to viable oral 
bacterial at the site of atherosclerosis.  Alternatively, as periodontal pathogens are mostly 
anaerobic, they may bury deep in the arterial tissue, making cultivation difficult.    
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Arterial infection may potentiate the onset and maintenance of atherosclerosis through 
interaction with the innate immune system (Edfeldt et al., 2002).  The expression of TLRs 
2, 4, 5 and 9, all of which possess the ability to recognise bacterial ligands, have been 
found to be upregulated in atheromatous tissue.  TLR stimulation will result in secretion of 
pro-inflammatory cytokines, which could potentiate atherosclerosis.  Arterial cells are 
responsive to a wide range of ligands for TLRs 2, 4, 5 and 9.  However, efforts to stimulate 
TLRs in vitro with homogenised atherosclerotic tissue have so far provided equivocal 
results, with ligands for only TLR2 only being stimulated by tissue homogenate (Erridge et 
al., 2008).  This observation may be the result of bacterial PAMPs being present in 
atheromatous tissue only transiently.  
If systemic bacterial infection was a risk factor for CVD, it could potentially allow 
intervention using conventional antibiotic treatment.  Antibiotic therapy with azithromycin, 
a broad-spectrum antibiotic suitable for treatment of Chlamydia pneumoniae and a range of 
periodontal pathogens in patients with history of myocardial infarction, did not 
significantly reduce any of the outcomes of CVD (myocardial infarction, angina and death) 
(O'Connor et al., 2003).  These results do not dismiss the possibility that bacteria play a 
role in the pathogenesis of CVD.  As previously mentioned, bacteria may exert their 
pathogenic effect only transiently, thus triggering an immune cascade capable of 
potentiating atherosclerosis.  
Antibiotics appropriate for the treatment of anaerobic pathogens, such as clarithromycin, 
ornidazole and levofloxacin, have been demonstrated to be effective against RA.  In one 
study, a significantly greater proportion of patients administered with 1000mg ornidazole 
met the 20% improvement criteria set by the American College of Rheumatology when 
compared to patients who were administered a placebo (Ogrendik, 2006).  However 
antibiotics, most notably clarithromycin, have been demonstrated to possess 
immunomodulatory functions and can inhibit TNFα and IL-1 synthesis.  As several 
biologic immunomodulatory drugs are currently used in the treatment of RA, it is possible 
that the mechanism of action of these antibiotics in the treatment of RA is not through their 
effect on bacterial viability. 
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1.5.5.3 Bacteria: a candidate to help explain the association between RA and CVD 
A high frequency of bacterial infection complicating RA has been described in case 
reports.  It has been suggested that this occurs due to both underlying disease 
complications as well as the side effects of immunosuppressive RA therapeutics (Smitten 
et al., 2008).  Data from longitudinal cohort studies have demonstrated that patients with 
RA are indeed at increased risk of developing infections compared to non-RA subjects 
(Doran et al., 2002) and that higher disease activity was associated with a higher 
probability of developing infections (Au et al., 2011).  Furthermore, it has been found that 
the elevated risk of infection leading to hospitalisation is associated with disease-
modifying anti-rheumatic drug (DMARD) use (Smitten et al., 2008).  
As previously discussed, RA is generally considered to have a multifactorial aetiology, 
with susceptibility presumed to be principally due to genetics combined with 
environmental triggers, of which bacterial infection is considered the most prominent.  
Most autoimmune diseases, including RA, are associated with specific HLA alleles.  
Greater than 90% of RA patients possess HLA-DR1 (Ebringer and Wilson, 2000).  It has 
been suggested that the involvement of HLA antigens in the pathogenesis of RA is due to 
molecular mimicry between certain bacterial antigens and HLA antigens (Wilson et al., 
2000).  
Considering all the evidence, it is plausible to hypothesise that RA increases a patient’s 
susceptibility to infection by bacterial pathogens.  Furthermore, the systemic inflammatory 
state present in RA may select for certain bacterial pathogens.  If correct, these could 
potentially increase the risk of pro-atherogenic bacteria entering the circulation of RA 
patients and help to explain why RA patients experience increased CVD burden. 
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1.6 Hypothesis and aims 
• It has been proposed that atherosclerosis begins in the aortic adventitia and 
progresses to the intima (the so-called ‘outside-in’ hypothesis), but this tissue has 
rarely been examined in the context of CVD.  Given that RA is a systemic 
inflammatory condition, it is plausible that this inflammation affects the vascular 
environment. 
 
  Is the aortic adventitia immunogenic? Does the inflammatory mileu of the 
aortic adventitia differ between CVD and RA+CVD patients? 
 
• Recently, infection has been proposed as playing an aetiological role in CVD.  
Owing to the pathological profile associated with RA, it is possible that patients are 
more susceptible to potentially pro-atherogenic bacterial infection. 
 
 Are bacteria present in the aortic adventitia, and do differences in the 
bacterial profile exist between CVD and RA+CVD patients?   
 
• Systemic inflammation in RA has been proposed as a major contributor to CVD co-
morbidity.  However, the immune profile of RA+CVD has not been characterised. 
 
 Does the systemic immune profile differ between RA, CVD and RA+CVD 
patients, and could any differences contribute to increased CVD burden in 
RA? 
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2 Materials and Methods 
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2.1  Immunohistochemistry 
2.1.1  Human subjects 
Patients were enrolled at a cardiac surgery centre (Feiring Heart Clinic, Feiring) and were 
matched at the group level for age and sex.  Patients were screened for the presence of RA 
according to the ACR and EULAR classification criteria (table 1.2).  The patients were 
evaluated preoperatively by a single rheumatologist (Ivana Hollan, Department of 
Rheumatology, Hospital for Rheumatic Diseases, Lillehammer, Norway) to verify the 
rheumatologic diagnosis and to assess disease severity and activity; blood samples were 
collected at that time.  Inclusion criteria for the RA group were age older than 18 years and 
a confirmed diagnosis of RA according to accepted criteria (Aletaha et al., 2010). 
 
2.1.2  Aortic adventitia paraffin sections 
The human aortic adventitia samples were from the Fering Heart Biopsy Study.  Aortic 
specimens were obtained from tissue that is routinely removed during CABG surgery.  
Subsequently, part of the adventitia covered by the epicardium was removed from the 
ventral part of the ascending aorta, and 1-3 punch holes were made through the vessel wall 
for proximal aortocoronary anastomoses in the same area.  To avoid thromboembolic 
complications, the specimens were obtained from areas with less pronounced gross signs 
of atherosclerosis.  A portion was fixed in formalin and then embedded in paraffin.  All the 
patients gave written informed consent.  Regional Ethics committee for Medical Research 
Norway approved the Feiring Heart Biopsy study. 
 
2.1.3  Haematoxylin and eosin staining 
Tissue sections were deparaffinised in two changes of absolute xylene for 10 minutes each 
followed by gradient rehydration in two changes of 100%, 90% and 70% ethanol (VWR, 
Lutterworth, UK) for three minutes each.  Sections were briefly rinsed in distilled water 
followed by immersion in Harris haematoxylin for five minutes.  Sections were then rinsed 
in running tap water for three minutes followed by differentiation in 1% acid alcohol for 30 
seconds.  The sections were then rapidly transferred into running water and rinsed for one 
minute and then blued in Scott’s tap water substitute for two minutes.  The sections were 
rinsed again in running tap water and counterstained in eosin for one minute.  Following a 
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rapid rinse in running tap water sections were dehydrated through an alcohol gradient of 
70%, 90% and 100% for three minutes each.  Sections were then transferred into absolute 
xylene for 10 minutes and then mounted with DPX (Sigma-Aldrich, Poole, UK). 
 
2.1.4  Optimisation 
Aortic adventitial tissue was scarce and prone to high levels of background staining.  As a 
result, immunohistochemistry staining was first established in human tonsil or RA 
synovium tissue.  Each antibody was optimised by altering elements of antigen retrieval, 
blocking systems and secondary antibodies.  Details of primary antibodies, retrieval 
systems and secondary antibodies are listed (table 2.1) and the final optimised protocol for 
each antibody is outlined in table2.2.  
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Table 2.1 Details of antibodies, antigen retrieval and immunohistochemistry system 
used in staining of human paraffin sections 
Antibody Code  Source Antigen Retrieval Staining System 
Heat shock ab1819 Abcam  Trypsin, 37oC,  Horse anti-mouse 
Protein 60     15 min   ImmPRESS 
 
Heat shock ab77609 Abcam  MW* 700w,   Horse-anti mouse 
Protein 47     15 min   ImmPRESS 
 
CD21  M0784  DAKO  Trypsin, 37oC,  ABC kit  
  Cytomation 30 min    
 
Calprotecin NA  NA  MW* 700w  Horse anti-mouse  
S100A9    15 min   ImmPRESS 
 
TNFα ab1793  Abcam             MW* 700w  Horse anti-mouse 
               15 minutes ImmPRESS 
CD68              MO876 DAKO             MW* 700w ABC 
 Cytomation     15 minutes 
 
 
2.1.5  Deparaffination and hydration 
Paraffin sections were cut (kindly performed by Ivana Hollan, Lillehammer, Norway)   to a 
thickness of 4-5 µm and then mounted on electrostatically coated microscope slides 
(VWR).  Deparaffination of the sections was carried out by initially incubating the slides at 
65oC for 45 minutes to soften the paraffin wax.  Sections were then deparaffinised by 
immersion in xylene for 10 minutes.  Following this, sections were hydrated by immersion 
in 100%, 90% and 70% ethanol for six minutes each followed by immersion in distilled 
water for five minutes.  The endogenous peroxidise activity was blocked by immersing 
sections for 30 minutes in 0.5% hydrogen peroxidise (Sigma-Aldrich) (Appendix 2) at 
room temperature.   
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2.1.6  Antigen retrieval 
Two different antigen retrieval methods (trypsin or citrate) were used, depending on which 
antibody was being used.  For trypsin retrieval each section was covered with trypsin 
(Vector Laboratories, Peterboroughm UK) working solution (appendix 2) and incubated at 
370C for 15 minutes to allow enzymatic activity and then left at room temperature for five 
minutes.  The sections were then washed in TBS buffer (Sigma-Aldrich) (appendix 2) for a 
further five minutes.  Antigen retrieval by citrate buffer (Vector Laboratories) (appendix 2) 
was performed by microwaving 600ml of citrate buffer for five minutes at 700 watts in 
order to bring the solution to the boil.  The slides were then added to the boiling solution 
and microwaved for a further eight minutes at 700 watts.  The sections were then left to 
cool for 15 minutes in the citrate buffer. 
 
2.1.7  Non-specific binding block and primary antibody 
Following antigen retrieval, and prior to primary antibody incubation, a non-specific 
binding block was performed for every section.  Non-specific binding was blocked by 
incubating sections with 5% normal horse serum (Vector Laboratories) for 30 minutes at 
room temperature.  This was followed by incubation with primary antibody overnight at 
4oC.  The optimal antibody concentration, and any alterations to the steps outlined here are 
listed in table 2.1 and 2.2.  Primary antibodies were diluted in TBS buffer (appendix 2) 
with 2.5% horse serum and 2.5% human serum.  
 
2.1.8  Secondary antibody and mounting  
Following incubation with primary antibody, sections were brought back to room 
temperature and washed twice in TBS buffer.  Each section was then incubated for 30 
minutes with the appropriate secondary antibody.  The most commonly used secondary 
antibody (table 2.2) was an antibody coupled to peroxidise molecules (ImmPRESS kit, 
Vector laboratories).  Sections were then washed twice in TBS buffer.  The staining was 
then developed with DAB (Diaminobenzidine: Vector Laboratories) (appendix 2) until 
positive proteins were visualised but background staining was not evident.  Stain 
development was stopped by immersing the sections in TBS buffer and then running under 
water.  Sections were then counter stained in haematoxylin and again immersed in running 
water.  The sections were then dehydrated by passing through 70%, 90% and 100% ethanol 
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for three minutes each and then immersing in xylene for 10 minutes.  A cover slip was then 
placed over each section using DPX (Di-N-Butyle Phthalate in xylene) (Sigma-Aldrich). 
 
2.1.9  Major staining steps for each antibody 
Immunohistochemistry protocols were optimised for each primary antibody (section 2.1.4).  
All optimisation was performed in paraffin-embedded human tonsil and if available 
rheumatoid synovium sections.  Antigen retrieval, antibody dilutions and staining systems 
were thus specific for each staining.  The major steps for each staining are highlighted in 
table 2.2 below. 
 
Table 2.2 Sequence of major immunohistochemistry steps performed 
Antibody Isotype   Order of primary steps     Positive 
dilution control    tissue 
  
CD21  Monoclonal      a) Antigen retrieval in 0.1% trypsin  Tonsil 
1/13  mouse IgG1      b) Endogenous peroxidise block 
         c) Non-specific block with 10% horse 
     serum 
         d) Primary antibody incubation in 2% 
     goat serum in PBS at RT for 90 minutes 
         e) Secondary antibody incubation with  
     biotinylated goat anti-mouse  
     immunoglobulin (1:200 dilution) 
         e) avidin/biotin complex 
         f) Developed with impact DAB 
TNFα  Monoclonal      a) Heat retrieval with citrate   Tonsil 
1/25  mouse IgG1      b) Non-specific block with 2.5% 
     horse serum 
         c) Overnight primary antibody incubation 
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     at 4oC 
         d) Endogenous peroxidise block 
         e)  Incubation with peroxidise linked  
     secondary antibody 
         f) Developed with impact DAB 
HSP60            Monoclonal      a) Antigen retrieval in 0.1% trypsin  Tonsil 
1/50             mouse IgG1      b) Non-specific block with 2.5% 
   horse serum 
       c) Overnight primary antibody incubation 
 at 4oC 
         d)  Endogenous peroxidise block 
         e) Incubation with peroxidise linked  
secondary antibody 
         f) Developed with impact DAB 
HSP47  Monoclonal      a) Heat retrieval with citrate   RA  
1/50 mouse IgG1      b) Non-specific block with 2.5%           synovium 
               horse serum 
            c) Overnight primary antibody incubation 
     at 4oC 
         d) Endogenous peroxidise block 
         e) Incubation with peroxidise linked 
     secondary antibody 
         f) Developed with impact DAB 
Calprotectin Monoclonal      a) Heat retrieval with citrate   Tonsil 
1/100  mouse IgG1      b) Non-specific block with 2.5% horse serum 
          horse serum  
         c) Overnight primary antibody incubation  
at 4oC 
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         d) Endogenous peroxidise block 
         e) Incubation with peroxidise linked  
     secondary antibody 
         f) Developed with impact DAB 
 
CD68 Monoclonal      a) Endogenous peroxidise block   RA        
1/100 mouse IgG1      b) Antigen retrieval with citrate            synovium 
        c) Incubation with non-specific binding 
    block plus avidin 
        d) Incubation with primary antibody 
    and biotin block 
        e) Secondary antibody incubation with 
    biotinylated pan-specific horse immunoglobulin 
        f) Incubation with avidin/biotin complex 
        g) Developed with impact DAB 
 
 
2.1.10  Analytical procedure and data collection 
The aortic adventitia is composed primarily of adipocytes, mesothelial, endothelial and 
smooth muscle cells.  There was also a varying extent of inflammatory infiltrate detectable 
in most sections.  Stained sections were analysed in random order while blinded to 
experimental data.  Sections stained by immunohistochemistry were analysed by light 
microscopy (Olympus IX51, Essex, UK).  When applicable, the extent of staining was 
measured in each cell type (mesothelial, endothelial, smooth muscle and inflammatory 
infiltrate).  The percentage of each cell type expressing the stained protein was then 
calculated and assigned a value (table 2.3). 
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Table 2.3  Scoring system for immunohistochemistry.  Percentage represents 
number of cells stained. 
 
2.1.11  Measuring surface area of section 
Total inflammation in the aortic adventitia was calculated using Cell^D software 
(Olympus).  Each section was first imaged by light microscopy at 100x magnification 
(Olympus IX51).  Sequential, non-overlapping images were captured spanning the entire 
surface area of each section.  The surface area of each picture was then measured using the 
Cell^D measurement package, thus allowing total section area to be expressed in µm2.  
Sites of inflammatory cell infiltrate were visually identified and measured in an identical 
manner.  Inflammatory cell infiltrate was then expressed as a percentage of the total 
section area. 
  
2.1.12  Statistical analysis 
Data was analysed using the most appropriate statistical test.  All results are accompanied 
with a description of the statistical test used.  When comparing two groups of normally 
distributed data a student’s t-test was used to determine statistical significance.  If the data 
was not consistent with normal distribution, differences in quantitative variables were 
analysed for with a non-parametric Mann Whitney U test.  In both cases a P value of <0.05 
was considered significant.  When applicable, graphs are displayed as dot plots to clearly 
illustrate the distribution of scores.  Statistical analysis was performed using either SPSS 
version 19 for PC (IBM Software, New York, USA) or GraphPad Prism version 4 for PC 
(GraphPad Software, Calofornia, USA).  
 
0% 0 
<10% 1 
10-25% 2 
>25% 3 
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2.2  Bacterial detection and investigation 
2.2.1  Aortic adventitia frozen sections 
Aortic tissue was collected as described in section 2.1.2.  A portion was snap frozen in 
liquid nitrogen upon removal and then stored at -80oC until required.   
 
2.2.2  DNA extraction from tissue samples 
At all stages a strictly aseptic procedure was used.  Tissue samples were lysed by 
incubation for 1 hour at 55oC with 15µl Proteinase K solution (20 mg/ml) (Sigma-Aldrich).  
Tissue samples were then homogenised on dry ice in 1.0ml TRIzol (Invitrogen, Paisley, 
UK) using a TissueRuptor kit and sterile probe (Qiagen Crawley, UK).  200µl of 
chloroform (Sigma-Aldrich) was added, followed by incubation at room temperature for 15 
minutes then centrifugation at 12.0 x g for 15 minutes at 4oC. The aqueous phase was 
removed, and the remaining interphase and organic phases were resuspended in 300µl of 
100% ethanol.  The sample was centrifuged at 12.0 x g for 5 minutes to form a DNA 
pellet.  The pellet was washed twice in 1ml 0.1M sodium citrate (Sigma-Aldrich) before 
being resuspended in 1ml 75% ethanol.  This was then centrifuged at 12.0 x g for five 
minutes at room temperature and the supernatant removed.  The remaining pellet was 
dissolved in 100µl of sterile water (Qiagen), and the DNA containing supernatant removed 
and stored at -20oC.  Control samples which replaced tissue sample with sterile water were 
run in parallel to monitor for sterility of reagents and apparatus (see section 2.2.7). 
 
2.2.3.  PCR amplification of 16S ribosomal DNA 
PCR amplification of 16S rRNA gene was performed using well established universal 
eubacterial primers (Marchesi et al., 1998): 5’- CAGGCCTAACACATGCAAGTC-3’ 
(63f) and reverse; 5’- GGGCGGWGTGTACAAGGC-3’ (1387r). The selected primers 
supported amplification of a 1324-bp segment of the 16SrRNA gene sequence.  PCR was 
performed in a total volume of 50μl containing 100ng of genomic DNA 1 x GoTaq® PCR 
buffer (Promega, Southampton, UK) 1.25 U GoTaq® polymerase (Promega) 1.5 mM 
MgCl2, 0.2 mM dNTPs (New England Biolabs, Hitchin, UK) and each primer at a 
concentration of 0.2 μM.  Thermal cycling was conducted using a MyCycler (Bio-Rad 
Laboratories, Hemel Hempstead, UK) and comprised one cycle of 95°C for 2 minutes, 
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followed by 35 cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1.5 minutes, 
followed by a final extension cycle at 72°C for 10 minutes. Each PCR reaction contained a 
negative control with sterile molecular grade water (Qiagen) replacing DNA; the positive 
control contained 100 ng DNA isolated from cat plaque (kindly donated by Sanne 
Dolieslager).  PCR products were then size separated by electrophoresis on a 2% agarose 
gel (Sigma-Aldrich) DNA bands were stained with ethidium bromide and visualised and 
photographed (Gel Doc XR+; Biorad). 
 
2.2.4  Cloning and restriction digestion 
PCR  products were ligated into the StrataClone® PCR Cloning Vector pSC-A-amp/kan 
(Agilent Technologies, Wokingham, UK)  followed by transformation into competent E. 
coli cells (Invitrogen) by heat-shock at 42oC.  Transformed cells were grown overnight at 
37oC on Luria-Bertani plates supplemented with 100mg/ml ampicillin (Invitrogen).  
Complete insertion was verified by PCR with M13 forward and reverse primers 
(Invitrogen).  The 16S rRNA gene insert was then subjected to restriction digestion.  0.5μl 
of each PCR reaction was digested in a total volume of 18μl containing 0.2μl of either RsaI 
or MnlI (Thermo Fisher Scientific, Loughborough, UK) at 37oC for one hour.  Digestions 
were spun down and run on a 2% agarose gel.  Clones were initially segregated into 
restriction fragment length polymorphism (RFLP) groups based on their RsaI profile, and 
then further discrimination was made based on the MnlI digestion profile. 
 
2.2.5  Sequencing 
The 16S rRNA gene insert of a single representative clone from each RFLP group was 
sequenced.  Sequencing was performed using the SequiTherm EXCELTM II DNA 
Sequencing Kit (Cambio, Cambridge, UK) and IRD800-labelled 357f sequencing primer 
(5’-CTCCTACGGGAGGCAGCAG-3’).  The following cycling parameters were used: (i) 
initial denaturation at 95oC for 30 seconds; (ii) 10 seconds at 95oC and 30 seconds at 70oC 
for 15 cycles.  Formamide loading dye (6μl) was added to each reaction mixture after 
thermal cycling and 1.5μl of each reaction mixture was run on a LI-COR Gene ReadIR 
4200S automated DNA sequencing system (MWG Biotech, Milton Keynes, UK). 
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2.2.6  DNA sequence analysis 
Sequencing data were converted to FASTA format and compared with bacterial 16S rRNA 
gene sequences from the EMBL and GenBank sequence databases using the BLAST 
program (Altschul et al., 1997).  The program was run through the National Centre for 
Biotechnology Information website (http://www.ncbi.nlm.nih.gov/BLAST).  Clone 
sequences that demonstrated at least 97% identity with a known sequence from the 
database were considered to be the same species as the matching sequence with the highest 
score.  Sequences with less than 97% identity were classified as potentially novel 
phylotypes. 
 
2.2.7   Contamination control  
Owing to the sensitivity of 16S rRNA gene sequencing it was vital to control for the 
introduction of contamination at every stage.  A negative control was processed in parallel 
with every tissue sample.  Each control was treated in exactly the same manner as the 
sample with the exception that sterile nuclease-free water was used instead of tissue.  To 
further ensure experimental sterility, each reagent used in the DNA extraction protocol was 
initially tested for the presence of possible bacterial DNA contamination.  Aliquots of 
TRIzol, chloroform, 100% ethanol, 75% ethanol, 0.1M sodium citrate (Sigma-Aldrich) 
isopropanol and DEPC treated water were allowed to completely evaporate from a 1.5ml 
eppendorf tube in a class II laminar flow hood and then resuspended in sterile nuclease-
free water (Qiagen).  Each sample was then subjected to Proteinase K digestion (Sigma-
Aldrich) followed by 16S rRNA gene amplification to determine if any contamination was 
present.  Each sample was diluted in mastermix (10, 4 and 1%) (Promega, UK) as 
excessive DNA concentrations can inhibit the PCR reaction by preventing product 
formation.  Samples were then subjected to PCR using exactly the same primers and 
conditions highlighted in section 2.2.3. 
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2.3        In vitro investigation of Methylobacterium sp. 
2.3.1     Culture of Methylobacterium mesophilicum and Methylobacterium 
oryzae 
Methylobacterium mesophilicum (1708) and Methylobacterium oryzae (18207) type strains 
were obtained from the DSMZ culture collection (DSMZ, Braunschweig, Germany).  Both 
strains were grown in nutrient agar (5g peptone, 3g meat extract, 15g agar for solid media, 
made up to 1000ml with distilled water) supplemented with 1% (v/v) methanol.  A pH of 
7.0 was maintained by the addition of hydrochloric acid (10mM). Strains were grown on 
solid agar in petri dishes or in 10ml tubes in a shaking incubator at 30oC. 
 
2.3.2  Scanning electron microscopy (SEM) 
Planktonic bacterial cells were examined by SEM, as previously described (Erlandsen et 
al., 2004).  Briefly, bacterial cells were centrifuged (400 x g) and resuspended in fixative 
(2% para-formaldehyde, 2% gluteraldehyde and 0.15M sodium cacodylate). The fixative 
was then replaced with 0.15M sodium cacodylate buffer, and samples washed for 3 x 5 
minutes. A 1% (w/v) osmium tetroxide (OsO4) solution was then added to an equal 
volume of 0.15M sodium cacodylate buffer for 1 hour. Samples were then rinsed three 
times with ddH2O for 10 minutes. 0.5% (v/v) aqueous uranyl acetate was then added, and 
samples were incubated in the dark for 30 minutes at room temperature. Samples were then 
dehydrated in an ascending ethanol series, followed by fixing in hexamethyldisilazane 
(HMDS) (Carbosynth, Berkshire, UK) for 2 x 5 minutes in separate containers. The 
samples were then placed in a dessicator overnight. The fixed and dried bacterial samples 
were sputter-coated with gold/paladium and viewed under a JEOL JSM-6400 scanning 
electron microscope (JEOL, Herts, UK). 
 
2.3.3  SVEC-10 murine cell culture  
A murine lymphoid vascular endothelial cell line (SVEC-10) (Oconnell and Edidin, 1990) 
immortalized with simian virus 40 (SV40) was grown in T-75 flasks at 37oC in 5% CO2 in 
Dulbecco’s medium (Sigma-Aldrich) supplemented with 100mM sodium pyruvate (Sigma-
Aldrich), 200mM L-Glutamine (Life Technologies, Paisley, UK), 10,000 units Pen-strep 
(Life Technologies) and 10% foetal calf serum (Sigma-Aldrich).  Cells were cultured until 
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90% confluence as determined by light microscopy and then split.  Growth media was 
removed then the cell monolayer was gently washed twice with sterile 1 x PBS (Sigma-
Aldrich).  The monolayer was then trypsinised by the addition of 5ml of sterile 1x 0.5% 
trypsin EDTA (Sigma-Aldrich).  This was then incubated at 37oC for three minutes or until 
de-attachment of the endothelial cells was visible by light microscopy.  The flask was then 
shaken firmly a couple of times and 10ml of complete media added to stop the 
trypsinisation reaction.   Cells were then removed and placed into a 15ml tube and 
centrifuged at 1500 rpm for 10 minutes.  The cells were then washed in fresh media and 
approximately 15% of the cells were used to seed a new T-75 flask. 
 
2.3.4  RAW 264.7 murine cell culture 
A murine leukaemic monocyte macrophage cell line (RAW 264.7) was grown in T-75 
flasks at 37oC in 5% CO2 in RPMI-1640 medium (Sigma-Aldrich) supplemented with 
200mM L-Glutamine (Life Technologies), 10,000 units Pen-strep (Life Technologies) and 
10% foetal calf serum (Sigma-Aldrich).  Cells were cultured until 90% confluence as 
determined by light microscopy and then split.  Growth media was removed and the cell 
monolayer was gently washed twice with sterile 1 x PBS (Sigma-Aldrich).  PBS was 
removed and 10ml of fresh complete media added.  The cells were then harvested using a 
cell scraper (Corning, USA).  The scraped cells in media were removed and placed into a 
15ml tube and centrifuged at 1500 rpm for 10 minutes.  The cells were then washed in 
fresh media and approximately 15% of the cells were used to seed a new T-75 flask. 
 
2.3.5 Isolation and culture of CD14+ monocytes by EasySep® positive 
selection 
Human buffy coats (the fraction of a total blood following gradient centrifugation that 
primarily contains white blood cells and platelets) were graciously provided by the 
Western Infirmary (Glasgow, UK).  The buffy coat was mixed in a 1:1 ratio with room 
temperature Dulbecco’s phosphate buffered saline (DPBS) without CaCl2 and MgCl2 
(Sigma-Aldrich).  3ml of Histopaque-1077 (Sigma-Aldrich) was added to 15ml falcon 
tubes and allowed to reach room temperature.  8ml of the diluted buffy coat was gently 
overlaid onto the histopaque-1077.  Tubes were spun at 400 x g with no brake for 30 
minutes at room temperature.  Peripheral blood mononuclear cells (PBMCs) were carefully 
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collected from the opaque interphase of PBS/Ficoll with a Pasteur pipette and transferred 
to a 50ml centrifuge tube.  The total volume was brought to 50ml by addition of DPBS 
modified without CaCl2 and MgCl2 and mixed by gentle inversion.  Cells were spun at 240 
x g for 10 minutes at room temperature with full break applied.  The supernatant was 
decanted taking great care not to lose any of the PBMC pellet.  The PBMC pellet was 
resuspended in 10ml of cell separation media (Ca2+/Mg2+ free PBS containing  2% FBS 
and 1mM sterile EDTA) and mixed by gentle trituration with a Pasteur pipette.  At this 
stage 50µl of PBMCs were removed for cell counting.  PBMCSs were then spun down at 
240 x g for 10 minutes at room temperature with full break applied and resuspended in a 
volume of cell separation media to obtain 1x108 PBMCs per ml. 
Once PBMCs had been isolated CD14+ cells were purified by EasySep® selection kit 
(StemCell Technologies, Grenoble, France) as per the manufacturer’s instructions.  This 
procedure supports processing of up to 2.5 x 108 PBMCs per preparation.  The cell 
suspension at a concentration of 1 x 108 PBMCs/ml of separation was transferred into a 12 
x 75mm polystyrene tube (Becton Dickson, UK) which fits into the EasySep®Magnet.  
PBMCs were labelled at room temperature for 15 minutes by addition of EasySep®Positive 
selection cocktail (StemCell Technologies) at 75µl/ml containing bispecific Tetrameric 
Antibody Complexes (TAC) directed against CD14 and dextran. Following this, dextran-
coated EasySep®Magnetic Nanoparticles (StemCell Technologies) were incubated with the 
cell suspension at 50µl/ml at room temperature for 10 minutes to allow cross-linking with 
the labelled cells.  The cell suspension was then placed into the EasySep®Magnet without 
the lid for 5 minutes.  The TAC + nanoparticle labelled CD14+ cells remain in the tube held 
by the magnetic field.  CD14+ cells were enriched by pouring off the material not held by 
the magnet.  This process of enrichment was repeated three times adding fresh separation 
media each time.  Finally, CD14+ enriched cells were harvested by removing the tube from 
the magnet.  
CD14+ monocytes were then cultured for seven days at 37oC in 5% CO2 in RPMI-1640 
medium (Sigma-Aldrich) supplemented with 200mM L-Glutamine (Life Technologies), 
10,000 units Pen-strep (Life Technologies) and 10% foetal calf serum (Sigma-Aldrich) as 
well as 15ng/ml human M-CSF (Peprotech, London, UK).  Cells were replenished in fresh 
media following three days of culture.  
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2.3.6   Purity evaluation of CD14+ cells by FACS analysis 
Flow cytometry was used to determine the final purity of the CD14+ monocytes obtained 
by the StemCell method.  Cell populations were analysed on a FACS caliber (BD 
Biosciences, Oxford, UK) with FlowJo software (Treestar, Ashland, USA) to evaluate pre 
and post separation cells.  The CD14+ purified cells, and CD14- cells (population not 
retained by the EasySep®Magnet) were stained for different cell surface antigens; CD3-
FITC (BD Biosciences), CD19-APC (BD Biosciences) and CD14-PE (BD Biosciences).  1 
x 106 cells from each population were transferred into FACS tubes and suspended and 
washed in 1ml of FACS buffer.  The supernatant was then aspirated and cells were 
resuspended in 50µl of FACS buffer.  2.5µl of each antibody was added to the cell 
suspension followed by a 15 minute incubation in the dark at 4oC.  500µl of FACS buffer 
was then added and FACS tubes were centrifuged at 421 x g for 5 minutes and the 
supernatant removed.  Cells were then fixed for later analysis by incubation with 250µl of 
Cytofix/Cytoperm (BD Biosciences) for 15 minutes at 4oC.  The cell suspension was then 
spun down at 400 x g for 5 minutes and the pellet was resuspended in 250µl 1 x permwash 
(BD Biosciences).  This was then centrifuged at 400 x g for 5 minutes and finally 350µl of 
FACS buffer was added.  Cells were then ready for acquisition. 
 
2.3.7 Methylobacterium challenge and RNA isolation 
Murine cell lines and human primary macrophages were cultured as described previously 
(section 2.3.3 – 2.3.5). 1 x 106 cells were seeded into each well of a 6-well plate and grown 
until they reached 100% (endothelial) and 70% (macrophage) confluence.  Cells were then 
challenged with exponentially growing Methylobacterium mesophilicum or 
Methylobacterium oryzae at an MOI of 200.  Methylobacterium sp. were spun down and 
resuspended in either Dulbecco’s media or RPMI media prior to inoculation.  Controls 
were included which were treated in exactly the same manner as above with the exception 
of no bacteria being inoculated into the flask.  Cells were harvested at 4 hours and 8 hours 
post infection. 
Total cellular RNA purification was carried out using an RNeasy Kit (Qiagen) according to 
the manufacturer’s instructions.  Briefly 600μl of buffer RLT was added to each well and 
allowed to incubate at room temperature for 2 minutes in order for complete cell lysis to 
occur.  Lysate was collected and 600μl of 70% ethanol added.  The sample was then mixed 
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and the entire contents loaded onto an RNeasy spin column and centrifuged at 8000 x g for 
15 seconds and the flow through discarded.  DNase digestion was then performed directly 
on the column to ensure no residual genomic DNA contamination.  Firstly the column was 
washed by spinning down for 15 seconds at 8000 x g with 350μl buffer RW.  10μl DNase I 
was mixed with 70μl buffer RDD.  The solution was then pipetted directly onto the 
membrane of the spin column and incubated at room temperature for 15 minutes, following 
which the reaction was then stopped by the addition of 350μl buffer RW1 to the column.  
The column was then centrifuged at 8000 x g for 15 seconds.  500μl of buffer RPE was 
then added to the column and also spun for 15 seconds at 8000 x g followed by disposal of 
the flow through.  As buffer RPE contains ethanol, an additional step to ensure no residual 
ethanol was present was carried out. This involved placing the spin column in a new 
collection tube and centrifuging for 1 min at full speed.  The RNA was then eluted into a 
sterile 1.5ml tube by placing 30μl of RNAse free water (Qiagen) onto the spin column and 
centrifuging for 1 minute at 8000 x g. 
 
2.3.8  cDNA synthesis 
Following RNA extraction the resulting concentration and purity was measured by 
NanoDrop spectrophotometry (Thermo Scientific).  RNA was regarded as sufficiently pure 
if the A260:A280 was within the range of 1.7-2.1.  500ng of RNA was subjected to reverse 
transcription.  As recommended for use with TaqMan Low Density Arrays (TLDA) 
(Applied Biosystems, Paisley, UK), cDNA synthesis was performed using a High Capacity 
RNA-to-cDNA Kit (Applied Biosystems, UK).  For each reaction the following reagents 
were added to a 200μl PCR tube on ice; 10μl 2x RT buffer, 1μl 20x RT enzyme mix; RNA 
(up to 9μl).  The total volume was then brought up to 20μl with the addition of nuclease-
free water (Qiagen).  For each sample a non-RT control was included.  For this, all stages 
remained the same with the exception of no 20x RT enzyme mix being added.  Each tube 
was briefly centrifuged to eliminate any air bubbles.  The tubes were then loaded onto a 
MyCycler Personal Thermal Cycler (Bio-Rad) and subjected to the following cycling 
conditions; 37°C for 60 minutes followed by 95°C for 5 minutes.  DNA contamination was 
analysed by standard PCR for murine or human GAPDH.  cDNA samples were stored at -
20°C until needed. 
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2.3.9  TaqMan mRNA analysis by RT-QPCR 
Gene expression was quantified using TaqMan Low Density Arrays (TLDA) (Applied 
Biosystems).  A TLDA array consists of a 384 well micro fluidic card that supports 384 
simultaneous RT-PCR reactions for targets that are pre-loaded onto each well.  A standard 
384-well Mouse Immune TLDA array or Human Immune TLDA array was used.  Each 
card contained 96 different Taqman gene expression targets and supported four parallel 
runs.  Appendix 6 lists the 96 genes that were included in this study, and provides a brief 
explanation of the corresponding protein function.  An average of 400ng of DNase-treated 
cDNA was used in each sample.  100μl of TaqMan gene expression mastermix (Applied 
Biosystems) and 100μl of cDNA in sterile water (Qiagen) was first mixed and then loaded 
onto the card.  This mixture was equally divided over two loading ports (100μl) each 
supplying 48 genes of interest.  The arrays were then centrifuged twice at room 
temperature for 2 minutes at 1300 rpm (Beckman Coulter, High Wycombe, UK, L-80 
ultracentrifuge) to ensure equal distribution of the sample.  Following this the card was 
sealed to prevent sample exchange between wells.  Real time qPCR was performed using 
an Applied Biosystems 7900HT Fast Real-Time PCR System.   The following thermal 
conditions were employed: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 
cycles of 30 seconds at 97°C and 1 minute at 59.7°C. 
 
2.3.10  TLDA analysis 
Gene expression was quantified using the comparative threshold (CT) method as suggested 
by the manufacturer (User Bulletin 2, Applied Biosystems).  This technique utilises the 
formula 2−ΔΔCT in order to calculate the relative number of gene transcripts.  The CT value 
represents the PCR cycle at which the amplified gene target reaches a defined threshold.  
40 PCR cycles were performed; accordingly the CT values can range from 0 to 40.  CT 
values for each immunological molecule were calculated.  If a CT value was greater than 
34, the datum was dismissed, as high CT values invariably give rise to poor precision and 
reliability.  CT values were calculated for the Methylobacterium sp.-stimulated sample and 
the non-stimulated control sample.  The CT of several endogenous control genes was also 
calculated.  GAPDH was calculated to be the most reliable endogenous control.  The ΔCT 
value was calculated [ΔCT = CT (target gene) − CT(GAPDH )].  This was performed for 
each gene in both the Methylobacterium sp.-stimulated sample and the non-stimulated 
control sample.  The relative expression of each gene was then calculated with the formula 
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ΔΔCT = ΔCT(positive sample) − ΔCT(control sample).  This was then expressed in terms of 
fold change relative to the control sample with the formula [fold change = 2- ΔΔCT].  For 
down-regulated genes (value less than 1) the negative inverse of the value was taken.  This 
allowed down-regulation to be expressed as a negative value.   
 
2.3.11  Ingenuity pathways analysis 
The ‘Core Analysis’ function included in the IPA (Ingenuity System Inc, Redwood City, 
USA) software package was used to identify and interpret the principal biological 
pathways and processes associated with human and murine macrophages following 
Methylobacterium sp., infection.  All identifier types (different gene transcripts) with a CT 
value of less than 34 were included in this study.  Identifier types were first normalised to 
GAPDH and then expressed as fold change relative to non-infected macrophages.   Both 
up- and down- regulated identifier types were defined as value parameters for analysis.  A 
working file was generated which contained one column including all the original gene IDs 
(Unigene nomenclature) and another column indicating fold change ± SD relative to 
control macrophages.  Following the analysis, generated canonical pathways and 
biofunctions were ranked by significance as tested by the Fisher’s exact test.  Canonical 
pathways were grouped into Signalling Pathways and Metabolic Pathways.  Similarly, 
biofunctions were grouped into Molecular and Cellular Functions and Disease and 
Disorders.  The number of molecules under investigation which are directly implicated in a 
given biological pathway or process were highlighted by the ration value function included 
in the IPA software package.  
 
2.3.12  TLR transfection assay 
HEK-293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-
Aldrich) supplemented with 10% foetal-calf serum for between three and seven passages.  
For the transfection assay HEK-293 cells were plated in 96-well plates at 8x103 cells per 
well in serum-free DMEM and transfected after 24 hours (50-80% confluent) using the 
Gene-juice kit (Novagen, Watford, UK) according to the manufacturer’s instructions.  
Amounts of construct per well were 30ng of human TLRs 2, 4 (co-expressing MD-2), 30ng 
pCD14, 20ng transfection efficiency control renilla luciferase-reporter construct (pRL-TK) 
and 10ng firefly luciferase-reporter construct driven by the NFkB dependent E-selectin 
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promoter (pELAM) cloned into pGL3 (Promega).  Cells were grown for 2-3 days post-
transfection prior to 18 hour challenge.  Reporter levels were normalised to co-transfected 
renilla luciferase and represented as fold induction relative to cells cultured in medium 
alone ± S.D.  Endogenous expression of TLRs in HEK-293 was ruled out by RT-PCR. 
 
2.3.13  Phenol extraction of LOS and LPS 
Bacteria were heat inactivated at 65oC for 1 hour.  Bacteria were then centrifuged at 6000 
rpm for 10 minutes (Sorvil centrifuge, SS34) and the supernatant discarded.  The pellet 
was resuspended at 10g/ml in dH2O and the cells were blended to a paste on ice using a 
homogeniser (Tissue Tearor, Biospec products Inc, Bartlesville, USA).  An equal volume 
of 85% liquid phenol (Sigma-Aldrich) was added and the solution was homogenised on ice 
for 5 minutes.  The mix was heated to 65oC and homogenised for 1 minute at 2 minute 
intervals for a total of 10 minutes.  The mix was then centrifuged at 600 x g at 4oC for 10 
minutes.  The aqueous layer was removed and stored temporarily at 4oC.  An equal volume 
of dH2O was added to the remaining sample and homogenised on ice repeating the steps 
outlined above.  The combined aqueous layers were then dialysed at 4oC for three days in 
six changes of 5 litres of dH2O using a 3.5kDa MWCO (molecular weight cut off) dialyser 
tube (Novagen, D-Tube Dialyzer Maxi).  The resulting extract was then stored at -20oC. 
2.3.14  Determination of LPS and LOS purity by silver stain 
SDS-PAGE electrophoresis of LPS and LOS was carried out using a NuPAGE 4-12% Bis-
Tris gel (Invitrogen) according to the manufacturer’s instructions.  5µg LPS/LOS was 
added to 5µl Tricine SDS sample buffer and 1µl Nupage reducing agent (Invitrogen).  The 
sample was heated to 95oC for 5 minutes and 10µl was loaded onto the gel.  The gel was 
run in Tricine SDS buffer (Invitrogen) at 125V for 90 minutes.  The gel was then subjected 
to silver staining using a SilverQuest staining kit (Invitrogen) as per the manufacturer’s 
instructions. 
 
2.4  Protein profile of human serum 
2.4.1  Patients and serum sample preparation 
Venous blood samples were collected from patients enrolled in the Feiring Heart Biopsy 
Study after a minimum of four hours fasting.  The subset of patients from the Feiring Heart 
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Biopsy Study examined included 16 patients with RA undergoing CABG (RA+CVD 
cohort), 19 patients without RA or any other form of IRD undergoing CABG (CVD 
cohort), 21 patients with RA and but no detectable CVD symptoms and 21 healthy controls 
(absence of any clinically significant disease, surgery or trauma; absence of drug or alcohol 
abuse; absence of pregnancy).  RA was confirmed according to the accepted ACR-EULAR 
diagnostic criteria (table 1.2).  Patient characteristics are outlined in table 5.1.  Whole 
blood was collected in sterile 4ml vacutainers without additives and allowed to coagulate 
at room temperature (<2 hours).  The samples were then spun to allow isolation of serum at 
2800 x g for 20 minutes at 4oC.  The serum was removed by pipette and transferred into a 
sterile 1.5ml tube for storage at -20oC until use.   
 
2.4.2  Luminex assay of human serum 
Serum samples from healthy individuals (n = 21), CVD patients (n = 19), RA patients (n = 
21) and patients diagnosed with both RA and CVD (n = 16) were analysed using a multi 
cytokine and chemokine bead array detection system capable of detecting human IL-1β, 
IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40/p70, IL-13, IL-15, IL-17, 
VEGF, TNFα, IFNα, GMCSF, MIP1a, MIP1b, IP-10, MIG, Eotaxin, RANTES, MCP-1, 
EGF, GCSF, FGF, HGF and IL-2R according to the manufacturer’s instructions (Human 
Cytokine Thirty-Plex Antibody Bead Kit, Invitrogen).  Briefly, 25μl 1 x beads (2.5 × 106 
beads ml-1 cytokine-1) with defined spectral properties were covalently conjugated to 
analyte specific monoclonal antibodies and then pipetted into each well of a 96-well filter 
bottom microplate.  The conjugated beads were exposed to 50μl of serum sample or 
standard solution containing a known concentration of each cytokine and incubated at 
room temperature on an orbital shaker (500-600 rpm) for two hours while being protected 
from light exposure.  After several washes and filtration by vacuum manifold to remove 
unbound protein, biotinylated detection antibodies specific for the epitopes of interest were 
added to the reaction and incubated for 1 hour at room temperature on an orbital shaker 
(500 – 600 rpm).  Following this incubation step, a series of washes and a vacuum 
filtration to remove unbound antibody was performed.   The reaction mixture was then 
detected by the addition of Streptavidin-R Phycoerythrin (Streptavidin-RPE) which binds 
with high affinity to the biotinylated antibodies.  A further series of washes and vacuum 
filtrations were then performed to remove any unbound material.  The beads were then 
resuspended in 100μl working wash solution and stored in the dark at 4oC until analysis.  
The reaction mixtures were analysed using a Luminex flow cytometer (Invitrogen).  The 
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lower detection limit for each mediator measured was 2pg/ml, any values lower than this 
were considered as 0 for this study.  The upper limit of detection was variable depending 
on the analyte and was dictated by the generated standard curve. 
 
2.4.3 sST2 ELISA 
96 well half-area ELISA plates (Corning Costar, Dorset, UK) were coated overnight at 
room temperature with 100μl/well of sST2 capture antibody (R&D Systems, Abingdon, 
UK) diluted to 2μg/ml in PBS.  Plates were washed twice with PBS/0.1% Tween (Sigma-
Aldrich) then blocked for 1 hour at 37oC with 300μl PBS/1% BSA (Sigma-Aldrich) per 
well.  After two washes in PBS/Tween followed by two washes in PBS, sST2 standards 
were diluted in PBS/BSA and added at 100μl per well to provide a standard curve.  A 
seven point standard curve using two-fold serial dilutions with a high standard of 
2000pg/ml was performed.  Serum samples were then added at 100μl per well and 
incubated at room temperature for two hours.  Plates were then washed with PBS/Tween 
before adding 100μl biotinylated detection antibody diluted to a working concentration of 
100ng/ml in PBS/0.1% Tween supplemented with 2% heat inactivated normal goat serum.  
Plates were then incubated for 2 hours at room temperature.  Once washed, 100μl of 
Streptavidin-HRP diluted to a working concentration of 2μg/ml in PBS/0.1% Tween was 
added to each well for 20 minutes at room temperature.  Following another wash step 
100μl substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine) (R&D Systems) 
was added to each well and incubated at room temperature for 20 minutes in the dark.  
Reactions were then stopped using the appropriate Stop Solution (2N H2SO4) (R&D 
Systems).  sST2 concentration was then quantified with reference to the standard curve at 
450 nm of a plate reader (Tecan, Sunrise and Magellan, Reading, UK). 
 
2.5  Lipoprotein isolation and oxidative modification   
2.5.1  Lipoprotein isolation 
50ml venous blood was taken from each of three healthy donors for LDL isolation.  All 
donors underwent a period of 12 hours fasting prior to blood collection.  Blood was 
collected in 0.4 mmol/EDTA.  Plasma was isolated from blood by centrifugation at 
3000rpm at 10oC for 30 minutes (L-80 ultracentrifuge, Beckman Coulter).  LDL isolation 
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was performed by density adjustment of plasma using potassium bromide (KBr) and 
discontinuous ultracentrifugation at 50,000 rpm at 10oC (L-80 ultracentrifuge, Ti 70 rotor).  
On the first day the non-protein solvent density of the pooled serum sample was adjusted 
to 1.022 g/ml by the addition of 0.2 g dry salt KBr per 10ml of plasma.  Following 
adjustment, the plasma was centrifuged at 10,000 rpm for 18 hours at 10oC.  On day two 
the non-protein solvent density of the serum sample was adjusted to 1.019 g/ml by the 
addition of solid salt KBr according to the following formula: 
𝐾𝐵𝑟 [𝑔] =  𝑣𝑜𝑙𝑢𝑚𝑒 𝑥 (𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝐴 − 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝐵)1 − 0.267 𝑥 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝐴 + 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝐵2  
where volume is the volume of the fluid (ml), density A is the desired density (g/ml), and 
density B is the actual density.  Following adjustment, the plasma was centrifuged at 
10,000 rpm for 18 hours at 10oC.  The top fraction (VLDL) was carefully removed and 
discarded.  The remaining plasma had the density adjusted to 1,063 g/ml by addition of 
KBr using the equation above and was again subjected to centrifugation at 10,000 rpm for 
18 hours at 10oC.  The top layer containing the LDL was gently removed using a pipette.  
Finally, the LDL stock was dialysed in dialysis tubes with a pore size of 50,000 Daltons 
(Millipore, Watford, UK) against 5 litres of PBS supplemented with 0.2mM EDTA in the 
dark (Note: if it was intended to oxidise the LDL stock immediately, there was no need to 
dialyse in the presence of EDTA).  Dialysis was performed over three days with two 
changes of buffer.  The resulting LDL was the stored at 4oC in the dark. 
 
2.5.2  Lipoprotein oxidation 
Prior to oxidation, the LDL stock was dialysed in dialysis tubes with a pore size of 50,000 
Daltons (Millipore) against 5 litres of PBS to remove all traces of EDTA.  Dialysis was 
performed over three days with two changes of buffer.   The preparation was then passed 
through a 0.45µm filter (Millipore) to sterilise and remove lipoprotein aggregates.  150µl 
of this preparation was stored at 4oC for a modified Lowry protein determination (Section 
2.5.3).  The remaining LDL stock (2mg/ml) was oxidised by addition of 10µM CuSO4 and 
incubated for 18 hours at room temperature in the dark.  To stop the oxidation reaction and 
prevent further modification 0.25mM EDTA was added to the solution.  Oxidised LDL 
was again sterilised by passing through a 0.45µm filter and then stored at 4oC in the dark. 
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2.5.3  Modified Lowry protein assay 
The modified Lowry protein assay was used to measure the final concentration of purified 
LDL.  A 2x Lowry concentrate was prepared by mixing three parts copper reagent 
(appendix 3) to one part (1% sodium dodecyl sulphate) and one part (1M NaOH).  A 
standard was prepared from 0.2mg/ml bovine serum albumin (BSA) (Thermo Scientific).   
Eight two-fold serial dilutions were made of both the LDL and the BSA.  50µl of 2x 
Lowry solution was added to every 50µl of sample and mixed thoroughly before 
incubating at room temperature for 10 minutes.  After this, 25µl of 0.2N folin reagent 
(VWR) was then added and incubated at room temperature for 30 minutes.  Finally, the 
samples were analysed using a plate reader at 502nm to obtain OD readings.  A standard 
curve was prepared from the BSA and the concentration of LDL was extrapolated.   
 
2.5.4  Lipoprotein electrophoresis 
Lipoproteins isolated from the blood of healthy donors were oxdatively modified by 
copper sulphate.  Electrophoresis was used to confirm that oxidative modification was 
occurring as necessary.  Native LDL from the same samples was used as a control.  Prior 
to agarose gel electrophoresis lipoprotein was stained with Nile Red.  This allows LDL to 
be visualised by UV light following electrophoresis.  20µl of working Nile Red solution 
(10µg per ml of acetone) (Sigma-Aldrich) was added to 1.5ml tubes and allowed to 
evaporate fully.  50µl LDL was added to the tube and agitated for 10 seconds, followed by 
addition of 5µl of 30% w/v sucrose solution.  A 0.6% agarose gel in 50mM barbital buffer, 
pH 8.6 was prepared by microwaving (appendix 3).  The agarose solution was allowed to 
cool for five minutes and then poured into the running tray.  Once the gel was fully set the 
electrophoretic chamber was filled with 50mM barbital buffer, pH 8.6.  The gel was loaded 
with 15µl of Nile Red stained LDL and subjected to electrophoresis at 56V for 2 hours.  
The gel was imaged under UV light (Alpha Innotech, Alphalmager, East Sussex, UK). 
 
2.6  In vitro foam cell investigation 
2.6.1  Foam cell formation 
Human primary macrophages were isolated (section 2.3.5) and cultured for six days in 24 
well tissue culture plates (BD Biosciences, UK) with RPMI (Life Technologies) 
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supplemented with 15ng/ml M-CSF.  Cells were then incubated with 200μg/ml oxLDL for 
1 hour.  Foam cell formation was then visualised following Oil-red-O staining (section 
2.6.2). 
 
2.6.2  Oil-red-O staining and foam cell quantification 
Oil-red-O staining was used to image lipid uptake.  The steps outlined here were optimised 
for cells cultured in a 24-well plate.  All reagents were used at room temperature.  Cell 
culture medium was removed and the cells were twice washed gently with 250µl PBS.  
Following complete removal of the PBS, cells were incubated in 250µl 10% formalin/PBS 
for 15 minutes and then washed twice in ddH2O.  Cells were then washed in 250µl of 60% 
isopropanol/H2O for 5 minutes.  Following complete removal of the wash solution, cells 
were incubated with Oil-Red-O working solution (appendix 3) for 30 minutes.  The cells 
were then washed in ddH2O until the water rinsed off clear.  The cells were then immersed 
in 200µl ddH2O and the intracellular distribution of lipid droplets was imaged by light 
microscopy (Olympus IX51).   
 
2.6.3  Luminex assay of GM-CSF stimulated macrophages 
Human primary macrophages were isolated (section 2.3.5) and cultured for six days in 24-
well tissue culture plates (BD Biosciences) with RPMI (Life Technologies) supplemented 
with 15ng/ml M-CSF.  Cells were then stimulated overnight with 125ng/ml GM-CSF or 
vehicle control before the supernatants were removed and subjected to Luminex analysis as 
described in section 2.4.2. 
 
 
2.6.4  Dextran sulphate-mediated inhibition of foam cell formation 
Human primary macrophages were isolated (section 2.3.5) and cultured for six days in 48-
well tissue culture plates (BD Biosciences) with RPMI (Life Technologies) supplemented 
with 15ng/ml M-CSF.  Cells were then stimulated overnight with 125ng/ml GM-CSF or 
vehicle control.  The following day cells were challenged with 200μg/ml oxLDL and 
varying concentration of dextran sulphate (Millipore) (0, 2 10, 20 and 40μg/ml) and 
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incubated at 37oC in 5% CO2 for 24 hours.  Resulting foam cell formation was then 
visualised following Oil-red-O staining (section 2.3.9). 
 
2.7  Quantitative PCR 
2.7.1  cDNA synthesis and normalisation 
cDNA was synthesised according to the manufacturer’s instructions using the supplied 
reagents (Superscript III First-Strand Synthesis System, Invitrogen) (Note: this method of 
cDNA synthesis was specific for qPCR, and differed from the method outlined in section 
2.3.8). 120ng RNA was diluted in 4μl RNase-free H2O (Qiagen) and 1μl random primers 
and 1μl dNTPs was added to each sample. Samples were placed in the thermocycler for 5 
minutes at 65oC and then on ice for 1 minute. The cDNA synthesis mix was prepared on 
ice by mixing 2μl of 10x RT buffer, 4μl 25mM MgCl2, 2μl 0.1M DTT, 1μl RNaseOUT 
and 1μl SuperScript III Reverse Transcriptase. 10μl cDNA Synthesis mix was added to 
each sample. For the control samples, Superscript III Reverse Transcriptase was replaced 
by an equivalent volume of RNase-free H2O. Samples were placed in the thermal cycler 
for 50 minutes at 50oC then 85oC for 5 minutes. In order to remove any remaining RNA, 
1μl RNase-H was added to each cDNA sample and incubated at 37oC for 20 minutes. 
cDNA was stored at -20°C. 
 
2.7.2  Primer design 
Sets of primers were designed for quantitative PCR using the PrimerBLAST software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  All primer sets used are described in 
appendix 4.  
QPCR primer specifications were as follows: 
• Amplicon size less than 150bp 
• Between 18 and 23 base pairs in length 
• Between 40 and 65% GC content (50% optimal) 
• Maximum 3’ self complimentarity: 1  
• Maximum self complimentarity: 2 
• Tm of primers within 59.5oC and 61oC (60oC optimal) 
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• Not more than two G or C bases in the last five bases at 3’ end of each primer (i.e. 
no GC clamp) 
• Avoid stretches of four or more G or C bases in a row 
If these conditions did not support generation of appropriate primers then the self 
complimentarity was relaxed from two to three and the primer Tm reduced to 59oC.  The 
only condition that was never relaxed was maximum 3’ self complimentarity. 
BLAST analysis was used to ensure that primer sequences were specific to the gene of 
interest alone and that no splice variants existed that could confuse the analysis.  
 
2.7.3  SYBR QPCR protocol 
Each QPCR reaction was performed in triplicate.  In order to ensure homogeneity a master 
mix was prepared for each reaction prior to plating out triplicates.  Each master mix 
reaction contained: 
• 33µl SYBR Green FastMix (Quanta Biosciences, Lutterworth, UK) 
• 23.3µl neuclease free water (Qiagen) 
• 1.2µl primer mix (each primer mixed together at 50pmol/µl) 
• 4µl cDNA (equivalent to 24ng cDNA) 
This was then mixed by pipetting at least five times.  20µl of the master mix was then 
pipetted into each of the three wells (triplicates) on a 96-well QPCR plate (Star Lab, 
Milton Keynes, UK).  A non-template control (NTC) was included to determine the level 
of contamination and to show the detection limit of the assay.  The plate was spun for 10 
seconds at 400 x g  to ensure that the contents of each well were at the bottom of the plate.  
Using the 9700HT QPCR machine (Applied Biosystems) a fast run was performed, which 
used the following reaction conditions: 
• Initial three minutes at 94oC (not repeated) 
• 5 seconds at 94oC then 15 seconds at 60oC, repeated 40 times (measuring 
fluorescence at the end of each 60oC elongation step). 
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2.7.4  Analysis of QPCR data  
Gene expression was quantified using the relative quantification (RQ) method.  This 
technique utilises the formula 2−ΔΔCT in order to calculate the relative number of gene 
transcripts.  The CT value represents the PCR cycle at which the amplified gene target 
reaches a defined threshold.  40 PCR cycles were performed; accordingly the CT values 
can range from 0 to 40.  CT values for each triplicate were measured and the mean 
calculated.  If a CT value was greater than 34, the data was dismissed.  CT values were 
calculated for the stimulated samples and the non-stimulated control samples.  The CT of 
the endogenous control gene 18S was also calculated.  The ΔCT value was calculated [ΔCT 
= CT (target gene) − CT(18S)].  This was performed for each gene in both the stimulated 
sample and the non-stimulated control sample.  The relative expression of each gene was 
then calculated with the formula ΔΔCT = ΔCT (positive sample) − ΔCT(control sample).  
This was then expressed in terms of fold change relative to the control sample with the 
formula [fold change = 2- ΔΔCT].  For down-regulated genes (value less than 1) the negative 
inverse of the value was taken.  This allowed down-regulation to be expressed as a 
negative value.   
 
2.8  FACS analysis of scavenger receptors 
Human primary macrophages were stained independently for both MARCO (extracellular) 
(Santa Cruz, Middlesex, UK) and SR-B1 (intracellular) (Novus Biologicals, Cambridge, 
UK).  Macrophages were washed in PBS and then resuspended in 50μl FACS buffer. Cells 
were then incubated with 5μl Fc Block (BD Biosciences) for 15 minutes at 4oC before 
being spun down at 400 x g for five minutes.  For antibodies specific to extracellular 
proteins (MARCO) cells were then aspirated and then incubated with 1μl un-conjugated 
rabbit anti-human primary antibody specific to MARCO (Santa Cruz) or rabbit IgG as the 
isotype control (BD Biosciences) for 15 minutes at 4oC in the dark.  For antibodies specific 
to intracellular proteins (SR-B1), macrophages were first permeabilised by incubating in 
250μl cytofix/cytoperm (BD Biosciences) for 15 minutes at 4oC in the dark before being 
washed twice in 1x permwash (BD Biosciences).  Cells were then aspirated and then 
incubated with 1μl of an un-conjugated rabbit anti-human primary antibody specific to SR-
B1 (Southern Biotech, USA) or rabbit IgG as the isotype control (BD Biosciences) for 15 
minutes at 4oC in the dark.  For both extracellular and intracellular specific antibodies, 
cells were then resuspended in 1ml FACS buffer or permwash respectively, before being 
69 
 
 
 
spun at 400 x g for 5 minutes and aspirated.  Samples were then incubated with anti-rabbit 
IgG-PE (Southern Biotech, Cambridge, UK) for 15 minutes at 4oC in the dark.  Finally the 
stained cells were spun down at 400 x g for five minutes before being resuspended in 
350μl FACS buffer and acquired on a MACSQuant (Miltenyi Biotec, Surrey, UK).  The 
resulting data was analysed using Flowjo software (Treestar). 
 
 
 
 
 
 
 
 
 
 
 
 
  
70 
 
 
 
3 Cellular composition and cytokine 
expression in the aortic adventitia of human 
subjects with cardiovascular disease in the 
presence and absence of rheumatoid arthritis 
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3.1  Introduction  
RA is a chronic systemic inflammatory disorder that principally affects synovial joints.  
RA is associated with increased CVD as a result of accelerated atherosclerosis.  Although 
the underlying mechanisms of vascular comorbidity in RA are not known, it is 
hypothesised that the increased risk of CVD is driven by systemic inflammation and/or 
increased expression of autoantigens (Sattar and McInnes, 2005). 
The extent of systemic inflammation is significantly greater in RA patients than in 
individuals without the disease.  Indeed, inflammation in RA patients is often well above 
the levels that arise as a result of lifestyle factors, including smoking, obesity, reduced 
activity or as a result of blood vessel pathology.  Several studies support the hypothesis 
that elevated inflammation plays a fundamental role in the accelerated CVD observed in 
RA: 
 Murine studies demonstrate that pro- inflammatory cytokines promote 
atherogenesis, whereas inhibition of these cytokines reduces CVD risk (Huber et 
al., 1999, Steffens et al., 2005) 
 Therapeutic reduction of inflammation in RA improves endothelial function and 
lipid profile (Dixon and Symmons, 2007) 
 RA severity predicts CVD risk (Jacobsson et al., 2001, Maradit-Kremers et al., 
2005) 
 CVD risk in RA cannot be accounted for by traditional risk factors (del Rincon et 
al., 2005). 
Analysis of protein and mRNA has revealed that many pro-inflammatory cytokines such as 
IL-1, IL-6, TNFα, GMCSF and TGFβ are abundant in the synovium and serum of patients 
with RA (Feldmann et al., 1996).  The release of pro-inflammatory cytokines in RA may 
be crucial in the initiation of co-morbid CVD.  It has been demonstrated that TNFα is 
capable of initiating a pro-inflammatory response and acts as an alarm to injury.  If the 
release of TNFα is blocked, expression of pro-inflammatory cytokines such as IL-6 and IL-
1 will decrease (Fong et al., 1989).  TNFα-mediated induction of numerous cytokines, 
chemokines and adhesion molecules (Doukas and Pober, 1990, Schroder et al., 1990) is of 
key importance in attracting leukocytes to areas of injury.  TNFα is a pleiotropic cytokine 
that orchestrates systemic inflammation and stimulates the acute phase response.  TNFα 
has previously been detected in both the RA synovium (Ohta et al., 2001) and murine 
atherosclerotic lesions (Zhang et al., 2007).  The reduction of inflammation in RA that is 
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observed following anti-TNFα therapy appears to be associated with a concomitant 
reduction in CVD risk (Avouac and Allanore, 2008).  As RA patients have elevated levels 
of systemic TNFα, we  hypothesise that TNFα may be over-expressed in the aortic tissue 
of these individuals, which may be associated with an increased risk of CVD. 
Atherosclerosis is a chronic inflammatory disease in which both humoral and cell-
mediated immune responses participate (Hansson, 1997).  In advanced stages of 
atherosclerosis, inflammatory cell infiltrates are often detected in the aortic adventitia 
adjacent to sites of atherosclerotic plaque.  Immunohistochemical studies by a previous 
PhD student (Ahmed, 2010) in our group showed small aggregates of CD20+ B cells and 
occasional plasma cells in the aortic adventitia of CVD patients (unpublished results).  
These observations suggest that lymphoid follicle-like organisations,  which develop in a 
variety of autoimmune mediated inflammatory diseases such as RA (Randen et al., 1995), 
may be present in the aortic adventitia of CVD patients.   
Follicular dendritic cells (FDCs) form a contiguous network that is vital for formation and 
survival of germinal centres in response to signals that include TNFα.  Mice expressing a 
mutant form of TNFα that cannot be released do not form primary follicles (Ruuls, 2001).  
In primary follicles, FDCs are localised in the central region, whereas germinal centre 
FDCs exhibit a polarised distribution.  In both primary follicles and germinal centers, 
FDCs and mature B cells are recognised by antibodies to CD21, also known as 
complement receptor 2 (Imal and Yamakawa, 1996).  CD21 is required for germinal centre 
development, antibody production and B cell tolerance.  To evaluate whether lymphoid 
follicle-like structures were present in patients with CVD, we used immunohistochemical 
staining for CD21.   
The role of autoantigens in the onset of atherosclerosis and RA has gained support in 
recent years.  Heat shock proteins (HSPs) are highly conserved molecules that execute a 
range of functions including assembly, folding and translocation of proteins (Hightower, 
1991).  In addition to being molecular chaperones, HSPs are immunodominant molecules 
and a substantial proportion of the immune response against pathogenic microorganisms is 
targeted towards pathogen-derived HSP peptides (Kaufmann, 1990, Young, 1990).  Given 
the phylogenetic homology between prokaryotic and mammalian homologues of these 
molecules (for example, 60% of residues are shared across the HSP60 family) there is a 
concept that pathogen-derived HSPs may be recognised by the host immune system as 
autoantigens, in a process known as molecular mimicry (Kaufmann, 1990).  
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Immunological recognition of cross-reactive HSP epitopes could present a link between 
autoimmunity and infection (Lamb et al., 1989).   
Among the immuno-pathological factors shared by RA and atherosclerosis, a subset of 
CD4+/CD28- T cells have been implicated.  HSP60 is a mitochondrial chaperone protein 
responsible for ATP dependent folding of 15-30% of total cellular protein.  It has been 
identified as a dominant autoantigen recognised by CD4+/CD28- T cells (Zal et al., 2004).  
As previously highlighted, molecular mimicry between host and pathogen HSPs may lead 
to the targeting of self HSP60 by auto- reactive T and B cells.  Although HSP60 is 
normally only expressed intracellularly, it can also be expressed on the surface of 
endothelial cells in response to pro-inflammatory cytokines such as TNFα and IL-1α (Xu 
et al., 1994).  We hypothesised that the systemic proinflammatory profile of RA patients 
may lead to overexpression of HSP60 in aortic tissue, triggering a CD4+/CD28- T cell 
autoimmune response that leads to an increased risk of atherosclerosis. 
HSP47 is a heat shock protein and molecular chaperone that interacts with procollagen 
during its folding, assembly and transport from the endoplasmic reticulum in mammalian 
cells (Tasab et al., 2000).  Histological studies demonstrate that little or no HSP47 is 
expressed in healthy artery samples.  Conversely, HSP47 is observed in ~65% of 
atherosclerotic tissue and is mostly expressed in lipid-rich regions of the fibrous cap and 
smooth-muscle-like cells (Rocnik et al., 2000).  Collagen plays a pivotal role in the 
pathogenesis of both CVD and RA.  The accumulation of fibrillar collagen during plaque 
formation can trigger arterial stenosis. Conversely, inadequate collagen production or 
failure in the breakdown of collagen can lead to plaque rupture (Davies and Thomas, 
1984).  RA is categorised as a collagen vascular disease  ― a group of diseases that also 
includes dermatomyositis and scleroderma  ― which affects the collagen that constitutes 
connective tissue, bones and tendons being affected (Das, 1991).  In RA, an autoimmune 
reaction is mounted against collagen structures and ultimately leads to their destruction 
(Kim et al., 2004).  As HSP47 is necessary for correct and regulated collagen expression, 
we hypothesised that dysregulation of HSP47 may be central to pathogenesis of both CVD 
and RA.  Furthermore, HSP47 antigen and antibody levels have been demonstrated to be 
significantly elevated in patients with RA (Yokota et al., 2003). 
Recently, two novel pro-inflammatory proteins belonging to the S100 family of calcium- 
binding proteins have been characterised: S100A8 and S100A9 (Striz and Trebichavsky, 
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2004).  These two proteins can form either monovalent homodimers or a heterodimer, 
termed calprotectin, in a calcium-dependent manner (Mortensen et al., 2009).  Calprotectin 
is principally expressed in neutrophil granulocytes, however  the level of expression is 
dependent upon inflammatory status and stage of myeloid cell differentiation (Striz and 
Trebichavsky, 2004). Current knowledge of the expression of calprotectin on other cell 
populations is limited.  Research into the regulation of calprotectin has elucidated that 
calprotectin expression can be induced by a variety of stimuli, including bacterial LPS, 
IFN-γ and TNF-α (Xu and Geczy, 2000).  The principal function of calprotectin is as an 
antimicrobial agent.  However, calprotectin can also participate in various innate immune 
processes, including chemotaxis and cellular adhesion (Ryckman et al., 2003).  We 
hypothesise that calprotectin expression will be detectable in the aortic adventitia of CVD 
patients and that calprotectin expression would be dysregulated in subjects with systemic 
inflammation resulting from RA.  Furthermore, detection of calprotectin in the aortic 
adventitia may indicate previous or present exposure to potentially pathogenic bacteria.  
To increase understanding of the link between RA and CVD, we collected aortic adventitia 
samples during CABG surgery from 20 patients with RA and 19 control patients matched 
for age, family history of CVD, BMI and other traditional CVD risk factors. 
The objective of the research described in this chapter was to determine and compare the 
expression of several possibly pro-atherogenic proteins and to determine the cellular 
composition in the aortic adventitia of patients with CVD either with or without RA.  The 
principal aims of this study were: 
1. Quantify the extent of inflammatory infiltration within the aortic adventitia 
of RA patients with CVD compared to patients with CVD alone. 
2. Determine whether the aortic adventitia of RA patients with CVD has an 
association with TNFα, which may orchestrate an elevated pro-atherogenic 
response, and to relate expression of TNFα to presence of inflammatory 
infiltrate. 
3. Investigate the presence of CD21, a marker of follicular dendritic cells, to 
determine whether lymphoid follicle-like organisations exist in the aortic 
adventitia of CVD patients. 
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4. Determine if the potential autoantigens HSP60 and HSP47 are present 
within the aortic adventitia of RA patients with CVD in comparison to CVD 
patients without RA . 
5. Detect and quantify calprotectin, a pro-inflammatory and anti-microbial 
protein, in the adventitia of RA patients with CVD and compare to patients 
with CVD alone. 
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3.2 Results 
3.2.1 Patient characteristics 
Human aortic adventitia biopsy samples were from the Feiring Heart Biopsy study.  All 
biopsies were obtained from patients undergoing routine coronary artery bypass graft 
(CABG) surgery.  The demographic data and prevalence of traditional CVD risk factors 
was similar in the group with RA and the control group (CVD only) (table 3.1).  The time 
period from initial angiography to CABG surgery was shorter for RA patients than control 
patients.  RA patients had higher levels of inflammatory biomarkers.  RA patients were 
treated with a range of steroidal and non-steroidal anti-inflammatory drugs.  A total of 39 
sections were included in the following studies, which comprised patients with RA and 
CVD (n=19) and patients with CVD only (n=20). 
 
3.2.2 Morphology of aortic adventitia sections 
Aortic adventitia sections were stained with Haematoxylin & Eosin and examined by light 
microscopy.  The aortic adventitia biopsies predominantly consisted of smooth muscle 
cells and connective tissue fibres and contained variable amounts of adipose tissue.  Small 
vessels, termed vasa vasorum were regularly visible; these vessels function to supply the 
adventitia with oxygen and essential nutrients.  Endothelial cells surrounded the vasa 
vasorum.  Nerves (nervi vasorum) were detectable in several sections.  Adventitial 
inflammatory infiltrates were frequently observed, consistent with biopsies being from 
patients with CVD.   The aortic adventitia was contained within a mesothelial layer.  
Figure 3.1 illustrates these key cell types. 
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 RA 
(n=19) 
Non-RA 
 (n=20) 
P value 
Age – years  69±9 68±9 0.746 
Males – no. (%) 12 (63) 14 (70) 0.651 
Duration of CVD – years 6.3±8.7 7.2±6.6 0.378 
History of myocardial infarction – no. (%) 15 (79) 9 (45) 0.048 
Acute coronary syndrome – no. (%) 9 (47) 4 (20) 0.096 
Time from angiography to CABG – days 17±30 31±60 0.944 
Left ventricle ejection fraction – no. (%) 59±13 64±13 0.237 
C-reactive protein – mg/litre 23±40 3±3 0.006 
Erythrocyte sedimentation rate – mm/hour  34±29 15±10 0.047 
Serum PTX3 2.07±1.00 1.48±0.86 0.067 
Body mass index – kg/m2 25±5 25±2 0.761 
Hypertension – no. (%) 13 (68) 9 (45) 0.200 
Family history of CVD – no. (%) 11 (58) 20 (100) 0.001 
Hyperlipidemia – no. (%) 16 (84) 20 (100) 0.106 
Diabetes – no. (%) 2 (11) 1 (5) 0.605 
Previous smoker – no. (%) 10 (52) 12 (60) 0.751 
Current smoker – no. (%) 2 (11) 1 (5) 0.605 
Current use of:    
   Oral glucocorticosteroids – no. (%) 8 (42) 0 (0) 0.001 
   Disease modifying drugs – no. (%)# 16 (84) 0 (0) <0.001 
   Cox2-selective inhibitors – no. (%) 5 (26) 0 (0) 0.020 
   Traditional NSAIDs – no. (%) 2 (11) 0 (0) 0.231 
   Lipid-lowering drugs – no. (%) 16 (84) 19 (95) 0.342 
   Acetylsalicylic acid – no. (%) 17 (90) 17 (85) 1.000 
   Betablockers – no (%) 15 (88) 15 (79) 0.662 
   ACE inhibitors – no. (%) 5 (31) 6 (30) 1.000 
Duration of IRD – years  17 (15) - - 
Patient global assessment of RA (VAS, 0-100 
millimetre) 
29±24 - - 
Number of swollen joints  4.2±5.3 0 <0.001 
History of aortic aneurysm 1 (5) 0 (0) 0.487 
Table 3.1.  Patient characteristics 
*Unless indicated otherwise, values represent mean ± SD. Numbers may not add up to the 
expected total due to missing data for some variables. ACE: angiotensin–converting 
enzyme. CVD: cardiovascular disease. NSAIDs: non-steroidal anti-inflammatory drugs. 
VAS: visual analogue scale. 
# Azathioprine=1, suphasalazine monotherapy=2, auranofine=1, CPH-82=1, 
leflunomide=2, methotrexate monotherapy=7, etanercept and methotrexate=1, 
suphasalazine and hydroxychloroquine=1. 
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Figure 3.1. Morphological and cellular characterisation of the aortic adventitia 
Representation of typical structures observed in the aortic adventitia.  Sections were 
stained with H&E and imaged by light microscopy (200x, unless otherwise stated).  
Smooth muscle cells (A); Connective tissue fibres (B); Vasa vasorum (C); Nerve (D); 
Endothelial cells* (E); Adipose tissue (F); Mononuclear cell infiltrate (G) and Mesothelial 
cells (100x)* (H).  Arrows have been inserted for clarity.   
*Endothelial and mesothelial cells were distinguished by location.  Endothelial cells lined 
the inner layer of the vasa vasorum.  Mesothelial cells form the simple squamous 
epithelium that lines areas of the adventitia. 
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3.2.3 Inflammation in the aortic adventitia 
Inflammatory cell infiltrates have previously been detected in the aortic adventitia of 
patients with CVD (Ramshaw and Parums, 1990).  As RA and CVD are both inflammatory 
conditions, we hypothesised that co-morbid patients may exhibit exaggerated aortic 
inflammation.    
We examined 19 CVD+RA and 20 CVD only aortic adventitia biopsies taken from the 
Feiring Heart Biopsy Study.  Atherosclerotic lesions (plaques or fatty streaks) were 
detected in 4 of 19 (21%) patients with RA and in 3 of 20 (15%) patients without RA 
(P=0.63).  All lesions were confined to the media of the biopsies (data based on surgeons 
perioperative observation).   
Nine of the 19 patients with RA (47%) and 9 of 20 CVD only patients (45%) had 
inflammatory infiltrate in the aortic adventitia (p=0.30).  There was no significant 
difference between the two cohorts in either the number of inflammatory infiltrates or the 
size of the largest inflammatory infiltrate per section (table 3.2).  Inflammatory infiltrates 
were detected in the perivascular region (around the vasa vasorum), diffusely in connective 
and adipose tissue and most commonly as a submesothelial infiltrate (figure 3.2). 
The occurrence of inflammatory infiltrates in the adventitia of 30 matched internal 
mammary samples was significantly lower than in the corresponding aortic adventitia 
(0.02%±0.001 and 0.2±0.67 respectively) (figure 3.5).  The largest inflammatory infiltrate 
as a percentage of the total section in the aortic adventitia and internal mammary was 3.6% 
and 0.2% respectively.  
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Figure 3.2 Histological examination of aortic adventitia inflammatory infiltration by 
light microscopy    
A, Localised submesothelial mononuclear cell infiltration in a patient with CVD only. B, 
Submesothelial mononuclear cell infiltration in a patient with co-morbid RA and CVD. C, 
Diffuse submesothelial infiltration in a patient with CVD only.  D, Pronounced 
mononuclear cell infiltration in the inner adventitia in a co-morbid patient.  Sections were 
stained with Haematoxylin and Eosin and imaged with a 10x objective.  
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RA + 
CVD CVD P value 
No. of adventitial inflammatory infiltrates 
  
0.22 
0 10 (21) 11 (55) 
 1 3 (16) 5 (25) 
 2 1 (5) 1 (5) 
 3 1 (5) 2 (10) 
 >3 4 (26) 1 (5) 
 Size of largest adventitial infiltrate as % of 
section 
  
0.35 
0 10 (53) 11 (55) 
 <0.5 8 (42) 7 (35) 
 0.5-1 1 (5) 1 (10) 
 1-3 0 (0) 0 (0) 
 3-5 0 (0) 1 (10) 
 >5 0 (0) 0 (0) 
 
    Total infiltrate as % of section 2.5 3.2 0.53 
 
Table 3.2  Number and size of inflammatory infiltrates in the aortic adventitia of 
patients with RA + CVD and CVD only   
Values represent the number (%) of patients. Data represents 19  RA + CVD patients and 
20 CVD only patients.  Statistical analysis was performed by Mann Whitney U test suitable 
for non-parametric data. 
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Figure 3.3 Inflammatory infiltrates in the aortic adventitia of RA+CVD and CVD 
only patients 
Sites of inflammation were measured and expressed as a percentage of the total section 
area.  The comparison between the CVD+RA and CVD only group was not significantly 
different (mean ± SD of 0.15±0.26 and 0.28±0.81 respectively).  Statistical analysis was 
performed with a Mann Whitney U test for non-parametric data.  A p-value of <0.05 was 
considered statistically significant.  
 
Figure 3.4 Number of inflammatory infiltrates in the aortic adventitia of RA+CVD 
and CVD only patients 
The number of independent inflammatory sites was not significantly different between the 
RA+CVD group and the CVD only group (mean ± SD of 1.6±2.5 and 0.8±1.2 
respectively).  Statistical analysis was performed with a Mann Whitney U test for non-
parametric data.  A p-value of <0.05 was considered statistically significant.  
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Figure 3.5 Aortic inflammation in matched human aortic adventitia and internal 
mammary artery 
Sites of mononuclear cell inflammation were measured and expressed as a percentage of 
the total section area.  Statistical analysis was performed with a Mann Whitney U test for 
non-parametric data.  A p-value of <0.05 was considered statistically significant and is 
represented as an (*). 
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3.2.4 Relationship between vascular inflammation and traditional CVD risk factors 
We analysed the relationship between the occurrence of inflammation, the number of 
inflammatory infiltrates and the total area of inflammatory infiltration in the aortic 
adventitia with the following factors: sex, age, duration of CVD, BMI, and CRP level.  
Vascular inflammation did not correlate with any of the CVD risk factors considered here 
(table 3.3 and figure 3.6).  
 
 
Figure 3.6 Analysis of potential inflammatory infiltrate risk factors 
The number of independent inflammatory infiltrates were determined in all patients (n=39) 
and correlated with a variety of potential risk factors.  Representative graphs show 
correlation of inflammatory infiltrate number with age, B.M.I, CVD duration and CRP.  P 
value was calculated by spearman rho and r2by linear regression. 
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Table 3.3 Predictors of the presence, number and area of inflammatory infiltrates in the aortic adventitia 
Area of inflammatory infiltrates was recorded as a % of the total section area occupied by inflammatory infiltrates.  Spearman’s rank correlation coefficient 
(non-parametric) was used to examine statistical dependence. Non-significant  (ns); *p<0.05; **p<0.01; ***p<0.001  
 All Patients  
(n=39) 
CVD only  
(n=20) 
RA + CVD  
(n=19) 
Predictor Inflammatory 
infiltrate 
presence 
Number 
of 
infiltrates 
Area of 
infiltrates 
Inflammatory 
infiltrate 
presence 
Number of 
infiltrates 
Area of 
infiltrates 
Inflammatory 
infiltrate 
presence 
Number of 
infiltrates 
Area of 
infiltrates 
Age 0.64 (ns) 0.68 (ns) 0.80 (ns) 0.52 (ns) 0.44 (ns) 0.79 (ns) 0.94 (ns) 0.88 (ns) 0.58 (ns) 
B.M.I 0.70 (ns) 0.81 (ns) 0.65 (ns) 0.81 (ns) 0.68 (ns) 0.81 (ns) 0.54 (ns) 0.62 (ns) 0.81 (ns) 
CVD duration  0.85 (ns) 0.85 (ns) 0.55 (ns) 0.80 (ns) 0.87 (ns) 0.70 (ns) 0.52 (ns) 0.59 (ns) 0.12 (ns) 
C.R.P 0.66 (ns) 0.13 (ns) 0.70 (ns) 0.11 (ns) 0.12 (ns) 0.41 (ns) 0.43 (ns) 0.99 (ns) 0.45 (ns) 
Hypertension 0.43 (ns) 0.75 (ns) 0.67 (ns) 0.31 (ns) 0.36 (ns) 0.27 (ns) 0.43 (ns) 0.46 (ns) 0.67 (ns) 
E.S.R 0.21 (ns) 0.57 (ns) 0.48 (ns) 0.82 (ns) 0.67 (ns) 0.38 (ns) 0.56 (ns) 0.05 (ns) 0.39 (ns) 
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3.2.5 Detection of TNFα in the aortic adventitia of CVD patients with and without 
RA 
Having confirmed the presence of inflammatory infiltrates in the aortic adventitia, the 
predominant inflammation in the vessel made TNFα an obvious choice for investigation.  
To investigate the presence of TNFα we first had to establish a technique for detection.  
The initial experiments were carried out on sections of tonsil biopsies, as the number of 
aortic adventitia sections was limited.  To determine the optimal antigen-retrieval method 
for TNFα immunohistochemistry, a series of methods with varying primary antibody 
concentration were performed (figure 3.7). 
 
3.2.6 TNFα immunohistochemistry established in human tonsil 
Tonsil biopsies were fixed in paraformaldehyde and then paraffin embedded.  Sections 
were cut and mounted on glass slides.  In order to determine optimal staining conditions, 
sections were subjected to different antigen retrieval mechanisms and different dilutions of 
anti-TNFα primary antibody, and the quality of staining was determined by light 
microscopy.  A trypsin retrieval system was used first: this enzymatic reaction is designed 
to break protein cross-links formed during fixation and unmask antigens and epitopes of 
interest.  The trypsin retrieval technique was desirable as, unlike alternative techniques, 
trypsin retrieval does not involve a boiling step and leads to less tissue damage during 
processing.  A 1/50 (as per manufacturers recommendation) and a 1/25 dilution of the 
primary antibody was used.  The results demonstrated that this antigen retrieval method 
was not successful at unmasking the TNFα epitope and rendered this technique unsuitable 
(figure 3.7.A and 3.7.B).   
The next antigen retrieval method evaluated used citric acid (pH 6).  Due to the boiling 
stage, this method is considered harsh and could lead to tissue damage.  This technique led 
to clear cell specific TNFα staining and left the isotype control completely clear (figure 3.7 
C and 3.7 D.).  Furthermore, there was no evidence of tissue remodelling or damage 
following the boiling stage.  It was also found that a 1/25 primary antibody dilution gave 
superior staining to a 1/50 dilution.  Additionally, a further improvement to the staining 
procedure was made by performing a peroxidise block following incubation with the 
primary antibody, instead of prior.  
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Figure 3.7 TNFα staining using different antibody concentration and antigen retrieval 
systems 
To establish optimal TNFα staining different antigen retrieval systems were tested on 
tonsil sections. Figures A and B show trypsin retrieval using a 1/50 and 1/25 antibody 
dilution respectively.  Figures C and D show citric acid retrieval using a 1/50 and 1/25 
antibody dilution respectively.  Figure D shows strong TNFα staining (brown colour) with 
no background staining detectable in the isotype control.  Sections were counterstained 
with haematoxylin to define nuclei and cytoplasm.  Images were acquired by light 
microscopy with a 10x objective lens.  
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To summarise, citric acid retrieval with a primary antibody dilution of 1/25 and peroxidise 
block following primary antibody incubation  resulted in clear isotype controls and a 
strong, cell specific positive staining.  Accordingly, this optimised staining technique was 
used to stain the aortic adventitia sections. 
 
3.2.7 Immunoreactivity for TNFα in RA+CVD and CVD only patients 
Tissue was obtained from the aortic adventitia of 19 patients with RA and CVD and 20 
patients with CVD only.  Mononuclear cell infiltrates expressing TNFα were identified in 
tissues from both cohorts, with strongest staining in areas of large submesothelial 
infiltration.  TNFα was also detected in inner adventitia inflammatory infiltrates but at a 
lower frequency.  Other cells that displayed immunoreactivity for TNFα included smooth 
muscle cells that surrounded larger vasa vasorums, however this staining was far weaker 
than that observed in the inflammatory infiltrates. Observable levels of TNFα were present 
in 12 of the 19 RA+CVD patients and 6 of the 20 CVD only patients (figure 3.8). 
TNFα staining was scored in a blinded manner.  Each section was imaged and the number 
of independent sites of TNFα staining were recorded.  All inflammatory and smooth 
muscle cells were then imaged at high magnification, and the overall percentage of cells 
that expressed TNFα was recorded and assigned a score of 0-3 (no staining, >0%<10%, 
10-25% and  >25% respectively).  The TNFα score was significantly greater in the 
RA+CVD group compared to the CVD only group (p=0.02) (figure 3.9).  Furthermore, 
there was a trend towards an increased number of independent TNFα-expressing sites in 
the RA+CVD group compared to the non-RA group (figure 3.8), however the difference 
did not reach statistical significance (p=0.06).   
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Figure 3.8 Number of sites of TNFα staining in the aortic adventitia of RA+CVD 
and CVD only patients   
(A) The number of independent sites of TNFα staining was not significantly different 
between the RA+CVD and CVD only group with a mean ± SD of 1.5±1.7 and 0.6±1.1 
respectively.  Statistical analysis was performed with a Mann Whitney U test for non-
parametric data (p=0.06). (B) Representative image of TNFα in an inflammatory infiltrate 
of the aortic adventitia (400x magnification).   
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Figure 3.9 Quantitative scoring of TNFα in smooth muscle cells and inflammatory 
cells in the aortic adventitia of RA+CVD and CVD only patients   
The number of smooth muscle cells and inflammatory cells were approximately counted 
and each section was scored according to the percentage of cells expressing TNFα. 0, 
negative; 1, >0%<10%; 2, 10-25%; 3, >25%.  A significant difference was observed 
between the RA+CVD and CVD only cohort with a mean ± SEM of 1.2±0.26 and 0.3±0.13 
respectively.  p=0.02 represented (*) (Mann Whitney U test). 
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3.2.8 Relationship between TNFα and adventitial inflammation 
Our data have so far demonstrated that TNFα is expressed in the aortic adventitia of 
patients with CVD.  Furthermore we have observed a significant increase in TNFα 
expression in patients with co-morbid RA.  We also found inflammatory cells are present 
in the aortic adventitia of a large proportion of patients with CVD (n=39) and that TNFα 
was principally expressed by inflammatory cells in the tissue.  We therefore hypothesised 
that, in the aortic adventitia, TNFα expression would positively correlate with the number 
of inflammatory infiltrates.  A linear regression analysis revealed that the number of sites 
of TNFα expression did not significantly correlate with the number of inflammatory 
infiltrates when all patients were included (n=39) (p=0.055, r2=0.26), however there was a 
strongly significant correlation when considering only the RA+CVD patients (p=0.0058 
**, r2=0.59) (figure 3.10 & figure 3.11).  These data suggest that the increased CVD 
burden in RA patients may be partly explained by an increase in risk of TNFα expression 
within inflammatory infiltrates of the aortic tissue.   
 
3.2.9 Relationship between TNFα expression and traditional CVD risk factors 
The relationship between the number of independent TNFα sites and the extent of TNFα 
staining (TNFα score) in the aortic adventitia with the following factors was analysed: age, 
duration of CVD, BMI, ESR, hypertension and CRP level.  When considering all patients 
(n=39), CRP positively correlated TNFα score (p=0.02).  However significance was lost 
when considering RA+CVD patients and CVD only patients independently.  No other 
significant correlations were observed.  Table 3.4 highlights all correlations performed.   
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Figure 3.10 TNFα and inflammatory infiltrates in all patients 
Levels of adventitial TNFα and number of inflammatory infiltrates were determined in all 
patients (n=39).  The number of inflammatory infiltrates was correlated with the number 
of independent sites of TNFα expression (p value=0.055 with r2 0.26) (A) and the TNFα 
score (p value=0.0073 with r20.18) (B).  P value was calculated by spearman rho and r2by 
linear regression. 
 
 
Figure 3.11 TNFα and inflammatory infiltrates in RA+CVD patients 
Levels of adventitial TNFα and number of inflammatory infiltrates were determined in 
RA+CVD patients (n=19).  The number of inflammatory infiltrates was correlated with the 
number of independent sites of TNFα expression (p value=0.0058 with r2 0.59) (A) and the 
TNFα score (p value=0.02 with r20.38) (B).  P value was calculated by spearman rho and 
r2by linear regression. 
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 All patients 
(n=39) 
 CVD only 
(n=20) 
 RA + CVD 
(n=19) 
 
Predictor No. of TNFα areas TNFα score No. of TNFα areas TNFα score No. of TNFα areas TNFα score 
Age 0.34 (ns) 0.53 (ns) 0.25 (ns) 0.22 (ns) 0.58 (ns) 0.89 (ns) 
B.M.I 0.39 (ns) 0.54 (ns) 0.41 (ns) 0.47 (ns) 0.97 (ns) 0.88 (ns) 
CVD duration 0.17 (ns) 0.17 (ns) 0.76 (ns) 0.82 (ns) 0.18 (ns) 0.26 (ns) 
C.R.P 0.06 (ns) 0.02 * 0.37 (ns) 0.43 (ns) 0.29 (ns) 0.12 (ns) 
Hypertension 0.34 (ns) 0.36 (ns) 0.18 (ns) 0.19 (ns) 0.48 (ns) 0.45 (ns) 
E.S.R 0.37 (ns) 0.31 (ns) 0.46 (ns) 0.39 (ns) 0.89 (ns) 0.96 (ns) 
 
Table 3.4 Predictors of the number of TNFα areas and the extent of TNFα (TNFα score) in the aortic adventitia 
For each section the number of independent TNFα areas was recorded and a score assigned (percentage of smooth muscle cells and inflammatory cells were 
scored according to the percentage of cells expressing TNFα. 0, negative; 1, >0%<10%; 2, 10-25%; 3, >25%).  Spearman’s rank correlation coefficient 
(non-parametric) was used to examine statistical dependence. Non-significant (ns); *p<0.05; **p<0.01; ***p<0.001  
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3.2.10 Expression of TNFα in RA+CVD serum 
Serum samples were collected from 15 of the 20 CVD patients and all 19 RA+CVD 
patients (n=19).   TNFα levels were measured by Luminex assay and found to be 
significantly higher in the RA+CVD group compared to the CVD only group [36.6 ± 22 
versus 3.7 ± 1.6 pg/ml respectively, p=0.0008] (figure 3.12).  However, converse to 
expectation, serum TNFα did not positively correlate with TNFα expression in matched 
aortic adventitia biopsies (p=0.10, spearman rho). 
 
 
 
Figure 3.12 Levels of TNFα expression in serum of RA+CVD and CVD only patients  
A significant difference was observed between the RA+CVD and CVD only cohort with a 
mean ± SE of 36.5±22 and 3.7±1.6 pg/ml respectively.  p=0.0008 (***) (Mann Whitney U 
test) 
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3.2.11 CD21 expression in the aortic adventitia 
Having confirmed the presence of inflammatory infiltrate, TNFα and B cells (experiment 
conducted by Ammad Ahmed 2010) in the aortic adventitia, we next sought to determine 
whether germinal centres, a site of intense B lymphocyte maturation, were present in the 
aortic adventitia of patients with CVD.  I therefore set out to establish primary 
follicle/germinal centre staining in human tonsil with an antibody raised against CD21. 
To optimise the staining I tried trypsin, citrate and Tris EDTA antigen retrieval with the 
immPRESS method.  Positive staining was not apparent in any of these attempts.  I next 
attempted to use the Avidin/Biotin (ABC) method with a biotinylated secondary antibody.  
Again attempts with all three antigen retrieval methods similarly resulted in no positive 
staining.  In an effort to further optimise this staining method I altered the primary 
antibody incubation conditions.  Unlike other immunohistochemistry experiments 
illustrated in this chapter, I did not incubate the samples with the primary antibody at 4oC 
overnight, instead incubating at room temperature for 90 minutes.  This approach led to 
clear cell-specific staining with no background and no signal detectable in the isotype 
control (figure 3.13).  The quality of staining was further improved by performing a non-
specific block with 10% horse serum, instead of the usual 2.5%, and by incubating the 
primary antibody in a solution made up of PBS and 2% goat serum. 
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Figure 3.13 CD21 mAb selectively stains germinal centers 
In an attempt to detect follicular dendritic meshwork was highlighted by staining for CD21 
in human tonsil sections.  Isotype controls are shown in the left column (negative).  (A) 
Representative image of failed CD21 staining attempts (100x). (B) CD21 staining using 
avidin/biotin complex with primary antibody incubation at room temperature for 90 
minutes. (C) Same as B with altered serum block and primary antibody buffer conditions. 
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Germinal centers were detected in tonsil sections and the surrounding follicular mantle 
zone ― the outer ring of lymphatic follicles that surround  a germinal centre and contains 
transient lymphocytes (figure 3.14).   Dense networks of FDCs were visible in germinal 
centres and, to a lesser extent, in the follicular mantle. 
 
 
Figure 3.14  mAb CD21 stains tonsillar germinal centres                                                          
(A) anti-CD21 staining of FDC networks within a germinal centre (GC) as well as B 
lymphocytes within the follicular mantle (FM) (100x) (B) High magnification of the 
germinal centre shown in figure A.  FDCs can be distinguished as large cells containing 
one or two big nuclei and branched projections.  Follicular dendritic networks are clearly 
visible (400x). 
 
We were not able to detect CD21 positive cells in any of the aortic adventitia samples 
(figure 3.15).  This interesting observation is surprising as morphology presumed to be 
follicle-like structures were microscopically observed in several of the aortic adventitia 
sections (figure 3.15 D).  However these support the notion that germinal centers are not 
present in the aortic adventitia. 
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Figure 3.15  CD21staining in aortic adventitia 
CD21 was not detectable in the aortic adventitia.  Images above are representative of 
sections that were hypothesised to contain CD21 positive germinal centres.  (A) 
Submesothelial infiltrate (400x) (B) Pronounced adventitial infiltrate (400x) (c) 
Pronounced adventitial infiltrate with localised areas of dense inflammatory cells (100x) 
(D) High magnification image of  follicle-like structure observed in C (400x).    
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3.2.12  Immunoreactivity of HSP47 in RA+CVD and CVD only patients 
Immunohistochemistry was performed on human aortic adventitia paraffin sections using a 
monoclonal mouse anti-human antibody raised against HSP47.  HSP47 expression was 
detectable in 13 of the 19 RA+CVD patients (68.4%) and 11 of the 20 CVD only patients 
(55%).  HSP47 was detected in smooth muscle-like cells, endothelial cell, mesothelial cells 
and the inflammatory infiltrate (figure 3.16).  No HSP47 staining was observed in 
adventitial adipocytes. 
The extent of HSP47 staining was analysed using a semi-quantitative scoring method in a 
blinded manner.  Each section was imaged by light microscopy and the overall percentage 
of each cell type to express HSP47 was recorded and assigned a score of 0-3 (no staining, 
<10%, 10-25%, and >25% respectively).   
No significant differences in HSP47 staining between the RA+CVD and CVD only 
patients was detected in any of the cell populations studied.  However, there was a trend 
towards greater HSP47 expression in smooth muscle cells, mesothelial and endothelial 
cells in patients who had both RA+CVD compared to CVD only, however these results did 
not reach significance (figure 3.17).  We also observed a significant correlation between 
smooth muscle HSP47 expression and mesothelial HSP47 expression when considering all 
patients (n=39) (p=0.024, Spearman’s rank).  The power of this correlation increased when 
considering CVD only patients (n=20) (p=0.011) but was lost when considering the RA + 
CVD patients (n=19) (p=0.4).   
 
3.2.13 Relationship between HSP47 expression and traditional CVD risk 
factors 
The relationship between the expression of mesothelial, endothelial, inflammatory cell and 
smooth muscle cell HSP47 in the aortic adventitia with the following factors was analysed: 
sex, age, duration of, BMI, CRP, CVD, ESR, and hypertension.  When considering all 
patients (n=39), hypertension positively correlated with smooth muscle cell (p=0.027) and 
inflammatory cell (p=0.02) HSP47 expression.  A positive correlation between mesothelial 
HSP47 expression and age (p=0.02) was observed when considering all patients and this 
significance remained when considering the RA+CVD group only (p=0.02).  C.R.P 
positively correlated with mesothelial HSP47 expression in the RA+CVD group only.  
Table 3.5 highlights all correlations performed.   
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Figure 3.16 HSP47 immunohistochemistry in the aortic adventitia 
Representation of typical HSP47 staining in the aortic adventitia.  Images were captured 
by light microscopy at 100x magnification.  Cell-specific staining is clearly observable in 
mesothelial cells (A); endothelial cells (B); smooth muscle cells (C) and mononuclear cell 
infiltrate (D).   
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Figure 3.17  HSP47 expression in the aortic adventitia of patients with RA+CVD and 
CVD only 
 HSP47 was detected in four independent cell populations (smooth muscle, endothelial, 
mesothelial and inflammatory cells).  Statistical analysis was performed by Mann-Whitney 
U test for non-parametric data.   Y-axis units represent semi-quantitative analysis (0=0%, 
1=<10%, 2=10-25%, 3=>25%).  
Note: Statistical analysis was also performed by Pearson chi-squared analysis suitable for 
comparing categorical variables.  A significant difference was detected in mesothelial 
HSP47 expression between RA+CVD and CVD only patients (p=0.022).  No significant 
differences were detected in the remaining cell populations.
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Table 3.5 Predictors of the expression of HSP47 in the aortic adventitia. 
HSP47 expression was recorded as a semi-quantitative score.  Spearman’s rank correlation coefficient (non-parametric) was used to examine statistical 
dependence. Non-significant (ns); *p<0.05; **p<0.01; ***p<0.001. Inflammatory infiltrate (II)
 All Patients  
(n=39) 
 CVD only  
(n=20) 
 RA + CVD  
(n=19) 
 
Predictor Endothelial Mesothelial SMC II Endothelial Mesothelial SMC II Endothelial Mesothelial SMC II 
Age 0.51 0.02* 0.21 0.99 0.62 0.49 0.54 0.83 0.64 0.02* 0.54 0.74 
B.M.I 0.25 0.13 0.35 0.55 0.79 0.84 0.58 0.62 0.29 0.13 0.53 0.68 
CVD 
duration  
0.70 0.98 0.84 0.28 0.25 0.74 0.56 0.86 0.83 0.83 0.87 0.16 
C.R.P 0.34 0.17 0.93 0.41 0.56 0.61 0.79 0.64 0.49 0.04* 0.92 0.95 
Hypertension 0.27 0.41 0.027* 0.02* 0.45 0.78 0.41 0.15 0.64 0.41 0.07 0.19 
E.S.R 0.25 0.24 0.51 0.382 0.94 0.46 0.93 0.93 0.45 0.15 0.18 0.06 
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3.2.14  Heat shock protein 60 in the aortic adventitia 
Immunohistochemical analysis of human aortic adventitia (n=39) showed no 
immunoreactive HSP60 in any cases.  Clear cell specific staining was observed in the 
positive control and no background signal was detected in the isotype control (figure 3.20). 
 
3.2.15  Calprotectin protein antigen expression in the aortic adventitia 
Immunohistochemistry was performed on human aortic adventitia paraffin section (n=39) 
using a monoclonal mouse anti human antibody raised against calprotectin (antibody 
kindly donated by Prof. Magne K. Fagerhol, (Ullevaal University Hospital, Oslo).  
Specifically, aortic adventitial sections were analysed for the s100A9 epitope as this 
proved to be the most reliable antibody of those available for calprotectin detection. 
The calprotectin complex was expressed in areas of mononuclear cell infiltration. 
Calprotectin expression was detected in inflammatory cells in both the submesothelium 
and adventitia.  Calprotectin was detectable in 8 of the 19 RA+CVD patients (42.1%) and 
9 of the 20 CVD only patients (45%).  There was no significant difference in either the 
number of patients expressing calprotectin or the extent of calprotectin expressed across 
the two cohorts (figure 3.18). 
Interestingly, very low levels of calprotectin were occasionally detected in smooth muscle 
or endothelial cells surrounding areas of inflammation.  This suggests that neutrophils may 
be releasing small amounts of calprotectin into surrounding tissue either due to cell 
disruption or death or as an antimicrobial mechanism.  However this hypothesis remains to 
be investigated. 
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Figure 3.18 Calprotectin in the aortic adventitia 
(A) Representative image of calprotectin staining in the inflammatory infiltrate of human 
aortic adventitia (100x). (B) Semi-quantitative scoring of calprotectin in the aortic 
adventitia of RA + CVD and CVD only patients.  The number of inflammatory cells was 
approximately counted and each section was scored according to the percentage of cells 
expressing calprotectin.  0, negative; 1, >0%<10%; 2, 10-25%; 3, >25%.  No significant 
difference was observed between the RA + CVD and CVD only cohort (p>0.05) (Mann 
Whitney U test).    
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3.2.16  Calprotectin and TNFα correlation analysis 
Previous studies have demonstrated that TNFα can induce calprotectin production from 
human monocytes (Suryono et al., 2005).  In this study, calprotectin expression did not 
correlate with either the number of independent adventitial TNFα sites or the extent of 
TNFα expression.  Furthermore adventitial calprotectin expression did not correlate with 
serum TNFα expression (figure 3.19). 
 
 
 
Figure 3.19 Calprotectin and TNFα correlation 
Levels of adventitial calprotectin and TNFα were determined by immunohistochemistry in 
RA+CVD patients and CVD only patients (n=39).  Serum TNFα concentration was also 
determined in 12 of these patients. Correlation analysis was performed for calprotectin 
expression with: (A) the number of independent adventitial TNFα sites; (B) the extent of 
TNFα expression (score).  Furthermore adventitial calprotectin expression did not 
correlate with serum TNFα expression.  P value was calculated by spearman rho and r2by 
linear regression (all >0.05). 
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3.2.17  Immunohistochemical quality control 
The work outlined in this chapter relied heavily upon immunohistochemistry, and as such 
the strictest quality control was maintained throughout.  All experiments carried out here 
used monocolonal antibodies (table 2.1) which removes the risk of contaminating antibody 
due to impure antigen used to immunise the host animal. 
All experiments, with the exception of the HSP47 immunohistochemistry, carried out on 
the aortic adventitia sections were first worked up on tonsil sections.  HSP47 was worked 
up on RA synovium sections as these proved to have a source of HSP47 antigen, whereas 
tonsil tissue did not.  Accordingly RA synovium was used as both the positive and negative 
control.  Staining was only performed on aortic adventitia sections once the desired quality 
of staining was attained and there was no staining in the negative control.   
A positive and negative control was carried out in tandem with each experiment.  Control 
images captured from each experiment are provided in figure 3.20.  In each case, staining 
is observed in the positive control, whereas no staining is evident in the negative (isotype) 
control.  
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Figure 3.20 Immunohistochemistry quality control 
All images were captured from the positive and negative controls carried out in tandem 
with each experiment (A) calprotectin S100A9; (B) CD21; (C) HSP60; (D) HSP47 and (E) 
TNFα.  Higher magnification of S100A9 and HSP47 has been included for clarity.  Control 
tissue is human tonsil tissue with the exception of HSP47 which is RA synovium..    
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3.3 Discussion 
A growing body of evidence supports the observation that patients with RA experience an 
increased risk of CVD morbidity and mortality.  However, patients with RA do not exhibit 
a corresponding increase in traditional CVD risk factors that could explain an increased 
atherosclerotic burden (Wilson, 2008).  Evidence exists to suggest that inflammation, being 
of major importance in the pathogenesis of both RA and CVD, may represent the missing 
link in explaining the CVD burden observed in RA patients (Aubry et al., 2007, Libby, 
2008, Abou-Raya and Abou-Raya, 2006).  However, the majority of these studies have 
concentrated on measuring systemic and general downstream inflammatory markers (e.g. 
CRP, ESR and total leukocyte counts) as well as traditional inflammatory cytokines (e.g. 
TNFα, IL-1 and IL-6).  To date, only a handful of studies have focused on determining 
differences in inflammatory profiles between CVD and CVD-RA patients (Hollan et al., 
2007, Breland et al., 2010).  In the present study we have built upon previous studies by 
quantifying the extent and incidence of inflammatory infiltration into the aortic adventitia 
of patients with CVD and CVD+RA. 
The aortic adventitia comprises the outermost layer of the aortic wall and has received little 
attention in research to understand the underlying pathophysiology of atherosclerosis.  
Additionally, the majority of ex vivo human studies on CVD have concentrated on sites of 
severe atherosclerotic disease.  The adventitial sections studied here were taken from areas 
with reduced macroscopic signs of atherosclerosis.  As expected, the atherosclerotic lesion 
was confined to the intima and on no occasion were the atherosclerotic plaque or lesion 
observed in the corresponding adventitia.   
In this study, we hypothesised that increased aortic inflammation would be observed in 
patients with both RA and CVD compared to those without RA.  When evaluating 
inflammatory infiltrates in the aortic adventitia we detected inflammation in 18 of the 39 
(46%) samples analysed.  This data supports descriptions from other authors who have 
detected inflammatory cells in the outer most layers of the vessel wall.  Aubry et al (2004) 
found prominent B-lymphocyte infiltrates in the adventitia of two men with CVD and RA 
(Aubry et al., 2004).  Millonig et al (2002) observed inflammatory infiltration in the aortic 
adventitia of children pre-disposed to atherosclerosis and using immunohistochemistry 
demonstrated that these were principally composed of T cells and mast cells, (Millonig et 
al., 2002).   
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However, in our study, despite the relatively high proportion of patients with adventitial 
inflammation, no significant difference in either the size or the number of inflammatory 
sites was observed between the CVD and RA+CVD groups.  These findings are in 
disagreement with Hollan et al who examined the severity of inflammatory infiltrates in 
the aortic adventitia that were removed during routine CABG surgery in 66 patients with 
inflammatory rheumatic disease and 51 control patients (Hollan et al., 2007).  They 
observed that mononuclear cell infiltrates occurred with greater frequency in the inner 
adventitia of the rheumatic disease group compared with controls (47% versus 20%; 
p=0.002).  Several factors may explain these conflicting data.  Firstly, the study of Hollan 
et al (2007) included a much larger number of patients with a diverse range of rheumatic 
diseases (including RA, psoriatic arthritis, ankylosing spondylitis, giant cell arteries).  
Experimental outcome is likely to change when including diseases such as giant cell 
arteries, as although this is an inflammatory disease of the blood vessels most commonly 
involving large and medium arteries of the head the disease can involve other large vessels 
such as the aorta. Furthermore, Hollan et al distinguished between inner adventitial 
infiltrates and infiltrates adjacent to the mesothelium, which they classified as 
submesothelial (epicardial).  As there is no clear anatomic border between epicardial and 
adventitial loose connective tissue, this differentiation was based on the judgement of 
pathologists rather than histopathological examination.  Due to our relatively small sample 
numbers and desire to minimise subjectivity we accurately measured total inflammation in 
each aortic adventitial sample. 
The clinical significance of the observed chronic adventitial inflammation remains 
unknown.  Inflammation may have spread from surrounding tissue into the aorta, or may 
occur in situ as a secondary response to atherosclerosis.  Alternatively, it may reflect an 
inflammatory process that is critical to the pathogenesis of atherosclerosis and plaque 
formation (Higuchi et al., 2002, Scott et al., 1996, Wilcox and Scott, 1996). 
In our study, inflammatory infiltration was significantly greater in the aortic adventitia 
compared to matched internal mammary artery specimens (0.22% ± 0.67and 
0.001%±0.003 respectively).  As with the aortic adventitia, inflammation in the mammary 
tissue was observed in and around the perivascular adipose tissue.  This is not surprising, 
as the regulatory effects of adipose cells on inflammation are well characterised, as are the 
effects of obesity and lipid metabolism on CVD (Ryden et al., 2002, Berg et al., 2004).  
The very low inflammatory presence in the internal mammary samples supports the fact 
that this tissue is highly resistant to atherosclerosis.  The difference in atherosclerotic 
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burden between the coronary aortic adventitia and internal mammary artery adventitia may 
be due to differences in systemic inflammatory mediators, susceptibility to local infection, 
or due to the presence of autoantigens (HSPs, lipoprotein) at these sites.  Unfortunately, 
owing to sample limitations, we could not investigate these factors.  However, future 
efforts to characterise the atherosclerotic resistance mechanisms of internal mammary 
artery tissue could have significant therapeutic implications.  
Inflammation is a natural defence mechanism against infection and toxic compounds such 
as lipids and oxidised proteins.  Markers of inflammation such as TNFα have been 
associated with an increased risk for CVD (Ridker, 1997).  Furthermore, the pathology of 
RA is attributable to the pleiotropic biological activities of TNFα (Romas et al., 2002, 
Keystone, 2001).  TNFα is a key cytokine in both the recruitment and activation of 
inflammatory cells.  Furthermore it promotes matrix degradation (Rajavashisth et al., 1999) 
and thus facilitates the influx of inflammatory cells into the vessel wall.   
We set out to ascertain whether TNFα is expressed in the aortic adventitia.  This study was 
principally performed to test the hypothesis that patients with RA would exhibit greater 
adventitial TNFα expression.  TNFα was detected in the aortic adventitia of 12 of the 19 
RA+CVD patients (63%) and 6 of the 20 CVD patients (30%), and TNFα expression was 
significantly greater in the RA+CVD cohort.  Elevated TNFα in the aortic adventitia of 
RA+CVD patients cannot be explained by an excess of inflammatory cells, as we have 
already demonstrated that there is no difference in inflammatory infiltrate presence 
between the RA+CVD and CVD groups.  However, we have identified that serum TNFα 
expression is roughly ten times greater in the RA+CVD group compared to the CVD 
group.  Although TNFα is initially synthesised as a transmembrane molecule (Ishisaka et 
al., 1999), upon cleavage by metalloprotease TNFα converting enzyme (TACE or 
ADAM17), the secreted monomers that are generated form biologically active 
homotrimers (Smith and Baglioni, 1987).  We hypothesise that elevated levels of secreted 
TNFα in the serum of the RA+CVD group may infiltrate into and reside in the aortic 
adventitia, possibly potentiating the onset of CVD in RA.  It is worth noting that although 
there was a trend towards adventitial TNFα correlating with serum TNFα that this did not 
reach significance.  This lack of significance is most likely attributable to our limited 
sample size. 
Sixteen of the 19 RA+CVD patients were taking disease modifying drugs at the time of 
serum removal and CABG surgery.  Only one of these patients was administered anti-TNF 
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therapy (etanercept).  However the possibility that other disease modifying drugs may 
affect TNFα expression cannot be ignored.  As most of the other disease modifying drugs 
(e.g. methotrexate, azathioprine) administered to RA patients are believed to function by 
reducing immune cell activation it is highly unlikely that these drugs would cause the 
elevation of TNFα expression observed in this study.  Conversely, it seems highly likely 
that TNFα expression would be greater in the RA+CVD group if these patients were not 
confounded by the action of disease modifying drugs. 
The overexpression of TNFα in the aortic adventitia of CVD+RA patients suggests that 
systemically targeted anti-TNFα therapy in RA patients may have beneficial effects in the 
prevention of CVD and may lead to a reduction in TNFα expression at the sites of 
atherosclerosis progression.  In accordance with these results Jacobson et al followed 983 
RA patients, 531 who were undergoing anti-TNFα therapy, and measured subsequent CVD 
events.  Their findings suggested that the risk of developing CVD was significantly lower 
in patients treated with TNF blockers (Jacobsson et al., 2005). 
The presence of inflammatory infiltrate, TNFα and B cells (Ahmed., 2010) in the aortic 
adventitia has been confirmed.  In occasional instances, we observed possible nodular 
lymphoid aggregates which resembled germinal centers in the adventitia.  Such structures 
could accumulate T cells and follicular dendritic cells and support rapid proliferation and 
differentiation of B cells and corresponding class switch of their antibodies (Perez et al., 
2002).  To ascertain whether these structures were indeed germinal centres we stained for 
CD21, as this receptor provides a signal independent of antigen that is required for survival 
of B cells in the germinal centre (Fischer et al., 1998).  In no cases was CD21 detected in 
the aortic adventitia. This was a surprising result, as CD21 is also involved in the cell 
activation of B cells and is engaged in homotypic aggregation of B cells (Bjorck et al., 
1993).  These results are in disagreement with Houtkamp et al who identified CD21+ B 
cells and CD21+ follicular dendritic cells in occasional nodular aggregates resembling 
lymphoid follicles in the aortic adventitia of CVD patients (Houtkamp et al., 2001).  These 
contrasting results could in part be explained by a recent study by Isnardi et al who found 
that CD21-negative B cells are enriched in patients with autoimmune disease, and that 
many RA patients also displayed an increased frequency of CD21- B cells (Isnardi et al.). 
Heat shock protein 47 is a stress protein that acts as a molecular chaperone during 
intracellular processing of procollagen (Nakai et al., 1992).  A relationship between HSP47 
expression and fibrosis has been identified in human coronary arteries, in which HSP47 
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was identified in abundance in the fibrous cap of atherosclerotic plaque (Rocnik et al., 
2000).  Studies also indicate that autoantibodies and inflammatory reactions are directed 
against surface exposed HSP47 in patients with RA (Hattori et al., 2005).  Such studies led 
us to hypothesise that HSP47 expression may be elevated in the aortic adventitia of 
patients with both RA and CVD.  HSP47 was detected in endothelial, mesothelial, smooth 
muscle or inflammatory cells.  There was no difference between HSP47 expression in 
endothelial, mesothelial, smooth muscle and inflammatory cells between the CVD and 
RA+CVD.   
As far as we are aware, our study is the first to identify HSP47 in human aortic adventitia 
tissue.  Yokota et al have also demonstrated that HSP47 antigen and autoantibody levels 
are significantly elevated in the serum of RA patients (Yokota et al., 2003).  Taken 
together these findings generate the hypothesis that elevated levels of autoantibodies 
specific to HSP47 in RA patients may target HSP47 in the aortic adventitia and lead to 
accelerated atherosclerosis.   
When considering all patients (n=39) we observed a strong correlation between smooth 
muscle and inflammatory cell HSP47 expression and hypertension.  Hypertension is 
associated with structural changes in blood vessels including an increase in the thickness of 
the media, which is caused by increased cell mass and increased deposition of extracellular 
matrix.  An important component in the latter outcome is collagen, the deposition of which 
may cause an increase in stiffness of the vessel wall (Deinum, 2002).  Thus, it is possible 
that hypertension may be, in part, due to overexpression of HSP47 and associated collagen 
accumulation, however this remains to be determined. 
Previous studies have demonstrated that human anti-HSP60 autoantibodies are associated 
with the development of atherosclerosis and can cross react with bacterial HSP60 (Zhu et 
al., 2001b, Huittinen et al., 2002).  Furthermore, subjects with elevated HSP60 in their 
circulation exhibited vascular dysfunction (Halcox et al., 2005).  Experiments in adjuvant-
induced arthritis models also suggest that HSP60 may play a vital role in the immune 
regulation of arthritis (van Eden and Waksman, 2003) and that HSP60 of microbial origins, 
as well as those of endogenous origins, are targets of immune responses (vanRoon et al., 
1997).  These studies led us to hypothesise that HSP60 may infiltrate into or reside in the 
aortic adventitia and could potentially trigger a pro-atherosclerotic response.  Converse to 
this hypothesis, our study of 39 biopsies revealed no HSP60 presence in the aortic 
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adventitia.  These results suggest that HSP60 expression or autoimmunity do not play a 
pathological role in the adventitia.   
Our study was limited to detection of human HSP60, as the only available anti-HSP60 
monoclonal antibody did not cross-react with the bacterial homologue.  It remains possible, 
therefore, that bacterial HSP60 may reside in the aortic adventitia and this antigen could 
potentially trigger a pro-atherogenic immune response.   
Several studies on patients with RA have shown strong associations between serum or 
plasma levels of calprotectin and clinical measurements of joint inflammation (Foell and 
Roth, 2004, Youssef et al., 1999).  Furthermore, Mortensen et al observed a negative 
correlation between plasma calprotectin and HDL, leading the authors to suggest that 
calprotectin may play a role in atherosclerosis (Mortensen et al., 2009).  With this 
exception, there is no indication that calprotectin has previously been studied in relation to 
CVD.  Our results demonstrate for the first time that calprotectin is expressed in the aortic 
adventitia and that inflammatory cells are responsible for the production of this peptide. 
Calprotectin, a major product of innate immune cells, is an antimicrobial peptide that 
protects cells and tissues against microorganism invasion and regulates adhesion of 
leukocytes to the endothelium and extracellular matrix during the inflammatory process 
(Terrin et al., 2011).  The presence of calprotectin in the aortic adventitia, as demonstrated 
in our study suggests that bacteria may penetrate the vascular wall and reside in the 
adventitia where they can trigger a calprotectin anti-microbial response.  Such an immune 
reaction could potentiate the onset of atherosclerosis.  These findings support one of the 
most interesting hypotheses of recent years that suggests one or more infectious agents 
may play a role in atherosclerosis through a direct proinflammatory effect on the vessel 
wall (Shah, 2001, Leinonen and Saikku, 2002).  Further studies to characterise bacterial 
presence in the aortic adventitia may help explain why calprotectin is expressed in the 
adventitia and may help to understand the pathophysiology of atherosclerosis.  
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4 The bacterial composition of the human 
aortic adventitia: possible implications for 
inflammatory disease  
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4.1  Introduction  
Premature CVD as a result of advanced atherosclerosis is now understood to be the leading 
cause of mortality among RA patients (Solomon et al., 2003).  Following experiments 
described in the previous chapter, it was established that the aortic adventitia of CVD 
patients exhibit extensive inflammatory infiltration.  It was also determined that TNFα, a 
cytokine involved in systemic inflammation that stimulates the acute phase reaction is 
present in the aortic adventitia.  TNFα is released from macrophages in response to 
stimulation by lipopolysaccahride (LPS) and other bacterial products.  Expression of this 
TNFα was established as being greater in RA + CVD patients than patients with CVD 
only.  It was also observed that calprotectin, a calcium binding protein present 
predominantly in neutrophils with antimicrobial activity, was detectable in the aortic 
adventitia of CVD patients in both the presence and absence of RA.  Taken together, these 
findings led to the hypothesis that bacteria observed within the aortic adventitia may 
generate a pro-atherosclerotic environment.  
The mechanisms underlying the pathogenesis of atherosclerosis remain unclear.  Recently, 
infection has received much attention as a potential contributing factor towards 
atherosclerosis.  Specific pathogens have been detected in the arterial vessel wall of CVD 
patients, and there have been reports of an association between CVD and serological 
responses to bacterial and viral pathogens such as Helicobacter pylori, Chlamydia 
pneumonia, herpes simplex virus or cytomegalovirus (Saikku et al., 1992, Chiu et al., 
1997, Danesh et al., 1999).  Furthermore, periodontitis, a disease that results in 
bacteraemia from oral lesions, has been implicated as a risk factor for the development of 
atherosclerosis (Haraszthy et al., 2000, Nakib et al., 2004).  Lehtiniemi et al (2005) 
observed a diverse bacterial colonisation of atherosclerotic plaques, and consequently 
hypothesised that atheromas act as mechanical sieves that collect bacteria from the 
circulation. 
To date, most studies have concentrated on Chlamydia pneumonia as a possible etiological 
agent for atherosclerosis (Deniset et al., 2009).  C. pneumonia-infected endothelial cells are 
thought to produce reactive oxygen species (ROS), which together with chlamydial 
antigens cHSP60 and LPS enhance the oxidation of LDL to oxLDL (Kalayoglu et al., 
1999).  Exposure of macrophages to C. pneumonia stimulates the uptake of oxLDL as well 
as native LDL, which causes macrophages to develop into pro-atherosclerotic lipid-laden 
foam cells (Kalayoglu and Byrne, 1998).  Furthermore, T cells activated by C. pneumonia 
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produce IFN-γ, which activates macrophages and triggers a persistent intracellular 
infection. 
Initial interventional studies with macrolide antibiotics that specifically targeted 
Chlamydia infection after acute coronary syndrome suggested a reduced risk of secondary 
cardiovascular complications following treatment (Etminan et al., 2004).  However, large 
randomised controlled studies (Azithromycin and Coronary Events Study [ACES], Weekly 
Intervention With Zithromax Against Atherosclerosis and Related Disorders [WIZARD] 
and a Randomised Trial of Roxithromycin in Non–Q-Wave Coronary Syndromes 
[ROXIS]) that tested benefits of treatment with antibiotics such as zithromax and 
azithromycin indicated no reduction in either CVD or associated complications (Grayston 
et al., 2005, O'Connor et al., 2003, Gurfinkel et al., 1999). 
Despite the major research focus on C. pneumonia, several other studies have identified a 
number of alternative organisms implicated in atherosclerosis.  Using 16S ribsosomal RNA 
(rRNA) molecular sequencing, Marques da Silva et al. (2006) detected a wide range of 
microorganisms in human aortic aneurisms.  These included Stenotrophomonas spp., 
Propioibacterium acnes, Brevundimonas diminuta, Herbaspirillum sp., and oral bacteria 
such as Streptococcus sanguinis, Lactobacillus delbrueckii and Tannerella forsythia 
(Marques da Silva et al., 2006).  However, potential etiological and pathological roles of 
these bacteria in atherosclerosis remain unclear.  
The 16S ribosomal RNA (16S rRNA) is the genetic marker of choice to detect bacteria to 
the species level.  16S rRNA is a highly conserved region which constitutes part of the 30S 
subunit of prokaryotic ribosomes.  The 16S rRNA gene is a powerful tool for phylogenetic 
analyses (Janda and Abbott, 2007) as universal PCR primers targeting these conserved 
regions can be used to amplify the gene in parts to provide the complete nucleotide 
sequence of the 16S rRNA without prior knowledge of which bacterial species are present.  
Concomitantly, the 16S rRNA gene also contains hypervariable regions that provide 
species-specific signature sequences and enable unbiased bacterial identification following 
sequencing.  
Autoimmune rheumatic diseases are generally considered to have a multifactorial 
aetiology, with susceptibility presumed to be principally due to genetics combined with 
environmental triggers, of which bacterial infection is considered the most prominent.  
Most autoimmune diseases, including RA, are associated with specific HLA alleles.  
Greater than 90% of RA patients possess HLA-DR1 (Ebringer and Wilson, 2000) and 
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significantly more psoriatic arthritis (PsA) than control patients carry the HLA-Cw*0602 
allele (Szczerkowska Dobosz et al., 2005).  It has been suggested that the involvement of 
HLA antigens in the pathogenesis of autoimmune diseases is due to molecular mimicry 
between certain bacterial antigens and HLA antigens (Wilson et al., 2000).  
Psoriatic arthritis is classified as a spondyloarthropathy and is characterised by spondylitis, 
dactylitis, enthesitis and synovitis, usually manifesting in people with nail and skin 
psoriasis (Mease, 2010).  There is accumulating evidence to support the hypothesis that 
PsA patients develop CVD prematurely, which may contribute to the early mortality 
associated with this disease (Wong et al., 1997, Han et al., 2006, Kimhi et al., 2007).     
Based on current understanding of the pathophysiology of PsA, potential contributors to 
CVD include inflammation-induced atherosclerosis and metabolic syndrome including 
hyperlipidiemia, hypertension and obesity (Ku et al., 2009).  It has been demonstrated that 
the use of TNF inhibitors in PsA are associated with a reduction in carotid intima-media 
thickness and was accompanied by a reduction in inflammatory biomarkers, which is 
independent of alterations in lipid profile (Mease, 2010). 
Although the aetiology of PsA remains unclear, it has been proposed that systemic 
bacterial infection and/or alteration of the gastrointestinal flora may trigger a Th17 
response and increased production of other pro-inflammatory biomarkers that contribute to 
disease progression.  If proved correct, this could help explain why PsA patients have a 
higher morbidity rate from CVD than the general population. 
Considering all the evidence, it is plausible to hypothesise that inflammatory rheumatic 
disease increases patient susceptibility to infection by specific bacterial pathogens.  The 
objective of the research described in this chapter was firstly to identify the bacteria 
present in the aortic adventitia of patients with CVD+RA, CVD+PsA and CVD only.  The 
second objective was to characterise the potential atherosclerotic pathogenicity of any 
species that appeared at an elevated frequency.  
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4.2  Results 
4.2.1  Study plan and patient characteristics 
The bacterial diversity of aortic adventia biopsies taken from patients with CVD+RA, 
CVD+PsA and CVD alone were analysed by amplification of the 16S rRNA gene from 
total extracted DNA.   16S rRNA gene amplicons were then cloned, sequenced and 
indentified by GenBank alignment. 
All human aortic adventitia (AA) biopsies were from patients who underwent routine 
coronary artery bypass graft (CABG) surgery, and were provided by the Feiring Heart 
Biopsy study.  All patients were confirmed as free from any clinically significant infection 
or malignancy prior to CABG surgery.   A total of 31 aortic adventitia samples were 
obtained, from patients diagnosed as having CVD.  Of these patients, 11 had coexisting 
RA, and nine patients had coexisting PsA.  The prevalence of known risk factors and the 
demographic distribution is outlined in table 4.1. 
 
AA 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Demographic and clinical characteristics of patients with CVD, RA+CVD 
and PsA ± SD  
  
Characteristics         CVD-only  RA+CVD  PsA  
(n=11)   (n=11)   (n=9)
   
Age, years     68±8   66±9  61±6 
Male sex, no. (%)    4 (36)   4 (36)  5 (55) 
Current smokers, no (previous)  0 (6)   2 (5)  4 (2) 
C – reactive protein mg/l   3.3±2   10±9  8.3±7 
Duration of coronary artery   
Disease, years     5.1±4   2.6±4  3.7±5 
Time from angiography to CABG 
surgery, days     6.7±8   9.7±8  15±18 
Acute coronary syndrome,no (%)  1 (9)   4 (36)  3 (33) 
Hypertension, no (%)    8 (72)   4 (36)  5 (55) 
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4.2.2  DNA extraction and contamination control 
To ensure experimental sterility a negative control was processed in parallel with every 
sample.  Furthermore, all reagents used (trizol, chloroform, 100% ethanol, 75% ethanol, 
0.1M sodium citrate, isopropanol and DEPC water) were tested for the presence of 
possible bacterial DNA contamination (Methods section 2.2.7).  In all cases the negative 
control did not show any bands.  Figure 4.1 illustrates two 16S PCR samples that were 
PCR-positive for the presence of the 16S rRNA gene (RA74 in lanes 2-4 and RA63 in 
lanes 6-8) and the respective positive and negative controls.  Figure 4.2 illustrates that 
patient RA37 was negative for the presence of the 16S rRNA gene and that bacteria were 
either absent or below the limit of detection.  Furthermore, in consonance with the negative 
controls, all experimental reagents were demonstrated to be sterile (figure 4.3). 
 
 
 
Figure 4.1.  Samples PCR-positive for 16S rRNA gene 
2% agarose gel electrophoresis of DNA extracted from the aortic adventitia of patients.  
Each sample was diluted in mastermix (10, 4 and 1%).  RA74 (lane 2, 10%; lane 3, 4%; 
lane 4, 1%) and RA63 (lane 6, 10%; lane 7, 4%; lane 8, 1%).  100-bp DNA ladder (lane 
9), negative controls (lanes 1 and 5), positive control (lane 10).  
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Figure 4.2.  Samples PCR-negative for 16S rRNA gene 
2% agarose gel electrophoresis of DNA extracted from the aortic adventitia of patients 
RA37.  The sample was diluted in mastermix (10, 4 and 1%).  100-bp DNA ladder (lane 1); 
positive control (lane 2); negative control (lane 6) and RA37 (lane 3, 10%; lane 4, 4%; 
lane 5, 1%) 
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Figure 4.3. Reagent sterility                                                                                                
2% Gel electrophoresis of DNA extracted and 16S rRNA gene PCR amplified from all 
reagents used in DNA extraction.  100-bp DNA ladder (lane 1); positive control (lane 2); 
trizol (lane 3); chloroform (lane 4); 75% ethanol (lane 5); 0.1M Sodium Citrate (lane 6); 
isopropanol (lane 7); 100% ethanol (lane 8); DEPC H2O (lane 9) & molecular grade 
water (lane 10) 
 
 
  
122 
 
 
 
4.2.3 Bacterial DNA signatures detected in the aortic adventitia of patients 
with and without RA 
 
Sequencing of a 1324bp region of the 16S rRNA gene was used to identify bacteria present 
in the aortic adventitia of CVD patients with and without RA.  Four of 11 non-RA patients 
and 3 of 11 RA patients had detectable levels of bacteria present in the aortic adventitia 
(p>0.05), whereas no bacteria were detected in negative controls.  All sequences analysed 
showed >98% similarity to their associated sequences in GenBank.  All of the positive 
specimens contained more than one bacterial species.  The four positive samples from non-
RA patients harboured a total of 31 different bacterial species (table 4.2), and the three 
positive samples from RA patients contained a total of 11 different bacterial species (table 
4.3).  A Fisher’s exact test resulted in a p-value <0.00001 indicating that there was a 
significant difference in the heterogeneity of bacteria present between RA and non-RA 
patients.   A non-RA patient, K53, displayed the most heterogeneity with 10 different 
bacterial species being detected.  Conversely, RA patient RA74 displayed the least 
heterogeneity, with only two bacterial species detected.  Methylobacterium sp. was 
detected in every positive sample from RA patients and represented the most prevalent 
bacteria in the RA group contributing 35.3% of the total bacteria detected in these samples.  
Stenotrophomonas sp. contributed 29.7% of all bacteria detected in the RA sample group, 
but was found in only one patient (RA63).  Among the non-RA patients Sphingomonas sp. 
was detected in three samples and was the largest contributor to the overall bacterial 
diversity (16.3%) of the non-RA group (table 4.3).  Oral Haemophilus sp. and 
Stenotrophomonas sp. were the next most commonly detected bacteria in the non-RA 
group, with Haemophilus sp. being detected in two samples and Stenotrophomonas sp. 
making up the majority of bacteria detected in one patient (K40).  Other oral bacteria were 
detected, including Streptococcus mitis, Porphyromonas endodontalis and oral Neisseria 
sp. in the non-RA group and Veillonella sp. and Streptococcus sanguinis in the RA group. 
The duration of RA did not significantly alter the risk of bacterial infection in the aortic 
adventitia (p=0.825).  The median duration of RA in this group was 137 months.  There 
were more men (n=13) than women (n=9) in this study, and chi-squared analysis showed 
that they fell equally into each of the patient groups.  None of the patients that entered this 
study had aortic aneurysms. 
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Patient % of 
clones 
Bacteria GenBank 
Accession 
No. 
    
Non-RA 
K48 
14 Acinetobacter sp.  GU339300.1 
 48 Sphingomonas sp. EF636054.1 
 8 Janthinobacterium aqaricidamnosum strain SAFR-022 AY167838.1 
 14 Pedobacter sp. TB2-14-II AY599662.1 
 16 Agrobacterium sp. GU120649.1 
    
    
K40 50 Stenotrophomonas sp. GQ416874.1 
 2 Rhodococcus sp. AB547168.1 
 6 Methylobacterium oryzae strain 1021b/DCY52 GU294332.1 
 30 Pedobacter sp. TB2-14-II AY599662.1 
 2 Bosea thiooxidans KNUC165 DQ424863.1 
 8 Pseudomonas fluorescens strain LMG 14571   
 2 Herbaspirillum putei strain AU14404 EU549857.1 
    
    
K53 10.5 Sphingomonas sp. EF636054.1 
 2.6 Neisseria sp. Oral taxon 014 str. F0314 GQ131417.1 
 7.89 Ralstonia pickettii strain MMA-BtI-3 clone FS1 FJ828883.2 
 21 Haemophilus sp. Oral clone JM053 AY349380.1 
 7.9 Escherichia coli IHE3034 CP001969.1 
 18.4 Pectobacterium carotovorum subsp. carotovorum strain 
Ecc1-16  
FJ527466.1 
 7.9 Uncultured Phyllobacterium sp. clone PSC19 GU293169.1 
 10.5 Methylophilus leisingeri  AB193725.1 
 2.6 Bradyrhizobium sp. Pha-1 AF510604.1 
 10.5 Uncultured Pseudomonas sp. clone F1Sjun.54  GQ417217.1 
    
K44 42.4 Haemophilus sp. oral clone JM053  AY349380.1 
 3.03 Pseudoxanthomonas sp. 11_4K  EF540482.1 
 6.06 Kineosporia rhamnosa strain I-132 NR028600.1 
 3.03 Uncultured Providencia sp. clone F4feb.62 GQ418015.1 
 21.1 Streptococcus mitis bv. 2 strain F0392  GU470907.1 
 6.03 Ralstonia pickettii strain MMA-BtI-3 FJ828883.2 
 9.09 Porphyromonas endodontalis ATCC 35406  AY253728.1 
 6.06 Sphingomonas sp. EF636054.1 
 3.03 Escherichia coli strain AC1 GU594306.1 
Table 4.2: Bacterial species detected in the aortic adventitia of CVD only patients               
species (at least 98% identity) identified by 16S rRNA gene sequencing of clones from four aortic 
adventitia biopsies of CVD patients without RA. 
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Patient % Bacteria Accession 
No. 
    
RA74 90 Methylobacterium oryzae strain 
1021b/DCY52 
GU294332.1 
 10 Afipia sp. FJ711197.1 
RA63 89.2 Stenotrophomonas sp. GQ416874.1 
 2.7 Streptococcus sanguinis  GU561393.1 
 2.7 Methylobacterium oryzae strain 
1021b/DCY52 
GU591546.1 
 5.4 Pedobacter sp. TB2-14-II AY599662.1 
    
    
RA73 6.67 Afipia sp. FJ711197.1 
 13.33 Methylobacterium oryzae strain 
1021b/DCY52 
GU294332.1 
 40 Streptococcus sanguinis  GU561393.1 
 13.33 Acinetobacter sp. GU339300.1 
 26.6 Veillonella sp. oral clone VeillC3  AY995752.1 
 
Table 4.3: Bacterial species detected in the aortic adventitia of CVD+RA patients 
Bacterial species (at least 98% identity) identified by 16S rRNA gene sequencing of clones from 
three aortic adventitia biopsies of CAD patients with RA 
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Figure 4.4 Total bacterial species identified by 16S rRNA gene sequencing                                                                                                                                           
Bars represent the percentage of isolated clones which belong to each species in the two cohorts [4 Non-RA (blue bars) and 3 RA patients (red bars)]. 
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4.2.4 Bacterial signatures detected in the aortic adventitia of patients with 
psoriatic arthritis 
 
The total DNA from the aortic adventitia of 9 patients with PsA was analysed for the 
presence of the bacterial 16S rRNA gene by PCR.  These patients were age- and sex-
matched to the 11 control patients (CVD only) described in the previous section.  Bacterial 
DNA was not detectable in any of the adventitial biopsies from the PsA cohort.  A Fisher’s 
exact test resulted in a p-value <0.00001 indicating there was a significant difference in the 
heterogeneity of bacteria present in the aortic adventitia between PsA and non-rheumatic 
patients.   
 
4.2.5  Description of M. oryzae bacterium 
This study demonstrated that M. oryzae was present in the aortic adventitia of all 16S PCR-
positive RA+CVD patients.  In order to support downstream analysis of host-pathogen 
interaction it was important to characterise M. oryzae.  The genus Methylobacterium 
includes a group of Gram-negative, pink-pigmented, facultatively methylotrophic bacteria 
characterised by their ability to utilise single carbon compounds via the serine pathway, as 
well as a wide range of multicarbon growth substrates (Madhaiyan et al., 2007).  Scanning 
electron microscopy images demonstrated that M. oryzae possess a bacillus-shaped 
morphology and that the bacterium measures roughly 4.6µm in length and 0.8µm in width 
(figure 4.5).  M. oryzae occurs singly, in pairs or in rosettes and the cells are convex with 
regular edges and no flagella.  M. oryzae grew on both nutrient agar and nutrient agar 
supplemented with 1% methanol.  M. oryzae is slow-growing at the optimal temperature of 
30oC and takes approximately 35 hours to reach the logarithmic growth phase (figure 4.6).  
Growth was also supported at physiological temperature (37oC) (data not shown). 
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Figure 4.5 Morphological characteristics of M. oryzae                                                               
Scanning electron micrographs  of M. oryzae: (A) Low magnification view of bacteria 
(5000x);  (B, C) Compact aggregation of M. oryzae (15,000x and 10,000x magnification 
respectively);  (D) Single high magnification micrograph of M. oryzae (15,000x).  
 
Figure 4.6 Growth rate of M. oryzae                                                                               
M. oryzae in the logarithmic phase was inoculated into fresh nutrient agar supplemented 
with methanol and incubated at 30oC.  The increase in optical density (OD600) was 
measured over time.  
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4.2.6 Broad spectrum analysis of cellular transcription following infection 
with Methylobacterium sp.  
 
The transcriptional profile of atherosclerosis-related genes following infection with 
Methylobacterium sp. was investigated in murine macrophage and endothelial cell lines.   
This was performed in order to determine if this bacterium could have a pro-atherogenic 
effect on these cell types. 
 
 
4.2.6.1 Sequence alignment of 16S rRNA genes of M. oryzae and M. 
mesophilicum 
 
At the time of study M. oryzae was unavailable, initial experiments in murine cell lines 
were therefore carried out with M. mesophilicum.  Prior to experimentation a 16S rRNA 
gene alignment was performed in order to provide a measure of genetic similarity between 
M. mesophilicum and M. oryzae (See Appendix 5).  A concise linear alignment across the 
16S rRNA gene identified a 95.1% genetic similarity, demonstrating that these bacterial 
species have a highly similar genome and implies very close genetic relationship. 
 
 
4.2.6.2  Genes analysed by TLDA qPCR array 
 
A qPCR array targeting 90 murine genes involved in immune regulation was used to 
profile the transcriptional response of murine macrophage and endothelial cell lines to M. 
mesophilicum.  Atherosclerosis is a process that involves thickening of vessel walls, a 
process related to inflammation, which then leads to the formation of plaque.  This process 
is dependent upon proteases, adhesion molecules, growth factors, extracellular matrix 
proteins and apoptosis signals.  A complete list of each of the genes analysed and their 
properties is provided in the Appendix (table 6.1-6.8). 
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4.2.7  Transcriptional response of murine macrophages to M. mesophilicum 
 
Murine RAW 264.7 macrophage cells were infected in duplicate with M. mesophilicum at 
a multiplicity of infection of 200.  To profile the cellular atherogenic transcriptional 
response to infection with M. mesophilicum analysis of sequential time points by 
transcriptional profiling of the 90 genes outlined in appendix 6 was conducted. 
Samples were analysed at four and eight hours post-infection.  Each independent sample 
was normalised to the housekeeping gene GAPDH and the transcriptional profile of 
infected macrophages was determined relative to the vehicle control (figure 4.7).  A fold 
change of greater than 1.5, or less than -1.5 was considered biologically relevant.  In order 
to ensure reliability, all replicates with a Ct above 33 were excluded in this study. 
Measurable levels of transcript was detected from 36 of the 90 genes examined.  As 
expected, gene expression changes were generally amplified with time.  Following eight 
hours of M. mesophilicum stimulation, the 10 most strongly upregulated genes and their 
fold change relative to control were as follows; Ptgs2 (5.1); Csf1 (4.6); Il1β (4.3); Ccl3 
(3.8); Fas (3.1); C3 (2.9); Hmox1 (2.7); Cd40 (2.6); Tnfα (2.6) and Cxcl10 (2.0).  All of 
these genes are associated with inflammation: for example, CD40 and Il1β upregulation is 
characteristic of activated macrophages.  The most strongly downregulated gene was IL-15 
(-2 fold).  Suitably, this gene is expressed by macrophages following viral but not bacterial 
infection.   
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Figure 4.7  Transcriptional profile of RAW 264.7 murine macrophages following M. mesophilicum stimulation       Cells were stimulated with M. 
mesophilicum at a multiplicity of infection of 200 for four and eight hours.  Bars represent experimental duplicates.  The fold change for each gene was 
generated by comparing the means of signal densities of stimulated vs non-stimulated control.  
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4.2.8 Biological pathway analysis by Ingenuity IPA analysis of murine 
macrophages infected with M. mesophilicum   
 
Following identification of differentially expressed genes from TLDA experiments, a 
subsequent post-analysis task was performed in order to find the main biological processes 
associated with the experimental data.  The ‘core analysis’ function included in IPA 
(Ingenuity System Inc, USA) was used to interpret the gene expression data for 
macrophages stimulated for eight hours with M. mesophilicum in the context of biological 
pathways, processes and networks.  Both up- and down- regulated genes were defined as 
value parameters for the analysis and all data with a Ct≤33 was included.   After the 
analysis, generated biological processes were ordered by a score representing significance.  
IPA analysis revealed significant biological functions and canonical pathways to be 
associated with the differentially expressed genes.  The most significant biological function 
associated with the TLDA-identified genes corresponded to ‘inflammatory response’ 
(p=1.32E-29 to 1.71E-10) with 29 of the analysed genes being directly implicated in this 
process.  Interestingly, several of the most significant canonical pathways were related to 
cardiotoxicity [cardiac inflammation (p=5.28E-10 to 1.1E-2), cardiac necrosis/cell death 
(p=1.24E-9 to 3.46E-2) and cardiac dysfunction (7.54E-6 to 5.54E-3)].  The remaining 
significant canonical pathways identified were related to renal and liver damage/necrosis. 
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4.2.9 Transcriptional response of murine endothelial cells to M. 
mesophilicum 
 
Murine SVEC endothelial cells were cultured until 100% confluent and stimulated with 
exponentially replicating M. mesophilicum at an MOI of 200.  As in the previous 
experiment (Section 4.7), total cellular RNA was extracted at four and eight hours post-
stimulation and the expression profile of 90 genes (Appendix 6) analysed by TLDA.  Raw 
fluorescence intensity was processed using the Applied Biosystems RQ data suite.  Each 
independent sample was first normalised to the housekeeping gene GAPDH and the 
transcriptional profile of infected macrophages was then determined relative to the vehicle 
control.  In order to ensure reliability all replicates with a Ct value above 33 were excluded 
in this study.  A resulting fold change of greater than 1.5, or less than -1.5 was considered a 
biologically relevant change.  
Following eight hours stimulation, only five of the 90 genes examined demonstrated a 
transcriptional fold change of greater than 1.5 or less than -1.5 (figure 4.8).  IL6, IL18 and 
Ccl2 were upregulated 1.8-, 2.32- and 2.3- fold respectively, whereas NFkb2 and Bcl2l1 
were downregulated by 1.67- and 1.6- fold, respectively.  The majority of genes (79 of 90) 
were either non-detectable or had a Ct≥33.  Furthermore, mRNA corresponding to sele and 
selp, which encode E-selectin and P-selectin respectively, were not detectable following M. 
mesophilicum infection.  Upregulation of these genes is a hallmark of endothelial cell 
activation.   
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Figure 4.8 Transcriptional profile of SVEC murine endothelial cells following M. 
mesophilicum stimulation        
Cells were stimulated with M. mesophilicum at a multiplicity of infection of 200 for four 
and eight hours.  Bars represent experimental duplicates.  The fold change for each gene 
was generated by comparing the means of signal densities of stimulated vs non-stimulated 
control.  
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4.2.10 Immune responses of human primary macrophages to 
Methylobacterium oryzae in vitro 
 
In Section 4.3 it was shown that M. oryzae was detected in the aortic adventitia of 100% of 
16S rRNA gene PCR-positive RA+CVD patients and contributed 35% to total bacterial 
burden.  Initial experiments in murine macrophage cell lines demonstrated that M. 
mesophilicum (closely related to M. oryzae) triggered a pro-inflammatory response (see 
Section 4.2.7).  In order to increase our understanding of how bacteria may behave during 
atherosclerosis and to increase clinical applicability we next challenged human primary 
macrophages with M. oryzae. 
 
 
4.2.10.1 Isolation and purity of human primary macrophages 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from the blood of 3 healthy 
donors.  Primary cultures of CD14+ monocytes were prepared using anti-CD14-conjugated 
magnetic beads.  Prior to culture, flow cytometry analysis was performed to assess the 
purity of CD14+ monocytes.  In all cases purity was in the region of 95% (figure 4.9).  
Highly purified adherent CD14+ monocytes were then cultured for seven days in the 
presence of 15ng/ml M-CSF to ensure monocyte differentiation into macrophages. 
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Figure 4.9 FACS plots illustrating purity of isolated CD14+ monocytes             
(A, B) FACS analysis on PBMCs prior to CD14+ isolation demonstrates that 37.3% of 
cells were CD14+ monocytes, 27.8% CD3+ T cells and 5.57% CD19+ B cells. (C) FACS 
analysis of PBMCs following CD14 separation showing that only 0.9% CD14+ cells 
remained. (D) FACS analysis following CD14 separation demonstrating that isolated 
monocytes were 94.9% pure. 
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4.2.10.2 Transcriptional analysis of human primary macrophages infected with 
Methylobacterium oryzae 
 
Analysis of the relative expression of 90 genes involved in immune regulation (Appendix: 
table 6.1-6.8) showed that, following in vitro infection with M. oryzae, 40 genes were 
differentially expressed in human primary macrophages.  Thirty-eight of the differentially 
expressed genes were upregulated and two genes were down-regulated.  In general, 
following 4 and 8 hours of infection with M. oryzae, macrophages displayed an excessive 
pro-inflammatory response.  
 
To facilitate analysis, the differentially expressed genes were divided into several 
categories based on biological activity.  For completeness, figures 4.10 to 4.16 list all the 
genes that were detected in primary macrophages following M. oryzae infection (Ct ≤33).  
However, the 40 genes which demonstrated at least two-fold increase or decrease in 
expression in infected macrophages relative to uninfected control cells are highlighted (#).   
 
After both four and eight hours of infection, many of the upregulated genes were those that 
encode pro-inflammatory cytokines (IL-1α, IL-1β, IL-6 and TNF-α) (figure 4.10) and 
chemokines (CCL3, CCL5, CCL19 and IL-8) (figure 4.12).  Interestingly, the gene 
encoding the anti-inflammatory cytokine IL-10 was also induced upon stimulation with M. 
oryzae (62-fold increase after eight hour stimulation).  Of the cytokines, IL-18 remained 
unchanged.  IL-18 is a pro-inflammatory cytokine principally produced by macrophages 
following infection with microbial products such as lipopolysaccahride (LPS).   
 
A set of genes up-regulated in response to the infection encoded co-stimulatory molecules 
involved in the induction of antigen-specific immune responses (CD40 and CD80) and cell 
adhesion molecules that are critical for immune cells to enter sites of infection (ICAM-1).  
Elevated mRNA levels were also observed for apoptosis-regulating genes (Bcl2 and 
Bcl2l1, showing 12- and 7-fold up-regulation, respectively, following eight hour bacterial 
stimulation); however mRNA levels of the pro-apoptotic gene Bax remained unchanged. 
 
Granzyme B (encoded by GZMB) is a serine protease that is highly expressed in cytotoxic 
T cells and natural killer cells.  The principal function of granzymes is to induce the death 
of virus infected and other transformed cells.  Following infection for four and eight hours, 
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GZMB was greatly increased in infected macrophages (24-fold at four hours and 197- fold 
at eight hours).  Granzyme B is discussed further in the general discussion (chapter 6).   
Among other genes whose expression was greatly increased was the pro-vasoconstriction 
agent endothelin 1(EDN1) and the enzyme PTGS2.  PTGS2 converts arachidonic acid to 
prostaglandin endoperoxide H2 and is the target of the NSAIDs used for the treatment of 
RA. 
 
Of the 90 genes analysed, CSF2 (GM-CSF) exhibited the greatest upregulation (23,000 and 
11,000 fold upregulation following four and eight hours stimulation respectively).  CSF2 is 
a cytokine that functions as a white blood cell growth factor which leads to rapid increase 
in macrophage number in vivo.  Conversely, the gene encoding the transcription factor 
SMAD3 (modulates signals of activin and is essential for TGF-beta-mediated immune 
suppression) exhibited the greatest down regulation following infection (9- and 12-fold 
down regulation following four and eight hours stimulation respectively).   
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Figure 4.10  Transcriptional profile of genes encoding cytokines in primary human 
macrophages following M. oryzae stimulation  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#). 
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Figure 4.11  Transcriptional profile of genes encoding enzymes or intracellular 
proteins in primary human macrophages following M. oryzae stimulation  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#).        
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Figure 4.12 Transcriptional profile of genes encoding chemokines in primary human 
macrophages following M. oryzae stimulation  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#).        
 
 
   
 
 
 
 
 
CX
CL
10
CX
CL
11
CC
L2
CC
L3
CC
L5
CC
L1
9
CC
R4
CC
R5
CC
R7 IL8
0
100
4 hours
8 hours
250
500
750
1400
1650
1900
2150
#
#
####
#
#
#
#
##
#
#
#
#
#
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 v
eh
ic
le
 c
on
tr
ol
141 
 
 
 
 
Figure 4.13 Transcriptional profile of genes encoding lineage markers in primary 
human macrophages following M. oryzae stimulation  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#). 
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Figure 4.14 Transcriptional profile of genes encoding signalling and transcription 
factors in primary human macrophages following M. oryzae stimulation  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#).        
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Figure 4.15 Transcriptional profile of genes encoding adhesion molecules and cell 
surface proteins in primary human macrophages following M. oryzae stimulation.  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control. Fold change >2 (#).          
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Figure 4.16 Transcriptional profile of genes encoding growth factors, immune 
effectors and pro-survival proteins in primary human macrophages following M. oryzae 
stimulation.  
Primary human macrophages were stimulated with M. oryzae at a multiplicity of infection 
of 200 for four and eight hours.  Each column represents the mean ± standard error of 
three experiments.  The fold change of each transcript was generated by comparing the 
means of signal densities of stimulated vs non-stimulated control.  Fold change >2 (#).         
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4.2.10.3 Biological pathway analysis by Ingenuity IPA analysis of human 
primary macrophages infected with M. oryzae  
 
Genes identified as being differentially expressed in primary human macrophages 
following M. oryzae were analysed using IPA pathway analysis software (Ingenuity 
System Inc, USA).  Analysis was used to interpret the eight hour data and conditions were 
matched to those used in section 4.8 with the exception that human instead of murine 
pathways were cross-referenced.    
 
IPA analysis revealed significant biological pathways and canonical pathways associated 
with the pattern of differential gene expression following M. oryzae infection.  The 
transcriptional profile observed in the infected human primary macrophages correlated 
with expression seen during ‘immunological disease’ (p=2.93E-32 to 1.55E-15) and 
‘inflammatory disease’ (p=8.90E-27 to 2.21E-15).  Similar to our previous study in murine 
cell lines (Section 4.8) we observed that the transcription profile of human infected 
macrophages was significantly related to cardiotoxicity canonical pathways.  Both ‘cardiac 
inflammation’ (p=8.76E-11 to 1.51E-02) and ‘cardiac necrosis/cell death’ (p=2.4E-14 to 
4.7E-02) were significantly related to the transcription profile identified following M. 
oryzae infection. 
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4.2.11  TLR response to M. oryzae 
 
In order to determine whether M. oryzae could stimulate TLR signalling, TLR deficient 
HEK-293 cells were transfected with a nuclear factor-kappaB (NF-kB)-sensitive reporter 
and TLR2 or TLR4 (kindly performed by Dr Clett Erridge, University of Leicester).  All 
TLR signalling pathways culminate in activation of the transcription factor nuclear factor-
kappaB (NF-kB), which controls the expression of an array of inflammatory cytokine 
genes.  Previous studies have demonstrated that TLR2 and TLR4 are the most abundant 
TLRs in human atherosclerotic lesions and that transcription was elevated >3-fold 
compared to healthy arteries (Edfeldt et al., 2002).  With this in mind, the following work 
concentrates on these two receptors.  TLR2 mediates host response to bacteria principally 
by recognition of the lipopeptides (e.g. Lipoteichoic acid), and TLR4 mediates host 
response to bacteria by recognition of lipopolysaccahride (LPS).  E. coli is known to 
stimulate both TLR2 and TLR4 (Lee et al., 2002).   
 
M. oryzae and E. coli K12 (starting concentration of 1x108 cells/ml), Pam3CSK4 
(10ng/ml) (a TLR2 agonist) and LPS (10ng/ml) were suspended in DMEM and incubated 
with transfected HEK-293 cells for 18 hours.    NF-kB signalling was expressed as mean 
fluorescent intensity of the reporter construct (pELAM) normalised to co-transfected 
renilla expression to account for fluctuations in plasmid transfection and expression 
efficiency.  Clear TLR2 and TLR4 dependent signalling of Pam3CSK4 and LPS, 
respectively were detected (figure 4.17 and figure 4.18).  As expected, E. coli activated 
signalling via both TLR2 and TLR4. It was also observed that LPS was a mild activator of 
TLR2-mediated signalling.   
 
TLR4 was entirely insensitive to M. oryzae (figure 4.18).  Mild TLR2 dependent signalling 
was observed when TLR2 HEK-293 transfected cells were challenged with the highest 
concentration of M. oryzae (1x107 cells/ml) (figure 4.17).  However at decreasing 
concentrations (1x106 and 1x105 cells/ml) no significant increase in TLR2 signalling 
relative to the control was observed.  Signalling detected in the negative controls represents 
homeostatic NF-kB signalling.  All experiments were carried out in triplicate.  These data 
suggest that M. oryzae expresses small amounts of TLR2 ligand but does not possess the 
TLR4 ligand LPS.   
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Figure 4.17 M. oryzae and TLR2 signalling.                                                                 
HEK-293 cells co-transfected with NF-kB sensitive reporter (pELAM) and TLR2 were 
challenged for 18 hours with M. oryzae (1:10 dilution equivalent to 1x107 cells/ml), E. coli 
K12 (1x107 cells/ml), Pam3CSK4 (10ng/ml) and LPS (10ng/ml).  The vehicle control was 
treated with medium only.  Arbitrary units (a.u.) represents mean fluorescent intensity of 
the reporter construct normalised to co-transfected renilla.   Data are representative of 
three experiments ± S.D.  **p<0.01 vs. control; ***p<0.001 vs. control.  
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Figure 4.18 M. oryzae and TLR4 signalling.                                                                 
HEK-293 cells co-transfected with NF-kB sensitive reporter (pELAM) and TLR4 were 
challenged for 18 hours with M. oryzae (1:10 dilution equivalent to 1x107 cells/ml), E. coli 
K12 (1x107 cells/ml), Pam3CSK4 (10ng/ml) and LPS (10ng/ml).  The vehicle control was 
treated with medium only.  Arbitrary units (a.u.) represents mean fluorescent intensity of 
the reporter construct normalised to co-transfected renilla.   Data are representative of 
three experiments ± S.D.  **p<0.01 vs. control; ***p<0.001 vs. control.  
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4.2.12  Detection of LPS in M. oryzae 
In section 4.11, it was determined that M. oryzae does not stimulate TLR4 signalling.  To 
determine whether M. oryzae possesses a TLR4 ligand, total cellular LPS and LOS was 
isolated from the bacteria using a hot phenol/water extraction protocol.  To ensure 
extraction efficacy, LPS from E. coli K12 was extracted in tandem.  In order to 
characterise extracted LPS/LOS, sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by silver staining was performed.  Commercially 
available (Sigma-Aldrich) Salmonella typhimurium rough LPS, Salmonella typhimurium 
smooth LPS, Pam3CSK4 and LOS were also visualised for comparison.   
LPS profiling discriminated between isolated E. coli LPS, Salmonella rough LPS, 
Salmonella smooth LPS and LOS (figure 4.19).  The LPS extracted from E. coli exhibited 
similar band patterns to Salmonella smooth LPS.  Salmonella rough LPS was characterised 
by having no repeating units.  SDS-PAGE confirmed the absence of the TLR4 ligands LPS 
and LOS in M. oryzae.   
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Figure 4.19 LPS/LOS profile of M. oryzae                                                                                  
SDS-PAGE (13%) and silver staining of LPS/LOS following hot phenol extraction from M. 
oryzae.   
E. coli K12 was used as the positive control.  Smooth and rough LPS from Salmonella 
typhimurium and purified LOS were included for visual comparison (5µg per lane).  
 
 
 
 
 
 
 
 
  
151 
 
 
 
4.3  Discussion 
 
Bacterial DNA from a diverse range of species was identified in biopsies of aortic 
adventitial tissue obtained from patients following CABG surgery. The principle finding of 
this study was that RA patients had a significantly reduced heterogeneity in the bacterial 
species associated with the diseased aortic adventitia when compared to non-RA patients. 
Furthermore, M. oryzae was detected in all aortic adventitia samples from RA patients that 
were PCR-positive for the 16S rRNA gene, but in only 25% of samples from non-RA 
patients.  The clinical relevance of M. oryzae is further discussed in chapter 6 (general 
discussion). 
 
The bacteria identified in this study included an array of environmental and oral species.  
Many of these species have previously been reported as opportunistic or nosocomial 
pathogens. For example Stenotrophomonas sp., which was detected in both RA and non-
RA patients, has recently emerged as an important opportunistic pathogen in debilitated 
individuals (Looney et al., 2009).  Furthermore, it is reported to infect 
immunocompromised individuals at a high frequency (Rolston et al., 2005).  Indeed, 
sequences of Stenotrophomonas sp., have been reported in up to 60% of aneurysm samples 
(Marques da Silva et al., 2006).  Stenotrophomonas sp., have also been demonstrated to 
cause bloodstream infections (Park et al., 2008).  Several species of Stenotrophomonas, 
including the most widely studied S. maltophilia, express a protease (StmPr1) that is 
capable of breaking down fibrinogen, fibronectin and collagen (Windhorst et al., 2002).  
This may ultimately result in local tissue damage and as such, may be a potential 
atherogenic trigger. 
 
Several oral bacteria were detected in the present study, including Veillonella sp., 
Porphyromonas endodontalis, Streptococcus sanguinis. Streptococcus mitis, Haemophilus 
and a Neisseria oral clone.  Veillonella species exist as part of a healthy oral, 
gastrointestinal and female genital flora. However, in a rare number of cases Veillonella 
species have been implicated as the aetiological agent of infective endocarditis (Greaves 
and Kaiser, 1984, Loughrey and Chew, 1990, Loewe et al., 1946), a condition that shares 
many pathophysiological features with atherosclerosis. Similarly, Streptococcus sanguinis 
has been reported to be a causative agent in endocarditis (Douglas et al., 1993).  The 
detection of oral bacteria in the aortic adventitia provides support for the concept of 
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haematogenous spread of oral pathogens to the atherosclerotic site. Oral bacteria can 
potentially enter the bloodstream during tooth brushing, chewing, oral infection and 
invasive dental procedures (Chung et al., 1986).  
 
Surprisingly, despite a variety of oral pathogens having been identified in the aortic 
adventitia, not a single periodontal pathogens was detected in these samples.  Periodontal 
disease has been proposed as a significant risk factor in CVD (Destefano et al., 1993, 
Mattila et al., 1989).  In contrast to data presented in this study, Haraszthy et al, reported 
that 22 of 50 endarterectomy samples tested positive for the presence of periodontal 
pathogens (Haraszthy et al., 2000). 
 
Chlamydia pneumoniae has been the subject of the majority of research investigating 
bacterial infection and atherosclerosis.  Strong associations between C. pneumoniae and 
atherosclerosis have been demonstrated by: (i) detection of C. pneumoniae within 
atherosclerotic lesions, but not adjacent normal tissue by PCR, IHC and electron 
microscopy (Shor et al., 1992, Kuo et al., 1993); (ii) sero-epidemiological studies 
demonstrating that patients with CVD have higher titres of anti-C. pneumoniae antibodies 
compared to healthy patients; (iii) showing that C. pneumoniae can cause exacerbation of 
atherosclerotic lesions in murine models (Hu et al., 1999, Campbell et al., 2000).  
Nonetheless, the association between C. pneumoniae and CVD has been inconsistent from 
study to study, in a manner that has been ascribed to varying diagnostic methodology 
(Boman and Hammerschlag, 2002).  However, as no C. pneumoniae was detected in any of 
the samples studied here, it would appear unlikely that C. pneumoniae plays a major role in 
adventitial derived pathology.   
 
The differences in bacterial species identified in this study compared with other studies 
could have several explanations.  These include differences in geographical location of 
patients sampled, diagnostic methodology used and anatomical site sampled. 
 
Clinical samples used for the present study were all taken from an age- and sex-matched 
Norwegian cohort.  Owing to socioeconomic status, diet, environment and lifestyle the 
microbial profiles are likely to vary from one geographic location to another.  Research to 
determine the geographical variation in aortic microbiota remains to be performed.  
However, Haffajee et al, determined that the microbial profile of subgingival plaque 
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samples from chronic periodontitis subjects varied significantly across four analysed 
countries and these differences persisted despite adjustment for age, gender and smoking 
status (Haffajee et al., 2004).   
 
PCR-based sequence analysis of the 16S rRNA gene was used to identify bacterial DNA in 
the aortic adventitia.  16S rRNA gene analysis is a powerful and essential tool for studying 
bacterial diversity and has enabled detection of unculturable bacteria.   However, the PCR 
procedure intrinsically leads to bias and error.  This is attributable to complex factors such 
as preferential annealing between primers and templates, self-annealing between primers 
and templates, self-annealing between PCR products, different copy numbers of the 
targeted genes and the formation of chimeric sequences (Suzuki and Giovannoni, 1996, 
Qiu et al., 2001, Hongoh et al., 2003).  In the present study, a low annealing temperature of 
55oC was used so as to suppress amplification bias caused by primer mismatches, and the 
number of PCR cycles was limited to 30 in an effort to minimise primer mismatch but still 
retain detection sensitivity.  Despite the widespread use of 16S rRNA gene PCR in clinical 
research, there remains no conformity with regard to either primer design or PCR 
conditions.  These anomalies are likely to contribute to the variations observed in data 
generated from different research groups. 
 
Another major concern when using 16S rRNA gene sequencing analysis to identify 
bacteria in clinical specimens is the lysis efficiency of different bacteria in a complex 
environment.  Ideally, lysis of bacterial cells should be equally efficient for all bacterial 
species and independent of growth phase and the concentration of cells in the sample 
(Zoetendal et al., 2001).  The present study employed a powerful DNA isolation 
mechanism involving proteinase K digestion prior to homogenisation in Trizol® reagent.  
This technique differs from other published work studying 16S rRNA gene presence in 
human tissue and may lead to differences in the bacterial species detected.  For example, 
Marques da Silva et al, (2006) homogenised tissue samples in a sterile mortar with liquid 
nitrogen whereas Haraszthy et al (2000) purified DNA directly from tissue samples.  
 
Importantly, the present study is unique as it was carried out in aortic adventitia tissue that 
was removed for the establishment of aortocoronary anastomoses during CABG surgery.  
This tissue is located downstream of the site of atherosclerotic lesion.  Considerable 
attention has been given to the atherosclerotic lesion itself, as well as endothelial cells on 
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the luminal surface of arteries and the media with regards infection and vascular lesion 
formation.  However, virtually no attention has been paid to the potential role of the 
adventitia in this process.  This lack of research attention may be due to the previous 
perception that the adventitia is nothing more than ‘loose connective tissue’ that enclosed 
blood vessels and is devoid of function other than to act as support for large vessels 
(Wilcox and Scott, 1996).  Contrary to this, in chapter 3 of this thesis it was determined 
that the adventitia is a site of considerable immunological activity, possessing 
inflammatory infiltrate and detectable levels of TNFα, heat shock protein and calprotectin.  
Furthermore, the adventitial layer of vessels have been suggested to exhibit properties 
resembling a stem/progenitor cell niche.  Indeed, progenitor cells have been isolated from 
the adventitia of both human and murine blood vessels with the potential to form 
endothelial, osteogenic and mural cells (Majesky et al., 2012).  Progenitor cells from the 
adventitia have been suggested to migrate into the intima where they proliferate and 
differentiate into neo-smooth muscle cells which play a functional role in the formation of 
the atherosclerotic lesion (Xu, 2005).   
 
Adventitia-derived inflammatory cells, cytokines, progenitor cells and microvasculature 
likely contribute significantly to many different vascular disease states (Maiellaro and 
Taylor, 2007).  The involvement of the adventitia in vascular pathology suggests that 
concomitant to the traditional ‘inside-out’ view of atherogenesis that there is an ‘outside-
in’ component.  The establishment of bacterial presence in this under-studied niche 
suggests that bacterial infection may trigger an ‘outside-in’ inflammatory response.  
However, future research is required to verify this hypothesis. 
 
The detection of bacterial DNA in the aortic adventitia supports the hypothesis that 
bacterial infection may contribute to the pathophysiology of atherosclerosis, but to what 
extent remains uncertain. It has been postulated that the atherosclerotic tissue may act as a 
‘mechanical sieve’ trapping bacteria present in blood circulation and that detected bacteria, 
although present, may have no pathological significance (Lehtiniemi et al., 2005).  
Furthermore, it is possible that bacterial colonisation is secondary to atheromatous lesion 
formation and may potentiate acceleration of the disease process. Extending our 
understanding of the principal factors that lead to accelerated atherogenesis in RA patients 
is necessary in order for specific therapeutic intervention and prevention to be 
implemented. 
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The findings of our study implicate a diverse range of bacterial species within the 
atherosclerotic lesion, supporting the hypothesis that a wide range of bacterial species 
rather than a single aetiological agent may contribute to atherosclerotic burden. In keeping 
with this, Ott et al. (Ott et al., 2006) reported a mean bacterial diversity of 12.33 different 
species in 38 CHD patients studied. Furthermore, the current study has demonstrated that 
the bacterial population in the aortic adventitia of CABG patients is significantly less 
diverse in patients with RA (see general discussion). These data may help in the on-going 
debate to explain why the incidence of CVD is significantly elevated in RA patients.  
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5 Systemic immune profile in cardiovascular 
disease with co-existing rheumatoid arthritis 
and implications in foam cell formation  
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5.1 Introduction 
The reasons for the increased CVD morbidity and mortality observed in RA are likely to 
be multifactorial, with the majority of data supporting a predominant role for systemic 
inflammation in driving premature atherogenesis.  
Evidence suggests that atherosclerosis is an inflammatory disease sharing a similar 
pathophysiology to synovial inflammation and pannus formation in RA (Snow and Mikuls, 
2005).  Furthermore, these diseases share several pathogenic features including the 
predominant role of pro-inflammatory cytokines (e.g. TNFα and IL-6), angiogenesis, 
increased expression of leukocyte adhesion molecules and the elevation of serum acute 
phase proteins (e.g. CRP and fibrinogen). 
Population-based studies support an association of cardiovascular events with 
inflammation.  In a study involving over 100 male participants, base-line plasma CRP was 
identified as an independent predictor for future myocardial infarction (Ridker, 1997, 
Ridker et al., 2002).  The men in the quartile with the highest CRP had three times the risk 
of myocardial infarction compared to men in the lowest quartile.  In a joint statement the 
Centre for Disease Control (CDC) and the American Heart Association (AHA) categorised 
individuals with serum levels of CRP >3mg/L as high risk for future CVD events (Graf et 
al., 2009).  Serum CRP levels in RA patients are frequently above the 3mg/L cut-off 
associated with high risk of CVD in the general population.  For example, cross-sectional 
examination of 767 RA patients revealed a median CRP serum level of 11mg/L (Aletaha et 
al., 2005). 
Endothelial dysfunction as a result of reduced vasodilator function is among the earliest 
features of atherosclerosis (Gotto, 2004).  Systemic inflammation observed in RA may act 
as a potent mediator of endothelial dysfunction.  For example, in vivo human studies 
demonstrate that pro-inflammatory cytokines induce transient and reversible endothelial 
dysfunction (Bhagat and Vallance, 1997), an effect that may be mediated by increased 
oxidative stress and reduced vascular nitric oxide bioavailability (Clapp et al., 2004). 
The notion that systemic inflammation present in RA alters vasodilation was reinforced in 
a study involving 32 RA patients under the age of 60.  Young to middle aged RA patients 
with low disease activity without clinically overt atherosclerosis or traditional CVD risk 
patterns were found to have significant reductions in brachial flow-mediated vasodilation 
and these reductions positively correlated with serum CRP levels (Vaudo et al., 2004). 
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If the hypothesis that inflammation as a result of RA contributes to the development of 
CVD events is correct, then it is probable that the use of anti-inflammatory therapeutics in 
RA may decrease CVD morbidity.  Consistent with this, Jacobsson et al., examined 983 
RA patients, 531 of which were receiving treatment with the anti-TNF agents etanercept or 
infliximab and observed that subsequent CVD events were considerably lower in the anti-
TNF-treated patients (Jacobsson et al., 2005). Halm et al., investigated the association 
between CVD and the use of conventional disease-modifying antirheumatic drugs 
(DMARDs) in 613 RA patients.  After correction for other CVD risk factors DMARD use 
was associated with a significant CVD risk reduction.  The risk reductions remained 
significant after additional correction for the presence of rheumatoid factor and erosions 
(van Halm et al., 2006).  These studies highlight the protective role of anti-inflammatory 
therapeutics for the risk of CVD morbidity in RA patients 
Macrophages play a central role in atherosclerosis as modulators of both the immune 
response and lipid metabolism.  A critical event in atherogenesis is the focal accumulation 
of foam cells derived from macrophages (Shashkin et al., 2005).  Foam cell formation is 
thought to be induced by Low Density Lipoproteins (LDL), including acetylated LDL 
(acLDL) and oxidised LDL (oxLDL).  Although far less well established, it has also been 
suggested that the microvasculature has a pathogenic role in RA (Rothschild and Masi, 
1982) and immunohistochemical analysis has identified foam-like cells within the region 
of synovial blood vessels (Winyard et al., 1993).  
Scavenger receptors are known to be involved in the transformation of macrophages into 
lipid-laden foam cells (de Villiers and Smart, 1999).  The term “scavenger receptor” 
initially described the macrophage cell surface proteins that mediate the uptake of modified 
LDL in cell culture (Goldstein et al., 1979).  Eight classes of macrophage scavenger 
receptors exist (Classes A to H).  Among the growing number of scavenger receptor 
members, SR-A1, SR-B1, MARCO and CD36 which recognise both oxLDL and acLDL 
are thought to be the principal receptors responsible for the uptake of modified LDL and 
the subsequent formation of foam cells (Kunjathoor et al., 2002, McLaren et al., 2010).  
The uptake of oxLDL and acLDL, the primary modified LDL particles found in 
atherosclerotic plaque, is increased in THP-1 macrophages following stimulation with 
IFN-γ (Wuttge et al., 2004, Reiss et al., 2004).  Furthermore, IFN-γ was found to increase 
SR-A expression in early differentiated THP-1 macrophages (Grewal et al., 2001).  
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Macrophages are inherently reactive and respond to a broad range of cytokines including 
IL-4, IL-13 and TNFα (Stein et al., 1992, Doherty et al., 1993, Khera et al., 2011).  
 It thus seems probable that pro-inflammatory factors that are over expressed in the serum 
of patients with RA+CVD may prime macrophages to enhance the uptake of modified 
lipoprotein resulting in increased foam cell formation.  
To increase understanding of the link between RA and CVD we collected human serum 
samples from healthy controls as well as patients with RA, CVD and RA+CVD.  The 
principal aims of this study were:  
1. To determine which pro-inflammatory markers and immune mediators are 
over-expressed in patients with RA+CVD relative to healthy controls and 
patients with RA or CVD only. 
2. To uncover whether inflammatory markers over-expressed in RA+CVD 
may have implications in modified LDL uptake and subsequent foam cell 
formation. 
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5.2 Results 
5.2.1 Patients characteristics 
Human serum samples were from the Feiring Heart Biopsy Study.  Patient characteristics 
are shown in Table 5.1.  A total of 77 patients were included in the following human 
studies, and comprised patients with CVD (n=19), RA (n=21), RA+CVD (n=16) and 
healthy controls (n=21).  Attempts were made to minimise inter-cohort variability of both 
the demographic data and pre-existing cardiovascular risk factors.  However, owing to the 
inherent differences in the diseases under investigation, and the limited samples available, 
this was not always possible. 
There was no significant difference in the gender composition of each cohort, however the 
mean age of the healthy group was significantly lower than both the CVD and RA+CVD 
patients.  As expected, the incidence of hypertension and hyperlipidaemia was significantly 
elevated in the CVD and RA+CVD cohorts.  There was a significant increase in the 
number of current smokers in the RA cohort relative to both the RA+CVD and CVD 
cohorts.  Data regarding both current and previous smoking was unavailable for the healthy 
controls. 
The use of current cardiovascular medication (ACE inhibitors, acetylsalicyclic acid and 
statins) was similar in both the CVD and RA+CVD cohorts.  Most of the patients with RA 
exhibited low to moderate disease activity.  The use of DMARDs was similar in both the 
RA and RA+CVD cohorts; however the use of traditional non-steroidal anti-inflammatory 
drugs (NSAIDs) was greater in the RA cohort relative to the RA+CVD cohort.  This 
anomaly is accounted for by the significantly increased use of COX-2 selective inhibitors, 
which are a form of NSAID, in the RA+CVD cohort relative to the CVD cohort.   
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 CVD 
(n=19) 
RA 
(n=21) 
RA+CVD 
(n=16) 
Healthy 
(n=21) 
P † 
 
Age-years 
B.M.I. 
 
68±9 
25±4 
 
62±8 
25±5 
 
69±9 
26±6 
 
60±9 
NA 
 
<0.05‡ 
0.65 
Female-no. (%) 5 (26) 14 (66) 6 (38) 10 (48) 0.07 
Duration of CVD - months 88±80 - 97±110 - 0.9 
Time from angiography to CABG – 
days 
32±61 - 20±32 - 0.49 
Duration of RA - months - 126±114 221±184 - 0.14 
Number of swollen joints - 9±10 4±6 - 0.12 
C- reactive protein - mg/l 3±3 7±9 11±10 1±0.4 <0.0001§ 
Erythrocyte sedimentation rate - 
mm/hour 
15±9 19±17 34±28 4±3 <0.0001ɸ 
Hypertension - no. (%) 8 (42) 6 (29) 10 (62) 0 (0) <0.001¥ 
Hyperlipidemia - no. (%) 19 
(100) 
2 (10) 13 (81) 0 (0) <0.0001Җ 
History of myocardial infarction - no 
(%) 
8 (42) 0 (0) 11 (69) 0 (0) <0.0001₳ 
Diabetes - no (%) 1 (5) 0 (0) 1 (6) 1 (5) 0.74 
Acute coronary syndrome - no (%) 2 (11) 0 (0) 4 (25) 0 (0) <0.05₱ 
Previous smoker - no (%) 11 (58) 0 (0) 6 (37) NA <0.001α 
 
Current smoker - no (%) 1 (5) 11 (52) 2 (12) NA <0.05Ϫ 
Current use of:      
      Disease modifying drugs - no. (%)     0 (0) 18 (86) 14 (88) 0 (0) <0.0001Ѧ 
      Ace inhibitors - no. (%) 6 (32) 1 (5) 4 (25) 0 (0) <0.05Ѱ 
      Traditional NSAIDs - no. (%) 0 (0) 7 (33) 2 (12) 0 (0) <0.0001Ⱡ 
      Cox2-selective inhibitors - no. (%) 0 (0) 0 (0) 4 (25) 0 (0) <0.05♯ 
      Traditional statins - no. (%) 18 (95) 2 (10) 13 (81) 0 (0) <0.0001₵ 
      Acetylsalicylic acid - no. (%) 16 (84) 1 (5) 14 (87) 0 (0) <0.0001₴ 
Patient global assessment of RA (VAS, 
0-100mm) 
- 4±2 3±2 - 0.053 
 
Table 5.1 Patient characteristics 
Unless indicated otherwise, values represent mean ± SD.  Numbers may not add up to the 
expected total due to missing data for some variables.  ACE: angiotensin-converting 
enzyme.  NSAIDs: non-steroidal anti-inflammatory drugs.  VAS: visual analogue scale. 
NA: Not available 
†  P values for continuous dependent variables are from Kruskal-Wallis test followed 
by Dunn’s multiple comparison test.  Where only two cohorts have available data, 
analysis is by Mann-Whitney U test  
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‡ P<0.05 for comparisons between healthy and CVD or RA+CVD 
§ P<0.05 for comparisons between healthy and CVD.  P<0.01 for comparisons 
between healthy and RA.  P<0.001 for comparisons between healthy and 
RA+CVD. 
ɸ P<0.01 for comparisons between healthy and CVD, RA or RA+CVD 
¥ P<0.05 for comparisons between healthy and CVD or RA+CVD 
Җ P<0.001 for comparisons between: healthy and CVD or RA+CVD; CVD and RA; 
RA and RA+CVD 
₳ P<0.05 for comparisons between CVD and healthy or RA.  P<0.001 for 
comparisons between RA+CVD and healthy or RA 
₱ P<0.05 for comparisons between RA+CVD and healthy or RA 
α P<0.05 for comparisons between RA and RA+CVD.  P<0.001 for comparisons 
between CVD and RA 
Ϫ P<0.05 for comparisons between RA and CVD or RA+CVD 
Ѧ P<0.001 for comparisons between: healthy and RA or RA+CVD; CVD and RA or 
RA+CVD 
Ѱ P<0.05 for comparisons between healthy and CVD 
Ⱡ P<0.05 for comparisons between RA and RA+CVD.  P<0.001 for comparisons 
between RA and healthy or CVD 
♯ P<0.01 for comparisons between RA+CVD and healthy, RA, or CVD 
₵, ₴ P<0.001 for comparisons between: CVD and healthy or RA; RA+CVD and healthy 
or RA 
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5.2.2 Immune expression in serum of CVD, RA and RA+CVD patients 
In order to gain a better understanding of systemic inflammatory-derived events occurring 
within RA and CVD, a broad range of cytokines, chemokines, growth factors and receptors 
were analysed in RA (n=21), CVD (n=19) and RA+CVD patients (n=16) as well as 
healthy controls (n=21) (see section 5.2.1).  Protein concentrations within human serum 
samples were measured by LUMINEX and ELISA (sST2 only).  Details of the proteins 
analysed are outlined in table 5.2 and table 5.3. 
The research outlined in the following sections concentrates on uncovering potential 
biological mediators that may contribute to the increased CVD burden observed in RA 
patients.  Particular attention was paid to biomarkers that were significantly elevated in 
RA+CVD or RA patients relative to CVD patients or healthy controls.  Elevation of 
biomarkers in these patients could potentially lead to loss of vascular homeostasis and 
potentiate the onset of atherosclerosis.
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Protein Name Class Functions 
IL-1β Interleukin 1 β Cytokine Initiates cytokine cascade and vascular adhesion expression 
IL-2 Interleukin 2 Cytokine Stimulates proliferation of T and B cells 
IL-4 Interleukin 4 Cytokine Induces differentiation of naive helper T cells to Th2 cells 
IL-5 Interleukin 5 Cytokine Stimulates B cell growth and mediates eosinophil activation 
IL-6 Interleukin 6 Cytokine Pro-inflammatory pleiotropic cytokine 
IL-10 Interleukin 10 Cytokine Anti-inflammatory/resolving 
IL-12 Interleukin 12 Cytokine Differentiation of Th1 and Th2 cells and stimulates IFNγ production by PBMCs 
IL-13 Interleukin 13 Cytokine Inhibits inflammatory cytokine production 
IL-15 Interleukin 15 Cytokine Stimulates proliferation of T-lymphocytes 
IL-17 Interleukin 17 Cytokine Induces stromal cells to produce proinflammatory and hematopoietic cytokines 
TNFα Tumour necrosis factor 
alpha 
Cytokine Regulation of a wide spectrum of biological processes including cell proliferation, 
differentiation, lipid metabolism and apoptosis 
IFNα Interferon α Cytokine Produced by macrophages and have antiviral activities 
GM-CSF Granulocyte macrophage 
colony stimulating factor 
Cytokine Stimulates growth and differentiation of hematopoietic precursor cells from various 
lineages, including macrophages, eosinophils,  granulocytes and erythrocytes 
MIG Gamma interferon 
induced monokine 
Cytokine Chemotactic for activated T cells 
Eotaxin Eotaxin Cytokine Recruits eosinophils  
G-CSF Granulocyte colony 
stimulating factor 
Cytokine Controls the production, differentiation and function of granulocytes 
 
IL-1 RA Interleukin 1 receptor 
antagonist 
Cytokine Natural inhibitor of the pro-inflammatory effect of IL-1α and IL-1β 
 
Table 5.2  List of cytokines examined in the serum of healthy, RA, CVD and RA+CVD patients 
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Protein Name Class Functions 
FGF Fibroblast growth factor Growth factor Regulates cell growth, morphogenesis and tissue repair 
HGF Hepatocyte growth factor Growth factor Acts as a growth factor for a broad spectrum of tissues and cell types 
IL-7 Interleukin 7 Growth factor Stimulates proliferation of lymphoid progenitors and regulates B cell maturation 
VEGF Vascular endothelial 
growth factor 
Growth factor Induces endothelial proliferation and migration.  Inhibits apoptosis and induces 
permeabilisation of blood vessels 
EGF Epidermal growth factor Growth factor Stimulates growth of various epidermal and epithelial tissue 
IL-2R Interleukin 2 receptor Receptor High affinity receptor for IL-2 
sST2 Soluble suppression of 
tumorugenicity 2 
Receptor May be involved in the function of T helper cells.  Receptor for Il-33 which induces 
T cells, mast cells and basophils to produce type 2 cytokines 
IL-8 Interleukin 8 Chemokine Poly morphonuclear neutrophil chemoattractant   
MIP1α Macrophage 
inflammatory protein 1α 
Chemokine Involved in the acute inflammatory state for the recruitment and activation of 
polymorphonuclear leukocytes  
MIP1β Macrophage 
inflammatory protein 1β 
Chemokine Attracts CD4+ T lymphocytes 
IP-10 IP-10 Chemokine Chemotactic effect on activated T, NK and TH-1 cells 
RANTES Rantes Chemokine Promotion of inflammatory infiltrate and T-cell chemotaxis 
MCP-1 Monocyte chemotactic 
protein 1 
Chemokine Chemotactic factor that attracts monocytes and basophils but not neutrophils or 
eosinophils 
 
Table 5.3  List of growth factors, receptors and chemokines examined in the serum of healthy, RA, CVD and RA+CVD patients 
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5.2.2.1  Cytokine profile in CVD, RA, RA+CVD subjects 
The serum level of 17 different cytokines (table 5.2) was investigated in CVD (n=19), 
RA (n=21) and RA+CVD (n=16) patients and healthy controls (n=21) by Luminex 
assay.  Mean cytokine levels in pg/ml in whole serum shown in figure 5.1-5.2. 
The expression of all cytokines, with the exception of G-CSF was significantly elevated 
in the RA+CVD cohort relative to the healthy controls (Figure 5.1 & Figure 5.2).  
When considering RA patients relative to healthy controls, 12 of the 17 cytokines 
examined were elevated, four remained unchanged (IL-5, IL-10, IL-13, IL-17), and G-
CSF was significantly reduced.   
Somewhat surprisingly, IL-17 was found to be significantly elevated in the RA+CVD 
cohort relative to the RA cohort.  The T cell cytokine IL-17 is known to promote 
inflammation in RA through induction of monocyte migration (Shahrara et al., 2009).  
Il-17 was not significantly increased in CVD patients relative to healthy controls.  
Additionally, there was a non-significant trend towards elevated IL-1β, IL-2, IL-5 and 
IL-13 expression in the RA+CVD cohort relative to the RA cohort.  
Although CVD is an inflammatory condition, there was an overwhelming trend for 
reduced cytokine expression in CVD patients compared to RA patients.  IL-1β, IL-2 
and IL-6 were significantly lower in CVD patients compared to RA patients, and there 
was a non-significant trend towards reduced expression in all but one (G-CSF) of the 
remaining cytokines under investigation.  Furthermore, IL-12 was the only cytokine 
under investigation to show significant elevation in the serum of CVD patients relative 
to healthy controls. 
The pattern of G-CSF expression was distinct from all other cytokines analysed in this 
study.  Healthy controls and RA+CVD patients had high levels of serum G-CSF 
(875±363 and 1832±837, respectively) where as both CVD and RA patients expressed 
~10-fold less (105±5 and 66±8, respectively). 
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Figure 5.1 Interleukin concentrations in the serum of patients with CVD, RA, 
RA+CVD and healthy controls 
Serum was isolated from CVD (n=19), RA (n=21), RA+CVD (n=16) and healthy control 
samples (HS) (n=21).  Mean cytokine concentration is expressed as pg/ml and error bars 
represent ±S.E.M. Statistical analysis was performed by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test.  *P<0.05, **P<0.01, ***P<0.001 vs healthy control; 
#P<0.05, ##P<0.01, ###P<0.001 vs CVD; ϶ P<0.05, ϶϶P<0.01, ϶϶϶P<0.001 vs RA 
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Figure 5.2 Cytokine (non-interleukin) concentrations in the serum of patients with 
CVD, RA, RA+CVD and healthy controls 
Serum was isolated from CVD (n=19), RA (n=21), RA+CVD (n=16) and healthy control 
samples (HS) (n=21).  Mean cytokine concentration is expressed as pg/ml and error bars 
represent ±S.E.M. Statistical analysis was performed by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test.  *P<0.05, **P<0.01, ***P<0.001 vs healthy control; 
#P<0.05, ##P<0.01, ###P<0.001 vs CVD; ϶ P<0.05, ϶϶P<0.01, ϶϶϶P<0.001 vs RA 
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5.2.2.2  Chemokine and growth factor profile in CVD, RA, RA+CVD subjects 
Serum concentrations of six different chemokines (IL-8, MIP-1α, MIP-1β, IP-10, 
RANTES, MCP-1) and five growth factors (FGF, HGF, IL-7, VEGF, EGF) were analysed 
in patients with CVD, RA, RA+CVD and healthy subjects. 
The RA+CVD cohort had significantly higher serum levels of IL-8 than the RA (p<0.01), 
CVD (p<0.01) and healthy cohorts (p<0.001) (figure 5.3).  There was also a significant 
increase in serum IL-8 levels in RA patients relative to healthy controls.  The difference in 
serum IL-8 levels between the CVD and healthy control cohorts was not statistically 
significant.  These results present the possibility that IL-8 could be used as a biomarker for 
CVD in RA. 
The chemokine RANTES (also known as CCL5) is chemotactic for T cells, eosinophils, 
and basophiles, and plays an active role in recruiting leukocytes into inflammatory sites.  A 
significant elevation in serum RANTES was observed in RA+CVD patients compared to 
RA patients.  However, a significant increase was also observed in CVD patients compared 
to RA patients.  There was also a significant elevation in serum RANTES in CVD patients 
relative to healthy controls.  Taken together these data suggest that RANTES may be an 
effective CVD risk biomarker.     
Macrophage inflammatory proteins MIP-1α and MIP-1β shared similar expression 
patterns.  These chemokines are produced by activated macrophages resulting in the 
synthesis and release of various pro-inflammatory cytokines as well as activating 
granulocytes.  Serum levels of the chemokines MIP-1α and MIP-1β were significantly 
elevated in RA+CVD patients compared to CVD patients and healthy controls, however 
there was no significant difference observed between the RA+CVD and RA cohorts.  MIP-
1α and MIP-1β serum levels were also significantly elevated in the RA cohort relative to 
healthy subjects.  There was an apparent increase in the RA patients compared to the CVD 
patients, although this did not reach statistical significance. 
When considering growth factors, it was observed that the serum concentrations of FGF, 
HGF, IL-7 and EGF were significantly elevated in RA+CVD patients relative to CVD 
patients and healthy subjects (figure 5.4).  None of the growth factors analysed were 
significantly elevated in RA+CVD patients relative to RA patients.    
Levels of VEGF (mean ± S.E.M.), an endothelial cell specific growth factor, were 4±4 and 
3±3 pg/ml in RA patients and RA+CVD patients respectively, and were below the limits of 
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detection in CVD patients and healthy subjects.  No significant difference was observed 
between healthy subjects and diseased patients, suggesting that altered systemic 
concentration of VEGF does not play a role in the pathophysiology of either RA or CVD. 
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Figure 5.3  Chemokine concentrations in the serum of patients with CVD, RA, 
RA+CVD and healthy controls 
Serum was isolated from CVD (n=19), RA (n=21), RA+CVD (n=16) and healthy control 
samples (HS) (n=21).  Mean cytokine concentration is expressed as pg/ml and error bars 
represent ±S.E.M. Statistical analysis was performed by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test.  *P<0.05, **P<0.01, ***P<0.001 vs healthy control; 
#P<0.05, ##P<0.01, ###P<0.001 vs CVD; ϶ P<0.05, ϶϶P<0.01, ϶϶϶P<0.001 vs RA 
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Figure 5.4  Growth factor concentrations in the serum of patients with CVD, RA, 
RA+CVD and healthy controls  
Serum was isolated from CVD (n=19), RA (n=21), RA+CVD (n=16) and healthy control 
samples (HS) (n=21).  Mean cytokine concentration is expressed as pg/ml and error bars 
represent ±S.E.M. Statistical analysis was performed by Kruskal-Wallis test followed by 
Dunn’s multiple comparison test.  *P<0.05, **P<0.01, ***P<0.001 vs healthy control; 
#P<0.05, ##P<0.01, ###P<0.001 vs CVD; ϶ P<0.05, ϶϶P<0.01, ϶϶϶P<0.001 vs RA 
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5.2.2.3 sST2 and IL-2R expression in the serum of CVD, RA and  RA+CVD 
subjects 
Previously unpublished work from our lab identified IL-33 expression in the aortic 
adventitia of patients with both CVD and RA (Ahmad, 2010).  The receptor for IL-33 is 
ST2 and the membrane-bound form is constitutively expressed on fibroblasts, mast cells 
and Th2 cells.  A secreted isotype (sST2) is a soluble inhibitory receptor also known as 
IL1R1A and can be detected in human serum.  Binding of IL-33 to the membrane bound 
ST2 receptor in response to a cardiac event is believed to elicit a cardioprotective function.  
However, recent studies have shown that sST2 is a decoy receptor that disrupts the 
interaction of IL-33 with membrane bound ST2.  Elevated sST2 levels have been detected 
in patients early after acute myocardial infarction (Weinberg et al., 2002). 
In order to explore the hypothesis that sST2 may play a functional role in the increased 
CVD burden observed in RA, the serum concentration of sST2 was measured by ELISA in 
patients with CVD, RA, RA+CVD as well as healthy controls.  sST2 was detected in the 
serum of all four subject cohorts, however there was no significant difference between any 
of these cohorts (p>0.05, Kruskal-Wallis followed by Dunn’s multiple comparison) (figure 
5.5). 
Interlekin-2 (IL-2) has a central role in the initiation and development of immune 
responses through binding to the IL-2 receptor (IL-2R) and serum soluble IL-2R (sIL-2R).  
The exact biological role of sIL-2R is still not fully understood.  It is however known that 
increased  sIL-2R is associated with a broad spectrum of immunological conditions 
involving B- or T- cell activation and that soluble IL-2R is able to bind IL-2 (Caruso et al., 
1993, Boyman and Sprent, 2012).  In section 5.2.2.1 it was determined that IL-2 was 
significantly elevated in patients with RA relative to CVD patients and healthy controls.  In 
keeping with these previous data, soluble IL-2R was significantly elevated in RA patients 
relative to healthy controls, and in RA+CVD patients relative to CVD patients (figure 5.5).  
Unlike IL-2, there was no significant difference in soluble IL-2R expression when 
considering the RA and CVD cohorts.  This can be explained by the large variability in the 
RA cohort. 
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Figure 5.5 sST2 and IL-2R concentrations in the serum of patients with CVD, RA, 
RA+CVD and healthy controls 
Serum was isolated from CVD (n=19), RA (n=21), RA+CVD (n=16) and healthy control 
samples (HS) (n=21).  Mean concentration is expressed as pg/ml and error bars represent 
±S.E.M. Statistical analysis was performed by Kruskal-Wallis test followed by Dunn’s 
multiple comparison test.  *P<0.05, **P<0.01, ***P<0.001 vs healthy control; #P<0.05, 
##P<0.01, ###P<0.001 vs CVD; ϶ P<0.05, ϶϶P<0.01, ϶϶϶P<0.001 vs RA.  The lower 
detection limit for each mediator measured was 2pg/ml-1, any values lower than this were 
considered as 0 for this study. 
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5.2.3 Macrophages in the aorta of CVD patients with coexisting RA 
Essential to the pathophysiology of atherosclerosis is macrophage accumulation of 
intracellular lipid, resulting in foam cell formation.  Monocytes respond to a broad range of 
cytokines, chemokines and growth factors that are expressed both systemically and locally 
by smooth muscle cells, vascular endothelial cells and infiltrated cells.  Stimulated 
monocytes migrate from the peripheral blood into the arterial intima and differentiate into 
macrophages in the atherosclerotic lesion.  Macrophage colony-stimulating factor (M-CSF) 
is crucial for the differentiation of monocytes into macrophages and for survival of these 
cells in the atherosclerotic lesion (Takahashi et al., 2002).  Macrophages are known to 
express a variety of surface receptors, predominantly scavenger receptors, which recognise 
and support endocytosis of modified lipoproteins, including oxidised low-density 
lipoprotein (oxLDL).  
In the previous sections of this chapter (section 5.2.2 – section 5.2.2.3) it was established 
that a variety of cytokines and chemokines are over-expressed in the serum of RA patients.  
The following data explores the hypothesis that these signals may stimulate macrophages, 
leading to increased uptake of modified LDL and, consequently, increased foam cell 
formation. 
Firstly, verification that macrophages were present in the aorta of RA+CVD patients was 
sought.  As human atherosclerotic tissue was unavailable, aortic adventia sections from 
areas with no macroscopic signs of atherosclerosis were stained for CD68, a well 
established macrophage marker (IHC kindly performed by Ammad Ahmed).  CD68+ 
macrophages were detected in 17 of the 19 patients examined and staining was localised to 
areas of inflammatory cell infiltrate (figure 5.6). 
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Figure 5.6  Macrophage staining in the aortic adventitia of CVD patients 
Aortic adventitial staining for the macrophage marker CD68 can be seen (brown colour) 
in a lymphocyte aggregate (A).  The isotype control showed no background staining (B).  
Sections were counterstained with haematoxylin and images were captured by light 
microscopy at 40x magnification. 
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5.2.4 Low density lipoprotein isolation and oxidative modification 
In order to investigate the effect of cytokines and chemokines on oxLDL uptake by 
macrophages, native LDL was generated from healthy human serum using methods 
previously developed by Prof. Muriel Caslake (University of Glasgow). This involved the 
isolation of LDL by sequential flotation ultracentrifugation in a fixed angle rotor.  
Following isolation of native LDL it was necessary to quantify the concentration of LDL.  
This was performed using the modified Lowry protein assay.  Briefly, a standard curve was 
generated using bovine serum albumin (BSA) and the concentration of LDL was then 
determined by extrapolation from the standard curve.  Native LDL was then oxidised by 
addition of 10µM copper sulphate.  Following sufficient reaction lipoproteins were 
dialysed and stored in PBS containing 0.25mM EDTA.  Oxidation was verified by agarose 
electrophoretic mobility shift assay (figure 5.7). 
 
 
Figure 5.7 Electrophoretic mobility of oxLDL 
Native LDL and oxLDL prepared from the same donor were stained with Nile red in 
duplicate.  The LDL preparations were compared by electrophoresis using 1% agarose gel 
in sodium barbital buffer.  Lanes 1 & 2 are native LDL, lanes 3 & 4 are oxLDL. 
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5.2.5 Kinetics of oxLDL uptake and foam cell formation 
Prior to experimentation with oxLDL, it was first necessary to determine the kinetics of 
foam cell formation in M-CSF derived human primary macrophages.  CD14+ monocytes 
were isolated from human buffy coats and the resulting purity was verified by FACS 
(>97% purity) as previously outlined (section 4.10.1).  Monocytes were cultured for 7 days 
in the presence of 15ng/ml M-CSF to ensure complete differentiation into macrophages.  
Macrophages were then challenged with different concentrations of oxLDL (2, 20, 80, 200 
and 300µg/ml) for 24 hours (n=3).  Internalised oxLDL was visualised using Oil-red-O 
stain and the number of foam cells counted.  The percentage of macrophages exhibiting 
foam cell morphology increased with increasing oxLDL concentration (figure 5.8).   
Maximal foam cell formation was observed following incubation with 200µg/ml oxLDL.  
Having established that 200µg/ml oxLDL supported maximal foam cell formation, it was 
then necessary to quantify the kinetics of foam cell formation.  Macrophages were 
challenged with 200µg/ml oxLDL for 1, 2, 3, 4, 8, 12 and 24 hours.  Following one hour 
incubation, approximately 75% of macrophages exhibited foam cell morphology with 
saturation being reached after three hours (figure 5.8).   Although approximately 100% of 
macrophages were converting to foam cells following three hours incubation with 
200µg/ml oxLDL, the intensity of Oil-red-O staining increased for the 24-hour duration of 
the experiment (figure 5.8), indicating that lipid accumulation continued. 
 
 
 
 
 
180 
 
 
 
 
C 
 
 
 
Figure 5.8 Kinetics of oxLDL uptake by human macrophages 
(A) Concentration-dependent curve of foam cell formation induced by oxLDL (n=3).  
Human primary macrophages were incubated with different concentrations (2, 20, 80, 200 
and 300µg/ml) of oxLDL for 24 hours. Following Oil-Red-O staining, the percentage of 
macrophages exhibiting foam cell like morphology was calculated.  (B) Time-dependent 
curve of foam cell formation induced by oxLDL (n=2).  Human primary macrophages 
were incubated with 200µ/ml oxLDL for different lengths of time (1, 2, 3, 4, 8, 12 and 24 
hours) and the percentage of macrophages exhibiting foam cell morphology determined.  
(C) Representative images of the formation of foam cells over time (original magnification 
100x).  
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5.2.6  OxLDL loading in cytokine-treated human monocyte-derived macrophages 
Primary human macrophages were maintained in the presence of 15ng/ml M-CSF for 
seven days.  Cells were then stimulated overnight with GM-CSF (125ng/ml), IL-6 
(50ng/ml), IL-1β (5ng/ml), TNFα (50ng/ml), IL-15 (50ng/ml) or IL-17 (125ng/ml), all of 
which have been implicated in RA and CVD pathogenesis.  Control cells were stimulated 
with M-CSF (15ng/ml) only.   We previously demonstrated that these RA-associated 
cytokines were all significantly elevated in RA patients relative to healthy controls (section 
5.2.2.1).  Following overnight stimulation, cells were challenged with 200µg/ml oxLDL 
for 1 hour.  Subsequent Oil-red-O staining allowed the percentage of macrophages 
exhibiting foam cell morphology to be accurately determined.    
In keeping with previous kinetics experiments (section 5.2.5) approximately 70% of un-
stimulated control macrophages formed foam cells.  In contrast, only ~15% of 
macrophages stimulated with the growth factor GM-CSF formed foam cells.  GM-CSF 
significantly reduced the foam cell formation to 25% of control cells.  IL-6, IL-1β, TNFα, 
IL-15 and IL-17 had no significant effect on foam cell formation (figure 5.9). 
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Figure 5.9 OxLDL loading in cytokine-treated human monocyte-derived 
macrophages  (A) Human monocyte derived macrophages were maintained in M-CSF and 
then stimulated overnight with GM-CSF (125ng/ml), IL-6 (50ng/ml), IL-1β (5ng/ml), TNFα 
(50ng/ml), IL-15 (50ng/ml) or IL-17 (125ng/ml).  Control cells were maintained in M-CSF 
only.  Macrophages were then challenged with 200µg/ml oxLDL for one hour and the 
percentage of cells expressing foam cell morphology determined following Oil-red-O 
staining. Data are representative of three experiments ± SD.  Statistical analysis was 
performed by Kruskal-Wallis test followed by Dunn’s multiple comparison test. *P<0.05, 
**P<0.01, ***P<0.001.  (B) Visual representation of Oil-red-O staining. 
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5.2.7 The effects of GM-CSF on human macrophage responses 
In the previous section (section 5.2.6) it was demonstrated that GM-CSF inhibited both 
uptake of oxLDL by macrophages and the subsequent formation of foam cells.  However, 
as GM-CSF is a pleiotropic growth factor it likely affects several macrophage 
differentiation and effector functions which may contribute to the biological effects 
observed. 
To determine if GM-CSF caused downstream alteration in the immune profile, human 
monocyte-derived macrophages were stimulated overnight with GM-CSF or vehicle 
control and protein levels in the supernatant were measured by Luminex assay. 
GM-CSF was found to significantly increase the expression of 17 of the 23 proteins 
analysed (figure 5.10).  The majority of these were pro-inflammatory (IL-2, IL-4, IL-5, IL-
6 and MIP-1α), however the expression of the anti-inflammatory molecules, IL-10 and IL-
1RA were also found to be significantly increased.  Expression of the growth factor VEGF 
was also found to significantly increase following GM-CSF stimulation.  Although the 
implications for VEGF in foam cell formation remain unknown, this protein has been 
established as a potent angiogenic factor (Celletti et al., 2001) and may have implications 
for CVD acceleration in RA patients who over-express GM-CSF.  Interestingly GM-CSF 
was also found to significantly increase the expression of IL-15 and IL-17, although it was 
shown that they do not alter the rate of foam cell formation (section 5.2.6) 
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Figure 5.10 Immune profile of GM-CSF-stimulated human macrophages 
Human monocyte-derived macrophages were maintained in 15ng/ml M-CSF and then 
stimulated overnight with GM-CSF (125ng/ml).  Control cells were maintained in M-CSF 
and stimulated with vehicle control only.  Cell culture supernatants were removed and 
protein concentration measured by LUMINEX assay.  GM-CSF stimulated (n=6); control 
(n=11). (A) cytokines (interleukins); (B) cytokines (non-interleukin); (C) chemokines and 
(D) growth factors.  Error bars illustrate standard deviation.  Statistical analysis was 
performed by unpaired t-test. *P<0.05, **P<0.01, ***P<0.001. 
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5.2.8 Inhibition of foam cell formation using dextran sulphate 
 
Macrophages are thought to endocytose modified lipoproteins, including oxLDL, via 
scavenger receptors, resulting in accumulation of cholesterol ester and subsequent foam  
cell formation (Dhaliwal and Steinbrecher, 1999).  It is necessary to verify that scavenger 
receptors are responsible for the uptake of oxLDL observed in the previous experiments, 
and to determine if GM-CSF alters the kinetics of scavenger receptor-mediated oxLDL 
endocytosis.  To test these underlying hypotheses, samples were treated with varying 
amounts of dextran sulphate, a compound known to competitively bind and inhibit the 
function of scavenger receptors (Tsubamoto et al., 1994). 
 
Maximal foam cell formation was first ensured by incubating GM-CSF stimulated and 
control macrophages with 200µg/ml oxLDL for 24 hours.  Figure 5.11 demonstrates that 
this time point supported maximal foam cell formation.  It is worth noting, despite ~100% 
of GM-CSF- stimulated and control cells transforming into foam cells over this time 
period, that the GM-CSF-stimulated macrophages appeared to have taken up less oxLDL 
overall.  Although this was not quantified, it is visible in figure 5.12 as a reduction in Oil-
red-O staining intensity.   
 
GM-CSF and control cells were then incubated with 200µg/ml oxLDL and varying 
concentrations of dextran sulphate (2, 10, 20, 40µg/ml) for 24 hours.  As the concentration 
of dextran sulphate was increased from 0 to 40μg/ml the inhibition of foam cell formation 
increased (figure 5.11), indicating that scavenger receptor-mediated endocytosis plays a 
vital role in oxLDL uptake and foam cell formation.  Interestingly, dextran sulphate 
appeared to significantly decrease the extent of foam cell formation in GM-CSF-stimulated 
macrophages relative to control macrophages.  For example treatment with 10μg/ml 
dextran sulphate resulted in 5±8.6% and 44±13% inhibition of foam cell formation in 
control cells and GM-CSF stimulated cells, respectively. 
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Figure 5.11  Competitive inhibition of scavenger receptor-mediated uptake of oxLDL 
(A)  Human monocyte-derived macrophages were maintained in 15ng/ml M-CSF and then 
stimulated overnight with GM-CSF (125ng/ml).  Control cells were maintained in M-CSF 
and stimulated with vehicle control only.  Macrophages were then challenged with 
200µg/ml oxLDL for 24 hours.  The percentage of cells expressing foam cell morphology 
was determined following Oil-red-O staining.  Cells in (B) were treated in a similar 
manner with the addition of varying concentrations of dextran sulphate (0, 2 10, 20 and 
40μg/ml).  The percentage of cells expressing foam cell morphology was determined 
following Oil-red-O staining.  Graphed data represent percentage foam cell inhibition 
relative to macrophages incubated with 200µg/ml oxLDL for 24 hours but no dextran 
sulphate. Data are representative of three experiments ± SD.  Statistical analysis was 
performed by unpaired t-test. *P<0.05, **P<0.01, ***P<0.001.   
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Figure 5.12  Oil-red-O staining following inhibition of scavenger receptor mediated 
uptake of oxLDL  
Representative images of data used to generate figure 5.11.  Images were captured by light 
microscopy at 100x magnification. 
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5.2.9 Scavenger receptor expression in cytokine-treated human monocyte-derived 
macrophages 
 
In section 5.2.8 it was determined that GM-CSF-activated macrophages required a lower 
concentration of dextran sulphate (a competitive inhibitor of scavenger receptors) to inhibit 
oxLDL uptake and subsequent foam cell formation.  This finding suggests that GM-CSF 
activated macrophages either express less total scavenger receptors on the surface or 
express less of a specific scavenger receptor that possesses high affinity for oxLDL.  
Alternatively, although less likely, GM-CSF-stimulated macrophages may express 
scavenger receptors that are hypersensitive to inhibition by dextran sulphate.  
 
In order to investigate this further the transcriptional activity of SR-A1, SR-B1, CD36 and 
MARCO was analysed (figure 5.13).  Each of these receptors are known to recognise 
oxLDL and are thought to be the principal receptors responsible for the uptake of modified 
LDL.  Flow cytometry was also used to investigate the expression of SR-B1 and MARCO 
at a protein level.  For completeness, macrophages stimulated with GM-CSF as well as 
TNFα, IL-6, IL-1β, IL-15 and IL-17 were studied. 
 
GM-CSF-activated macrophages exhibited significantly greater transcriptional activity for 
SR-B1 relative to control cells (11±7 fold change) (figure 5.13, B), however this was not 
observed at the protein level (figure 5.14, B).  The transcription of SR-A1 and CD36 
remained unchanged by overnight stimulation with GM-CSF.  GM-CSF activated 
macrophages exhibited a trend towards transcriptional down regulation (-5.6-fold) of 
MARCO, however this did not reach significance.  Furthermore, this trend was not 
observed at a protein level. 
 
Interestingly, it was observed that TNFα and IL-6 significantly decreased the transcription 
of genes encoding SR-A1, SR-B1 and CD36, however this was not observed at the protein 
level (figure 5.14). 
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Figure 5.13 mRNA expression of scavenger receptors in cytokine treated human 
monocyte-derived macrophages       
Human monocyte-derived macrophages were maintained in M-CSF and then stimulated 
overnight with TNFα (50ng/ml), IL-6 (50ng/ml), IL-1β (5ng/ml), IL-15 (50ng/ml), IL-17 
(125ng/ml) or GM-CSF (125ng/ml).  Control cells were maintained in M-CSF only (black 
bar).  The relative abundance of SRA1, SRB1, CD36 and MARCO was determined by 
qPCR.  Left hand figures represent Ct values following normalisation to the housekeeping 
gene 18S.  Right hand figures represent fold change relative to control cells.  Data are 
representative of three experiments ± SD.  Statistical analysis was performed on Ct values 
by paired t-test. *P<0.05, **P<0.01, ***P<0.001.   
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Figure 5.14 FACS staining of MARCO and SRB1 in cytokine-treated human 
monocyte derived macrophages       
Human monocyte derived macrophages were maintained in M-CSF and then stimulated 
overnight with TNFα (50ng/ml), IL-6 (50ng/ml), IL-1β (5ng/ml), IL-15 (50ng/ml), IL-17 
(125ng/ml) or GM-CSF (125ng/ml).  Control cells were maintained in M-CSF only (black 
bar).  Cells were harvested and stained with primary antibodies which recognise 
extracellular MARCO (graph A) and total SRB1 (graph B).  Bar graphs show expression 
of scavenger receptors normalised to isotype-matched control antibodies. M.F.I: Mean 
Fluorescent Intensity.  The results shown are representative of three independent 
experiments ± SD.  Statistical analysis was performed for each condition relative to 
control by paired t-test. 
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5.3 Discussion 
 
In RA, the primary site of inflammation is the synovial tissue, from which cytokines are 
released into systemic circulation.  These circulating cytokines have been suggested to 
have an effect upon distant tissues, including liver, skeletal muscle, adipose, and vascular 
endothelium, to generate a variety of proatherogenic changes that include dyslipidaemia, 
insulin resistance, pro-oxidative effects, and endothelial dysfunction (Sattar et al., 2003).  
As such, systemic inflammation has been hypothesised to represent the missing link that 
could account for the higher burden of CVD observed in RA patients (Szekanecz and 
Koch, 2008).  Previous studies have mostly focused on the general inflammatory markers 
(e.g. CRP, ESR and leukocyte counts) as well as traditional inflammatory cytokines (e.g. 
TNFα and IL-6), and some studies have been published which characterise differences in 
CVD and RA+CVD patients (Breland et al., 2010).  The present study built upon previous 
findings by analysing the serum of patients with RA, CVD, RA+CVD and healthy control 
subjects for a range of 30 cytokines, chemokines, growth factors and receptors.   
The principle finding of this study was that serum levels of several immuno-proteins are 
elevated in RA+CVD patients relative to RA patients and CVD patients.  By examining a 
wide range of proteins it was shown that the mean concentration of eight cytokines (IL-1β, 
IL-2, IL-5, IL-13, IL-17, MIG, G-CSF and GM-CSF) and the chemokine IL-8 was greater 
in the RA+CVD cohort compared to the additive values of the RA only and CVD only 
cohorts. However, only IL-17, IL-8 and G-CSF were found to be significantly greater in 
the RA+CVD groups relative to both the CVD and RA groups.  These data lead to the 
hypothesis that these bio-markers, either individually or cumulatively, may form a pro-
inflammatory phenotype in RA which increases the risk of CVD. 
Many of these biomarkers have already been studied in the context of CVD; however, their 
exact role(s) in pathogenesis often remains elusive.  Studies have shown that knock-out of 
IL-1β and treatment with anti-IL-2 decreases the severity of atherosclerosis in Apo-E 
deficient mice (Kirii et al., 2003, Upadhya et al., 2004).  GM-CSF is also thought to be 
pro-atherosclerotic, with experiments showing that treatment of mice with GM-CSF 
increased cell proliferation in early lesions, whereas treatment with anti-GM-CSF inhibited 
proliferation (Zhu et al., 2009).  Conversely IL-5, as a result of its ability to expand natural 
IgM specific for oxLDL, has been demonstrated as having atheroprotective properties 
(Binder et al., 2004).  Recent studies have shown that IL-17 plays a pro-atherosclerotic role 
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(van Es et al., 2009, Erbel et al., 2009), where as a previous study suggests IL-17 is 
atheroprotective (Taleb et al., 2009).  Thus, the function of IL-17 remains controversial 
and requires additional direct studies.  Currently, little is known regarding the role that IL-
13 and MIG play in the pathogenesis of atherosclerosis 
G-CSF exhibited an unusual and unique expression pattern, with CVD and RA patients 
having considerably lower serum concentrations (105 and 66 pg/ml, respectively) than 
healthy and RA+CVD subjects (875 pg/ml and 1832 pg/ml, respectively).  If assuming that 
healthy patients have normal serum levels of G-CSF, it would appear that G-CSF is 
reduced in both CVD and RA, but remains relatively unchanged in RA+CVD patients.  
Although not investigated here, it would be of value to determine whether RA patients 
return to a ‘normal’ G-CSF concentration upon developing CVD, or whether these patients 
have always possessed a different G-CSF profile, which could increase CVD risk.  
Unfortunately, examination of the literature does not raise any reasonable hypotheses, and 
does not lend itself to speculation.   
The chronic inflammatory state observed in CVD is believed to result, at least in part, from 
immune cells such as monocytes being continually recruited to the atherosclerotic lesion.  
Macrophages are capable of ingesting modified LDL to form cholesterol-rich foam cells, 
which become the initial building blocks of atherosclerotic plaques.  However, an 
understanding of how the chronic inflammatory state observed in RA modulates 
macrophage foam cell formation is lacking.    
In section 5.2.6 it was demonstrated that GM-CSF stimulation significantly decreased the 
rate at which human primary macrophages could endocytose oxLDL.  It was further shown 
that TNFα, IL-6, IL-1β, IL-15 and IL-17 had no significant effects on the rate of oxLDL 
uptake.  Although clearly a very interesting result, these data have several limitations.  
Firstly, the GM-CSF effect was observed in isolation.  It is possible that in an environment 
containing an array of cytokines and chemokines, more closely representing human serum, 
the GM-CSF effect would be reduced or possibly eliminated.  Furthermore, in section 5.2.7 
it was demonstrated that GM-CSF stimulation significantly increases macrophage 
expression of several other cytokines and chemokines.  Of particular note, both MIP-1α 
and MIP-1β were significantly elevated following GM-CSF stimulation.  These 
chemokines are known for their chemotactic and pro-inflammatory effects but can also 
promote homeostasis (Maurer and von Stebut, 2004).  The cytokine G-CSF, which shares 
many properties with GM-CSF, was also significantly increased.  G-CSF has been 
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previously demonstrated to have a protective effect in a rabbit atherosclerosis model.   In 
this model G-CSF prevented an increase in neointima/media ratio and accelerated 
reendothelialisation (Hasegawa et al., 2006).  It is thus possible that GM-CSF stimulation 
per se is not responsible for the reduction in oxLDL uptake, but instead GM-CSF 
stimulates production of other proteins which may illicit the observed effect.  
Alternatively, this biological event may be a result of the additive function of the protein 
milieu secreted in response to GM-CSF stimulation. To fully understand the effect of 
elevated serum GM-CSF on atherosclerosis and foam cell formation, biologically relevant 
animal modelling would be necessary.  
In section 5.2.8 the effect of dextran sulphate, a known competitive inhibitor of scavenger 
receptors, on the ability of M-CSF and GM-CSF stimulated macrophages to produce foam 
cells was analysed.  This study demonstrated that GM-CSF decreases the concentration of 
dextran sulphate required to successfully inhibit scavenger receptor-mediated ox-LDL 
uptake and subsequent foam cell formation.  This would suggest that GM-CSF-stimulated 
macrophages either express less scavenger receptors on the cell surface or express 
scavenger receptors that are hyper-sensitive to inhibition by GM-CSF.  Initial 
investigations into the expression of SR-A1, SR-B1, CD36 and MARCO showed that none 
of these scavenger receptors were decreased at a transcriptional level following stimulation 
with GM-CSF.   
GM-CSF was originally characterised as a haematopoietic growth factor responsible for 
the differentiation of bone marrow progenitor cells (Burgess and Metcalf, 1980), however 
more recently it has also been established as a cytokine with important roles in both 
inflammation and infection (Shi et al., 2006).  Furthermore, a variety of studies have 
shown that GM-CSF promotes survival and activation of macrophages (Hamilton, 2008, 
Hamilton et al., 1980).  Although, the present study determined that GM-CSF protected 
from foam cell formation, it did not definitively show how such protection could occur.  
As a broad generalisation, in in vitro studies, GM-CSF preferentially generates, either 
alone or in the presence of M-CSF, populations with dendritic cell like and antigen 
presenting capabilities, whereas the progeny arising from M-CSF stimulation are 
phagocytic macrophage like cells (Fleetwood et al., 2007).  Surprisingly, despite this 
apparent shift to from ‘phagocytic’ to ‘antigen presenting’, no decrease in scavenger 
receptor transcript was detected following GM-CSF stimulation.  In order to further 
hypothesise as to why GM-CSF reduces foam cell formation, it would be useful to further 
consider the differences between macrophages stimulated with M-CSF and GM-CSF. 
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Several studies suggest that GM-CSF has a clear pro-inflammatory effect on macrophage 
populations and that GM-CSF expression is elevated at sites of inflammation (Sorgi et al., 
2012).  By contrast, macrophages are continually exposed to M-CSF as it is expressed 
constitutively during times of homeostasis.  Such macrophages have a comparably 
compromised ability to secrete pro-inflammatory mediators and other toxic intermediates, 
such as nitric oxide, but possess a capacity to promote tissue repair and angiogenesis 
(Fleetwood et al., 2007).  It is possible that M-CSF-stimulated macrophages in the ‘steady-
state’ have a phenotype which promotes effective scavenging of their environment and 
subsequent phagocytosis.  Alternatively, following a GM-CSF mediated shift to a pro-
inflammatory state, macrophages may favour activities such as recruitment of other 
immune cells and antigen presentation and expend less energy on processes such as 
phagocytosis. 
It has also been noted that there are differences in nuclear factor-κB (NF-κB) activity and 
RAS signalling pathways between M-CSF- and GM-CSF-stimulated macrophages 
(Fleetwood et al., 2007).  It is possible that these pathways determine alternative surface 
receptor expression and/or phagocytic activity.  Further experimentation is required to test 
this hypothesis. 
The current study set out to explore mechanisms by which RA increases the risk of CVD, 
but instead has identified GM-CSF, which is elevated in RA serum, as having potential 
atheroprotective properties.  Recently, however, antagonism of GM-CSF has been 
suggested as a novel therapeutic approach for a variety of autoimmune diseases, including 
RA (Cornish et al., 2009).  Phase I human clinical trials with Mavrilimumab, a human 
monocolonal antibody targeting GM-CSF receptor-α, demonstrated pharmacodynamic 
activity (Burmester et al., 2011).  Although it is still too early to say whether this 
therapeutic will make it to the market, these preliminary studies demonstrates both safety 
and an adequate pharmacokinetic profile and supports further clinical study in RA.  Novel 
RA therapeutics are increasingly necessary to treat the significant proportion of patients 
who fail to achieve minimum improvement criteria.  However the current study raises the 
possibility that anti-GM-CSF therapy would support increased foam cell formation and 
may have a potential long term detrimental cardiovascular effect.  Further studies would be 
needed to demonstrate conclusively whether anti-GM-CSF therapy has an adverse 
cardiovascular effect. 
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As already mentioned, the present study found TNFα to have no effect upon foam cell 
formation.  This was not entirely surprising as, despite a significant transcriptional down-
regulation of the scavenger receptors SR-A1, SR-B1 and CD36 being detected, no decrease 
in either SR-B1 or MARCO was observed at a protein level.  Previous studies have 
however shown TNFα to suppress macrophage scavenger receptor (specifically SR-A1) 
function and reduce subsequent foam cell formation (Vanlenten and Fogelman, 1992).  It 
has been suggested that TNFα regulates scavenger receptor expression by transcriptional 
and post-transcriptional mechanisms, but principally by destabilisation of scavenger 
receptor mRNA (Hsu et al., 1996).  The inconsistency between these data could have 
several explanations.  Importantly the present study was performed with primary human 
macrophages isolated from several different donors and differentiated in M-CSF, whereas 
Vanlenten & Fogelman (1992) used the human monocytic macrophage THP-1 cell line and 
differentiated in the presence of phorbol 12-myristate 13-acetate (PMA).  The functional 
consequences of using a PMA differentiated macrophage cell line instead of M-CSF 
derived human primary macrophages are relatively unknown, but it is likely that 
differences in scavenger receptor expression and phagocytosis activity exist.  Furthermore, 
the present study challenged macrophages with oxLDL whereas previous studies treated 
with acetylated LDL.  Evidence indicates that oxLDL, rather than acLDL, is the 
physiological representative of modified LDL (Palinski et al., 1989).  Furthermore, as 
oxLDL and acLDL are not identical ligands, certain scavenger receptors will exhibit 
varying affinities for each (Ottnad et al., 1995, Sparrow et al., 1989). 
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6 General Discussion 
 
RA causes pain and swelling in the joints and is accompanied by a marked reduction in 
quality of life  (Whalley et al., 1997); moreover, RA patients are at ~two-fold increased 
risk of developing CVD (Solomon et al., 2003, Turesson et al., 2003, Van Doornum et al., 
2002).  However, it is unknown how the underlying disease mechanism of RA influences 
the vascular environment. 
The present study was principally carried out in human aortic adventitial tissue which was 
removed from the ascending aorta during the establishment of coronary artery bypass 
grafts. Blood vessels are known to exhibit different susceptibilities to atherosclerosis.  
Veins, for example, are usually less vulnerable than arteries.  However, differences exist 
also within the arterial tree; for example the internal mammary artery (IMA), though of 
similar dimension to the coronary arteries, exhibits a ten-fold reduction in atherosclerosis 
risk (Ferro et al., 1990).  This is in keeping with data presented in chapter 3 which detected 
significantly less inflammation in the IMA than matched adventitial tissue.   
The ascending aorta is a region with a known risk of atherosclerosis (Mills and Everson, 
1991).  Within the present study, all aortic specimens were taken from areas with minimal 
signs of atherosclerosis, a procedure necessary to reduce the risk of thromboembolic 
complication.  However, as adventitial samples were removed from CVD patients 
requiring a bypass graft, this tissue provides a useful ex vivo model of aortic tissue that is at 
high risk of developing gross signs of atherosclerosis in the future.  Furthermore, as 
samples were collected from CVD patients and patients with both CVD and RA, it was 
possible to investigate whether RA pathophysiology is capable of altering the adventitia in 
ways that may potentiate the onset of atherosclerosis. 
Despite samples being removed from areas without gross clinical signs of atherosclerosis, 
the adventitia was found to possess an array of immunological properties.  Inflammatory 
infiltration was detected in 18 of the 39 (46%) samples analysed (section 3.2.3).  However, 
no significant difference in the extent of inflammatory infiltrate was observed between the 
CVD and RA+CVD cohorts.  It remains to be elucidated what causes inflammatory 
infiltration into the adventitia, and whether adventitial infiltration underlies atherosclerosis 
pathogenesis.  It would also be beneficial to characterise the IMA in more detail, with the 
aim of understanding why vascular inflammation is so rare in this tissue.  As with many 
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conditions, understanding why certain tissue is at a reduced risk of disease often leads to 
breakthroughs in clinical treatment.   
Despite no differences being detected in adventitial inflammation between the CVD and 
RA+CVD cohorts, it was found that TNFα expression was significantly greater in the 
RA+CVD cohort (section 3.2.3).  Clearly, elevated adventitial TNFα in RA+CVD patients 
cannot be explained by an excess of inflammatory cells.  However, further investigation 
revealed that serum TNFα expression is roughly ten times greater in the RA+CVD cohort 
compared to the CVD cohort.  It is possible that the elevated levels of serum TNFα present 
in RA+CVD serum may infiltrate into, and reside in, the aortic adventitia.  It remains to be 
investigated whether adventitial TNFα contributes to atherosclerosis, however it would 
appear likely, as several studies have shown TNFα to be associated with CVD and to 
posses pro-atherosclerotic properties (Ridker, 1997, McKellar et al., 2009).   
It was also found that RA+CVD patients exhibited a trend towards greater HSP47 
expression in the adventitia compared to CVD patients (section 3.2.12).  HSP47 is a stress 
protein that acts as a molecular chaperone during intracellular processing of procollagen 
(Nakai et al., 1992), and a relationship between HSP47 expression and fibrosis has been 
previously reported (Rocnik et al., 2000).   
As outlined in section 1.5.4, HSPs have been implicated as potential autoantigens in both 
RA and CVD (Pockley, 2002, Bodman-Smith et al., 2003).  Furthermore, HSPs are 
immunodominant molecules, providing a principle epitope during pathogen recognition 
(Kaufmann, 1990) and often being implicated in human autoimmune disease.  HSP 
expression is increased during exposure to cellular stress, a process which protects cells 
from the uncontrolled protein unfolding that often accompanies stress (Zuegel and 
Kaufmann, 1999).  Although it remains to be determined, it is possible that environmental 
stress signals which accompany RA pathogenesis result in elevated adventitial HSP47 
expression.  This overexpression could potentiate atherosclerosis by providing a target for 
HSP47 specific autoantibodies.  Alternatively, as it has previously been suggested that 
many of the HSPs have the property of damage-associated molecules (DAMPs), which are 
inducers of sterile inflammation and innate immunity (Kono and Rock, 2008), that HSP47 
overexpression may facilitate the formation of a pro-inflammatory environment.  The latter 
hypothesis would appear less likely when considering that it has already been shown that 
inflammation is not increased in the adventitia of RA+CVD patients. 
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The detection of inflammatory infiltrate, TNFα and the antimicrobial peptide calprotectin 
(section 3.2.15) in the aortic adventitia reinforced our previous hypothesis that bacteria 
may reside in the aortic adventitia and possibly contribute to atherosclerosis pathology.  
Furthermore, it is possible that the systemic inflammatory state which accompanies RA 
may alter patient susceptibility to certain bacterial species.   
Bacterial DNA from a diverse range of species were detected in the aortic adventitia.  
Furthermore, this study demonstrated that RA+CVD patients had a significantly reduced 
bacterial heterogeneity in the adventitia when compared to CVD patients. Furthermore, M. 
oryzae was detected in all aortic adventitia samples from RA patients that were PCR-
positive for the 16S rRNA gene, but in only 25% of PCR-positive samples from non-RA 
patients (section 4.2.3).   
 
The detection of M. oryzae was somewhat surprising as this pink-pigmented, facultatively 
methylotrophic bacterium was first characterised following isolation from rice stem tissue 
in Korea (Madhaiyan et al., 2007).  To the best of our knowledge, this is the first time that 
M. oryzae has been implicated in human disease.  16S rRNA gene sequencing analysis 
indicated that M .oryzae is most closely related to M. mesophilicum.  Interestingly, M. 
mesophilicum, which is also a pink-pigmented, facultatively methylotrophic bacterium has 
been reported as a cause of opportunistic infections in immunocompromised hosts 
(Sanders et al., 2000) and has been isolated from several clinical sites, including blood, 
synovial, cerebral spinal fluid (CSF) (Kaye et al., 1992, Liu et al., 1997, Gilardi and Faur, 
1984).  Although the source of infection remains unclear, infection has been associated 
with environmental exposure.  In particular, M. mesophilicum contamination of hospital 
tap water has been implicated as the source of an isolated nosocomial outbreak (Gilchrist et 
al., 1986). 
 
In order to further characterise the potential atherogenic properties of M. oryzae we 
infected human primary macrophages.  This study (section 4.2.10) highlighted that 
infection was characterised with an excessive inflammatory response, and subsequent 
analysis identified several pathways which could play a role in atherosclerosis.  Curiously, 
granzyme B (encoded by GZMB), a serine protease that is highly expressed in cytotoxic T 
cells and natural killer cells, was ~200-fold up-regulated in macrophages following 
infection with M. oryzae.  The principal function of granzymes is to induce the death of 
virus-infected and other transformed cells.  Macrophages have previously been 
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demonstrated to not produce granzyme B, however it has recently been demonstrated that 
macrophages express granzyme B in the lesion areas of atherosclerosis and RA (Kim et al., 
2007).   
 
M. oryzae has previously been reported to be a Gram-negative bacterium (Madhaiyan et 
al., 2007).   It was therefore very surprising when we determined that M. oryzae did not 
activate TLR4 signalling, but instead activated signalling from TLR2, the principle 
receptor for recognition of Gram-positive bacteria (figures 4.17 and 4.18).  However, 
subsequent analysis confirmed that M. oryzae did not possess measurable levels of LPS or 
LOS (figure 4.19).  Unfortunately, no images of the Gram stains performed on M. oryzae 
were available from the publication by Madhaiyan et al. (2007), so it is possible that owing 
to the inherent difficulty of Gram-staining certain bacillus species that staining was 
incorrectly interpreted.  It is worth noting that although Pam3CSK4 was included in the 
assay depicted in figure 4.18, due to a technical oversight the hot phenol/water would not 
support extraction of lipopeptides from M. oryzae. Therefore, despite functional 
stimulation of TLR2 having been determined, it remains to be confirmed whether M. 
oryzae does indeed posses TLR2 ligand.  
In a recent study, Canducci et al. (2012) characterised the antibody fragments produced by 
B-lymphocytes within the atherosclerotic lesions of four patients. Following molecular 
cloning, phage display and subsequent antibody generation it was demonstrated that all 
four patients possessed antibodies that cross-reacted with the outer membrane proteins 
(OMPS) of Gram-negative bacteria and with transgelin (TAGLN), a cytoskeleton protein 
expressed by smooth muscle cells (Canducci et al., 2012). Building upon this study, it 
would be beneficial to identify if antibodies raised against M. oryzae reside in the 
adventitia and whether these could similarly cross-react with self-antigens. It is possible 
that intermittent exposure to bacterial epitopes may lead to production of self cross-
reacting antibodies that may persist following bacterial clearance. 
 
Accumulating evidence suggests that alterations to the host microbiome precede RA and 
may play a key role in pathogenesis (Wu et al., 2010), however it is equally plausible that 
alteration to the microbiome follows RA and may lead to co-morbidity.  Intriguingly, RA 
patients exhibit elevated levels of TH17 cells and their signature cytokine IL-17 (figure 5.1) 
in the serum and although normal levels of circulating regulatory T-cells are expressed, 
they exhibit decreased functionality ex vivo (Valencia et al., 2006).  Conceivably, altered T 
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cell functionality in parallel with the elevation of systemic pro-inflammatory mediators 
characteristic to RA supports a notion for RA driven dysbiosis and vulnerability to 
infection by a few ‘select’ organisms (e.g. M. oryzae).  To what extent host immunity plays 
a role in aortic infection, and how the patterns of infection observed in this Norwegian 
population compare to others, remains to be elucidated.   
 
The present study was limited by the necessity to characterise bacterial populations based 
on the sequencing of DNA which corresponded to the 16S rRNA gene.  Ideally we would 
have expanded the value of these methods to generating a cDNA library and using 16S 
rRNA-targeted molecular biology tools to determine the transcriptional activity of bacterial 
populations.  Although attempted, RNA was deemed not to be of sufficient quality to 
support cDNA synthesis.  Owing to the inherent instability of RNA, it is likely that loss of 
quality was due to several freeze-thaw cycles that were incurred between surgery and 
experimentation.  The correlation between cellular rRNA content and growth rate is a well-
established concept (Poulsen et al., 1993), with rRNA transcription being approximately 
ten-fold elevated when the doubling time of E. coli decreases from 100 minutes to 24 
minutes (Lu et al., 2009).  16S rRNA analysis of a cDNA library would therefore have 
allowed determination of whether bacteria in the adventitia were viable at the time of 
CABG surgery rather than the result of an historical infection.  Furthermore, 16S rRNA 
cDNA analysis by quantitative PCR would allow the hypothesis that total bacterial burden 
may be altered in RA+CVD patients relative to CVD patients to be explored. 
 
As well as analysing the adventitia of CVD and CVD+RA patients, the adventitia of CVD-
PsA patients was also assessed for the presence of 16S rRNA.  Interestingly no bacterial 
signatures were detected in this patient cohort.  The symptoms of PsA closely resemble 
that of RA.  However, it has been shown that the incidence rate of infection in PsA is 
similar to that of patients with psoriasis but not RA (Haddad et al., 2011), and the overall 
rate of infection is higher in RA patients compared to non-RA subjects (Doran et al., 
2002).  As both PsA and RA patients are generally prescribed a similar course of NSAIDs, 
DMARDs and biologics it would appear that unlike PsA, the pathophysiology of RA 
predisposes patients to infection.  It remains to be determined whether the absence of 
bacterial DNA detection in the adventitia is due to PsA having a protective effect against 
infection.   
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In chapter 5 the serum concentration of a broad range of cytokines, chemokines and 
growth factors was determined in RA, CVD, RA+CVD and healthy subjects.  This study 
provided an opportunity to indentify biomarkers that were elevated in RA+CVD patients 
by a value greater than the sum of both RA and CVD patients.  As highlighted and 
discussed in section 5.3, nine such biomarkers were identified (IL-1β, IL-2, IL-5, IL-13, 
IL-17, MIG, G-CSF, GM-CSF and IL-8).  However, value was also attained from looking 
at the immune profile of the RA patients relative to healthy controls.  Despite these patients 
not presenting clinical signs of CVD at the time of study, there is an increased likelihood 
that they will go on to develop CVD (Turesson et al., 2003).  It is possible that the 
systemic immune profile of these patients could pre-dispose them to subsequent CVD.  
Although not possible due to time constraints in the current study, it would be beneficial to 
follow up the RA patients entered into this study and determine whether future CVD 
burden correlates with any of the biomarkers measured.  
 
If considering the function of the biomarkers found to be elevated in RA+CVD and RA 
patients (tables 5.2 and 5.3) it is possible to speculate as to how such an immune profile 
may promote atherosclerosis.  Endothelial dysfunction is considered to be an early step in 
atherosclerosis.  In RA and RA+CVD there was a marked increase in the expression of 
TNFα and IL-1β, both of which are known to activate and induce migration and 
proliferation of endothelial cells and increase vascular permeability (Millauer et al., 1993, 
Inoue et al., 1998).  Once activated, endothelial cells will support an infiltration of 
circulating monocytes/lymphocytes into the vessel wall.  Owing to the elevated expression 
of MIP-1α, MIP-1β and IL-8, it is likely that the numbers of activated circulating 
monocytes and macrophages is already elevated in these patients.  The concomitant 
presence of systemic IL-2 and IL-5 will support T- and B-cell expansion and 
differentiation, with the potential to generate antibodies against self (possibly HSP47) and 
bacterial antigens. Unless effective therapeutic intervention is achieved, monocytes and 
lymphocytes are likely to continue infiltrating into the vessel wall in an uncontrolled 
manner causing damage to the vessel wall and manifesting over time as an atherosclerotic 
lesion. 
 
This project provides insight into the immunological activity and functional capacity of the 
aortic adventitia in atherosclerosis pathogenesis. The detection of increased TNFα, HSP47 
and an altered bacterial profile in the adventitia of RA+CVD indicate that these important 
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factors may contribute to the increased CVD burden experienced in RA.  These data have 
led us to propose a possible model of atherosclerosis pathogenesis in RA (figure 6.1).  
Furthermore, this study revealed that RA+CVD patients are characterised by an increased 
systemic pro-inflammatory phenotype, supporting a role for inflammation in accelerating 
comorbid CVD. 
 
 
 
 
Figure 6.1 Model of adventitial-derived atherosclerosis in RA 
A schematic model illustrating the possible effects of molecules detected in the aortic 
adventitia in atherosclerosis pathogenesis in RA patients.  The altered systemic immune 
profile in RA may support M. oryzae infiltration into the adventitia.  Bacteria interact with 
macrophages and other components of the adventitial inflammatory infiltrate to produce a 
classical pro-inflammatory response.  This will further recruit inflammatory cells into the 
adventitia and lead to elevated expression of TNFα.  B-cells may interact with elevated 
adventitial HSP47 leading to autoantibody generation and further perpetuate the 
inflammatory response.  This molecular niche may accelerate atherosclerosis in RA and 
over time aid the formation of a characteristic lesion at the vessel wall. 
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Conclusions 
This research was scoped to address three research questions (section 1.6).  In conclusion it 
is necessary to summarise the principle findings. 
 
 Is the aortic adventitia immunogenic? Does the inflammatory mileu of the 
aortic adventitia differ between CVD and RA+CVD patients? 
 
The aortic adventitia of CVD and CVD+RA patients has been confirmed as a site of 
considerable immunological interest, frequently exhibiting diffuse inflammatory infiltrates, 
the pro-inflammatory cytokine TNFα, the potential autoantigen HSP47 and the 
antimicrobial peptide calprotectin.  The adventitia of RA+CVD patients was demonstrated 
to express significantly more TNFα than patients with CVD alone. These data may help 
explain why CVD is accelerated in RA patients and provides support for the involvement 
of the adventitia in atherosclerosis pathogenesis. 
 
 
 Are bacteria present in the aortic adventitia, and do differences in the 
bacterial profile exist between CVD and RA+CVD patients?   
 
Four of 11 CVD and three of 11 RA+CVD aortic adventitia samples studied possessed 
bacterial DNA.  The aortic adventitia of CVD+RA patients exhibited significantly lower 
bacterial heterogeneity.  Interestingly Methylobacterium orzyzae was detected in all three 
RA+CVD samples positive for bacterial presence.  M. oryzae was determined to be a mild 
TLR2 agonist and triggered a robust inflammatory response by macrophages.  These data 
reinforce the hypothesis that bacteria may play an aetiological role in atherosclerosis, and 
suggest that the pathophysiology associated with RA predisposes aortic infection to a few 
select organisms. 
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 Does the systemic immune profile differ between RA, CVD and RA+CVD 
patients, and could any differences contribute to increased CVD burden 
in RA? 
 
RA patients exhibit an altered systemic immune profile compared to non-RA CVD patients 
and healthy controls.  Furthermore, RA+CVD patients were shown to possess an altered 
systemic immune phenotype compared to both RA and CVD patients. Notably, IL-1β, IL-
2, IL-5, IL-8, IL-13, IL-17, MIG, G-CSF and GM-CSF expression was greater in the serum 
of RA+CVD patients compared to the additive values of the RA and CVD patients.  
Systemic elevation of pro-inflammatory cytokines in RA patients likely contributes to 
atherosclerosis pathogenesis.   Furthermore, GM-CSF was found to significantly decrease 
the rate at which human macrophages could endocytose oxLDL and form foam cells.  
When considered in isolation this finding suggests that the overexpression of GM-CSF 
observed in RA and RA+CVD patients may provide some atheroprotective benefit.   
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Appendix 
1.  Universal primer for 16S sequencing 
a) Bacterial 16S rDNA  Forward 5’ CAGGCCTAACACATGCAAGTC 3’ (63F) 
(Annealing temp 60oC)  Reverse  5’ GGGCGGWGTGTACAAGGC 3’  (1387r).  
  
2.   Immunohistochemistry Reagents 
Tris buffered saline (TBS) 8.76 g sodium chloride (150 mM), 6.05 g Tris base 
(50 mM) to 800 ml of distilled water.  pH to 7.5 by 
addition of HCl.  Make up to 1 litre by addition of 
distilled water.  Add Tween-20 (Sigma-Aldrich) to 
0.1% (v/v).  Stored for up to 1 week at room 
temperature. 
TBS + 0.05% Tween (TBST) Add 200ml 10X TBS to 1800ml of deionised water 
followed by addition of 1ml Tween (Sigma-Aldrich, 
P5927) then mix    
Trypsin working solution 0.5% Trypsin, 1% calcium chloride solution.  Adjust 
pH to 7.8 by addition of 1M NaOH. 
Citrate buffer 2.1 g of Citric acid (Sigma-Aldrich) dissolved in 
800ml of distilled water.  pH adjust to 6.0 by addition 
of 1 =M NaOH.  Volune made up to 1 litre by 
addition of distilled water.  
Hydrogen peroxide 0.5% Prepare fresh for every use.  Add 5ml of 30% 
hydrogen peroxide (H2O2) to 295ml of methanol 
(both supplied by Sigma-Aldrich) 
Impact DAB 1ml diluent, 1 drop chromagen, mex 
 (Vector Laboratories) 
Secondary Antibody Biotinylated anti-mouse IgG (produced in horse) 
 (Vector Laboratories) (1.5mg/ml) 
251 
 
 
 
 
Vacstatin Elite ABC kit  
Avidin and Biotinylated horseradish peroxidise macromolecular Complex (Vector 
Laboratories, PK6100) 
 To 5ml TBST:  2 drops of reagent A, mix 
    2 drops of reagent B, mix 
 Incubate at room temperature for 30 minutes before 
use 
Wax pens Immedge pen (Vector Laboratories, H-4000) 
Blocking serum 2.5% normal horse serum (Vector Laboratories, S-
2000) in TBST (unless otherwise stated) 
Negative control Mouse IgG2A, (500µg/ml) (R&D, MAB003) 
 Mouse IgG1, (500µg/ml) (R&D, MAB002)      
FACS buffer 3% BSA 0.05% NaN3 in 1 x PBS 
 
3.  Lipoprotein isolation/visulisation reagents 
a) Copper reagent  
20g sodium carbonate dissolved in 260ml H2O, 0.4g cupric sulphate pentahydrate 
dissolved in 20ml H2O and 0.2g sodium potassium tartrate dissolved in 20ml H2O.  
The resulting solutions are then combined. 
b) Barbital buffer 
18.2g (5, 5-Diethylbarbituric Acid), 10mmol/L reconstituted; 5, 5-Diethylbarbituric 
Acid sodium salt 50mmol/L 
c) Oil-red-O stock solution 
0.5g of Oil-red-O powder was dissolved in 100ml isopropanol.  This was 
performed overnight with gentle agitation. 
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d) Oil-red-O working solution 
Mix 6ml of Oil-red-O stock solution with 4ml of ddH2O.  Allow to sit at room 
temperature for 20 minutes and then filter (0.2μm). 
 
4.  Primers for quantitative PCR 
Human GAPDH  Forward 5’ ACA GTC AGC CGC ATC TTC TT 3’ 
(Annealing Temp: 55oC) Reverse 5’ AAA TGA GCC CCA GCC TTC T 3’ 
 
Human SRA-1  Forward 5’ GAC TTT GGT TCC CGT GTT GT 3’ 
(Annealing Temp: 55.6oC) Reverse 5’ GGA GAG AGG TGA TGG TGG AG 3’ 
 
Human CD36   Forward 5’ CAA GGA AAA TGT AAC CCA GGA C 3’ 
(Annealing Temp: 56.4oC) Reverse 5’ GCC ACA GCC AGA TTG AGA AC 3’ 
 
Human SRB1   Forward 5’ CCC TAA CCA GGA GGC ACA C 3’ 
(Annealing Temp: 56.9oC) Reverse 5’ CAG GAC CAC AGG CTC AAT CT 3’ 
 
Human MARCO  Forward 5’ TCT GGG GAG CAA GGA GTA AA 3’ 
(Annealing Temp: 58.1oC) Reverse 5’ ATT GTC CCC CAG GTA CCA CT 3’ 
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5  M. oryzae and M. mesophilicum sequence alignment 
Top line:   Methylobacterium oryzae  
Bottom line:   Methylobacterium mesophilicum 
 
Length: 1023 
Identity:     973/1023 (95.1%) 
Similarity:   973/1023 (95.1%) 
Gaps:          11/1023 ( 1.1%) 
 
 
EMBOSS_001         1 ctaaccgtggtcagcggcggacgggtgagtaacgcgtgggaacgtgcctt     50 
                     ||.  ||..|||||||||||||||||||||||||||||||||||||||.| 
EMBOSS_001         1 ctt--cggtgtcagcggcggacgggtgagtaacgcgtgggaacgtgccct     48 
 
EMBOSS_001        51 ccggttcggaataaccctgggaaactagggctaataccggatacgccctt    100 
                     |.|||||||||||||.|.||||||||.|.||||||||||||||||||||| 
EMBOSS_001        49 ctggttcggaataactcagggaaacttgagctaataccggatacgccctt     98 
 
EMBOSS_001       101 atggggaaaggtttactgccggaagatcggcccgcgtctgattagctagt    150 
                     .||||||||||.||.||||||||.|||||||||||||||||||||||||| 
EMBOSS_001        99 ttggggaaaggcttgctgccggaggatcggcccgcgtctgattagctagt    148 
 
EMBOSS_001       151 tggtggggtaacggcctaccaaggcgacgatcagtagctggtctgnnaga    200 
                     |||||.|||||||||..||||||||||||||||||||||||||||  ||| 
EMBOSS_001       149 tggtgaggtaacggctcaccaaggcgacgatcagtagctggtctg--aga    196 
 
EMBOSS_001       201 ggaagatcaagccacactgcgcactgaggacacggcccagactcctacgg    250 
                     |||.|||| |||||||||| |.||||| |||||||||||||||||||||| 
EMBOSS_001       197 ggatgatc-agccacactg-ggactga-gacacggcccagactcctacgg    243 
 
EMBOSS_001       251 gnaagcaacagtggagaatattagacaatgcgcgcaagcctgatccagcc    300 
                     | |.|||.||||||.|||||||.|||||||.||||||||||||||||||| 
EMBOSS_001       244 g-aggcagcagtggggaatattggacaatgggcgcaagcctgatccagcc    292 
 
EMBOSS_001       301 atgcctgagggagtgatgaaggccttagggttgttaaagctcttttatcc    350 
                     ||||| |.|.||||||||||||||||||||||| |||||||||||||||| 
EMBOSS_001       293 atgcc-gcgtgagtgatgaaggccttagggttg-taaagctcttttatcc    340 
 
EMBOSS_001       351 gggacgataatgacggtaccggacgaataagccccggctaactccgtccc    400 
                     |||||||||||||||||||||||.|||||||||||||||||||.|||.|| 
EMBOSS_001       341 gggacgataatgacggtaccggaggaataagccccggctaacttcgtgcc    390 
 
EMBOSS_001       401 agcagccgcggtaatacgaagggggctagcgttgctcggaatcactggcc    450 
                     ||||||||||||||||||||||||||||||||||||||||||||||||.| 
EMBOSS_001       391 agcagccgcggtaatacgaagggggctagcgttgctcggaatcactgggc    440 
 
EMBOSS_001       451 gtaaagggcgcgtaggcggcgttttaagtcgggggtgaaagcctgtggct    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       441 gtaaagggcgcgtaggcggcgttttaagtcgggggtgaaagcctgtggct    490 
 
EMBOSS_001       501 caaccacagaatggccttcgatactgggacgcttgagtatggtagaggtt    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       491 caaccacagaatggccttcgatactgggacgcttgagtatggtagaggtt    540 
 
EMBOSS_001       551 ggtggaactgcgagtgtagaggtgaaattagtagatattcgcaagaacac    600 
                     |||||||||||||||||||||||||||||.|||||||||||||||||||| 
EMBOSS_001       541 ggtggaactgcgagtgtagaggtgaaattcgtagatattcgcaagaacac    590 
 
EMBOSS_001       601 cggtggcgaaggcggccaactggaccattactgacgctgaggcgcgaaag    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       591 cggtggcgaaggcggccaactggaccattactgacgctgaggcgcgaaag    640 
 
EMBOSS_001       651 cgtggggagcaaacaggattagataccctggtagtccacgccgtaaacga    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       641 cgtggggagcaaacaggattagataccctggtagtccacgccgtaaacga    690 
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EMBOSS_001       701 tgaatgccagctgttggggtgcttgcaccgcagtagcgcagctaacgctt    750 
                     |||||||||||||||||||||||||||||.|||||||||||||||||||| 
EMBOSS_001       691 tgaatgccagctgttggggtgcttgcacctcagtagcgcagctaacgctt    740 
 
EMBOSS_001       751 tgagcattccgcctggggagtacggtcgcaagattaaaactcaaaggaat    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       741 tgagcattccgcctggggagtacggtcgcaagattaaaactcaaaggaat    790 
 
EMBOSS_001       801 tgacgggggcccgcacaagcggtggagcatgtggtttaattcgaagcaac    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       791 tgacgggggcccgcacaagcggtggagcatgtggtttaattcgaagcaac    840 
 
EMBOSS_001       851 gcgcagaaccttaccatcctttgacatggcgtgttacccagagagatttg    900 
                     |||||| |||||||||||||||||||||||||||||....||||||||.. 
EMBOSS_001       841 gcgcag-accttaccatcctttgacatggcgtgttatggggagagattcc    889 
 
EMBOSS_001       901 gggtccacttcggtggcgcgcacacaggtgctgcatggctgtcgtcagct    950 
                     ..|||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       890 cagtccacttcggtggcgcgcacacaggtgctgcatggctgtcgtcagct    939 
 
EMBOSS_001       951 cgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccacgtcc   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       940 cgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccacgtcc    989 
 
EMBOSS_001      1001 ttagttgccatcattcagttggg   1023 
                     ||||||||||||||||||||||| 
EMBOSS_001       990 ttagttgccatcattcagttggg   1012 
 
 
255 
 
 
 
6  Genes analysed by TLDA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1  List of human and murine cytokines examined by TLDA  
 
Gene Name Class Functions 
IL-1a Interleukin 1 alpha Cytokine Produced by macrophages and neutrophils with a central role in immune regulation 
IL-1b Interleukin 1 beta Cytokine Produced by macrophages and regulates inflammation, cell proliferation, 
differentiation and apoptosis 
IL-2 Interleukin 2 Cytokine Stimulates proliferation of T and B cells 
IL-4 Interleukin 4 Cytokine Induces differentiation of naive helper T cells to Th2 cells 
IL-5 Interleukin 5 Cytokine Stimulates B cell growth and mediates eosinophil activation 
IL-6 Interleukin 6 Cytokine Pro-inflammatory pleiotropic cytokine 
IL-7 Interleukin 7 Cytokine Stimulates proliferation of B, T and NK cells 
IL-9 Interleukin 9 Cytokine Produced by CD4+ cells and stimulates cell proliferation and inhibits apoptosis 
IL-10 Interleukin 10 Cytokine Anti-inflammatory/resolving 
IL-12a Interleukin 12 alpha Cytokine Differentiation of Th1 and Th2 cells and stimulates IFNγ production by PBMCs 
IL-12b Interleukin 12 beta Cytokine Differentiation of Th1 and Th2 cells and stimulates IFNγ production by PBMCs 
IL-13 Interleukin 13 Cytokine Inhibits inflammatory cytokine production 
IL-15 Interleukin 15 Cytokine Stimulates proliferation of T-lymphocytes 
IL-17 Interleukin 17 Cytokine Induces stromal cells to produce proinflammatory and hematopoietic cytokines 
Il18 Interleukin 18 Cytokine Pro inflammatory cytokine produced by macrophages 
TNF Tumour necrosis factor  Cytokine Regulation of a wide spectrum of biological processes including cell proliferation, 
differentiation, lipid metabolism and apoptosis. 
IFNγ Interferon gamma Cytokine Produced by macrophages and T cells and has antiviral and antibacterial activities 
Tgfb1 Transforming growth 
factor beta 1 
Cytokine Regulates cell growth, cell proliferation, cell differentiation and apoptosis 
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Gene Name Class Functions 
Cxcl10 Chemokine (C-X-C-
motif) ligand 10 
Chemokine Secreted by monocytes, endothelial cells and fibroblasts in reponse to IFNγ.  
Chemoattractant for macrophages, T cells NK cell 
Cxcl11 Chemokine (C-X-C 
motif) ligand 11 
Chemokine Chemotactic for activated T cells and is highly produced in peripheral blood 
leukocytes 
Ccl2 Chemokine (C-C motif) 
ligand 2 
Chemokine Recruits monocytes, memory T cells and dendritic cells to sites of infection and 
inflammation 
Ccl3 Chemokine (C-C motif) 
ligand 3 
Chemokine Involved in the acute inflammatory state for the recruitment and activation of 
polymorphonuclear leukocytes 
Ccl5 Chemokine (C-C motif) 
ligand 5 
Chemokine Promotion of inflammatory infiltrate and T-cell chemotaxis 
Ccl19 Chemokine (C-C motif) 
ligand 19 
Chemokine Chemoattractant for dendritic cells, antigen engaged B cells and CCR7+ memory T 
cells. 
Ccr2 Chemokine (C-C motif) 
receptor 2 
Chemokine Receptor for Ccl2 
Ccr4 Chemokine (C-C motif) 
receptor 4 
Chemokine Receptor for Ccl2, Ccl17, Ccl22 
Ccr7 Chemokine (C-C motif) 
receptor 7 
Chemokine Receptor for Ccl19, Ccl21 
Cxcr3 Chemokine (C-X-C 
motif) receptor 3 
Chemokine Receptor for Cxcl10, Cxcl11 
Il8 
(Human) 
Interleukin 8 Chemokine Functions as a chemoattractant and is a potent angiogenic factor 
 
Table 6.2 List of human and murine chemokines examined by TLDA.  Species specific genes are shown in bold. 
 
257 
 
 
 
 
Gene Surface lineage 
CD19 B lymphocytes 
CD28 T cells that provide co-stimulatory signals 
CD34 hematopoietic cells 
CD38 T cells, B cells, NK cells and plasma cells 
CD3e T cells 
CD4 T helper cells 
CD68 Macrophages 
CD80 B cells and monocytes that provides a costimulatory signal necessary for T cell 
activation and survival 
CD86 Antigen presenting cells 
CD8a Cytotoxic T cell 
Ctla4 T cell 
Icos Activated T cells 
 
Table 6.3  List of human and murine surface lineage markers examined by TLDA  
Gene Name Class Functions 
18S 18S ribosomal RNA Housekeeping 18S rRNA is part a component of the ribosomal subunit 
Gapdh Glyceraldehyde 3-
phosphate dehydrogenase 
Housekeeping Breaks down glucose during metabolism 
 
Table 6.4  List of human and murine housekeeping genes examined by TLDA  
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Table 6.5  List of human and murine genes encoding intracellular proteins and enzymes examined by TLDA.  Species specific genes are shown in 
bold 
Gene Name Class Functions 
Col4a5 Collagen alpha-5(IV) 
chain 
Structural 
protein 
Encodes one of six subunits of type IV collagen, the main component of connective 
tissue 
Actb Beta-actin Structural  Nonmuscle cytoskeletal actin involved in motility, structure and integrity 
Nos2 Nitric oxide synthase 2 Enzyme Synthesises the biological mediator nitric oxide which has antimicrobial activity 
Cyp1a2 Cytochrome P450 1A2 Enzyme A member of the mixed function oxidase system involved in xenobiotics metabolism 
Cyp7a1 Cholesterol 7 alpha 
hydroxylase 
Enzyme Oxidises cholesterol using molecular oxygen 
Gusb Beta-glucuronidase Enzyme Hydrolase that degrades glycosaminoglycans 
Hmox1 Heme oxygenase 1 Enzyme Essential enzyme in heme catabolism 
Ece1 Endothelin converting 
enzyme 1 
Enzyme Proteolytic processing of EDN1,2,3 to biologically active peptides 
Edn1 Endothelin 1 Peptide Vasoconstricting peptide having a key role in vascular homeostatsis 
Hprt1 
(Murine) 
Hypoxanthine-guanine Enzyme Plays a central role in generation of purine nucleotides through the purine salvage 
patheway 
Pgk1 Phosphoglycerate kinase 
1 
Enzyme Glycolytic enzyme that catalyses conversion of 1,3-diphosphoglycerate to 3-
phosphoglycerate 
Ptgs2 Prostaglandin-
endoperoxide synthase 2 
Enzyme Converts arachidonic acid to prostaglandin endoperoxide H2 during inflammation 
Lrp2 Low density lipoprotein-
related protein 1 
Receptor Mediates endocytosis of ligands leading to degradation in lysosomes or transcytosis 
Tfrc Transferrin receptor 1 Protein Iron delivery from transferring to cells 
Ski Ski proto-oncogene Protein Negatively regulates TGF-beta 
Fn1 Fibronectin Glycoprotein Glycoprotein of the extracellular matrix that binds integrins 
Gnly 
(Human) 
Granulysin Protein Present in cytotoxic granules of cytotoxic T cells, macrophages and natural killer 
cells and has antimicrobial activity 
Ace 
(Human) 
Angiotensin I converting 
enzyme 
Enzyme Converts angiotensin I to Angiotensin II and is also able to inactivate bradykinin 
Ren Renin Enzyme Activates the rennin-angiotensin system which mediates extracellular volume 
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Gene Name Class Functions 
Socs 2 
(Murine) 
Suppressor of cytokine 
signalling 2 
Transcription 
factor 
Regulation of IGF1R 
Smad3 SMAD family member 3 Transcription 
factor 
Transcriptional modulator activated by TGFb 
Smad7 SMAD family member 7 Transcription 
factor 
Antagonistic and locks activation of SMADs 
Tbx21 T-box transcription factor 
TBX21 
Transcription 
factor 
Controls expression of IFNG in Th1 and natural killer 
cells 
Ikbkb Inhibitor of kappa light 
polypeptide gene  
Signalling factor Phosphorylates inhibitors of NF-kappa-B thus leading to 
the dissociation of inhibitor/NF-kappa-B complex  
Stat1 
(Murine) 
Signal transducer and 
activator of transcription 1 
Signalling factor Upregulates genes in response to type I, II or III 
interferons 
Stat3 Signal transducer and 
activator of transcription 3 
Signalling factor Mediates genes that play key roles in cell growth and 
apoptosis 
Stat4 
(Murine) 
Signal transducer and 
activator of transcription 4 
Signalling factor Mediates responses to IL12 in lymphocytes 
Stat6 
(Murine) 
Signal transducer and 
activator of transcription 6 
Signalling factor Exerts IL4 mediated biological responses and induces 
expression of BCL2L1 
Nfkb1 
(Murine) 
Nuclear factor NF-kappa-
B p105 subunit 
Transcription 
factor 
Involved in many biological functions such as 
inflammation, immunity, differentiation and cell growth  
Nfkb2 Nuclear factor NF-k-B 
p49/p100 subunit 
Transcription 
factor 
Involved in cellular responses to stimuli such as cytokines 
and stress and plays a key role in regulating the immune 
response to infection 
Table 6.6  List of human and murine genes encoding transcription factors and signalling factors examined by TLDA.  Species specific genes are 
shown in bold. 
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Gene Name Class Functions 
Bax Bcl2-associated X protein Pro-apoptotic Promotes apoptosis by competing with Bcl2 
Fas FAS receptor Pro-apoptotic Death receptor on the cell surface which lead to programmed cell death 
Faslg FAS ligand Pro-apoptotic Ligand which binds the FAS receptor 
Bcl2 B cell lymphoma 2 Pro-survival Suppresses apoptosis in a variety of cell systems 
Bcl2l1 Bcl2-like 1 Pro-survival Inhibitor of cell death.  Inhibits activation of caspases. 
Csf1 Macrophage colony 
stimulating factor 
Growth factor Influences hematopoietic stem cells to differentiate into macrophages 
Csf2 Granulocyte macrophage 
colony stimulating factor 
Growth factor Stimulates stem cells to produce granulocytes and monocytes 
Csf3 Colony stimulating factor 
3 
Growth factor Controls the production, differentiation and function of granulocytes 
Vegfa Vascular endothelial 
growth factor A 
Growth factor Specifically acts on endothelial cells with effects including increased vascular 
permeability, inducing angiogenesis and inhibiting apoptosis 
C3 Complement component 
3 
Immune 
effector 
Plays a central role in the complement system and contributes to innate immunity 
Prf1 Perforin Immune 
effector 
A cytolytic protein found in granules of T cells and NK cells.  Upon degranulation, 
perforin inserts into the target cell’s membrane forming a pore.  
Gzmb Granzyme B Immune 
effector 
Expressed by cytotoxic T cells and NK cells and induces rapid induction of target cell 
apoptosis 
Lta Lymphotoxin-alpha Immune 
effector 
Mediates a large variety of inflammatory, immunostimulatory and antiviral responses 
and is also involved in the formation of secondary lymphoid organs 
Agtr1 
(Human) 
Angiotensin II receptor 
type 1 
Pro- apoptotic 
receptor 
Mediates programmed cell death 
Agtr2 Angiotensin II receptor 
type 2 
Pro- apoptotic 
receptor 
Mediates programmed cell death 
Table 6.7  List of human and murine growth factors, immune effector and pro/anti-apoptotic genes examined by TLDA.  Species specific genes are 
shown in bold. 
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Gene Name Class Functions 
B2m 
(Mruine) 
Beta-2 microglobulin Surface protein Component of MHC class I molecules and is involved in endocytosis 
regulation 
H2-ea 
(Murine) 
Histocompatibility 2, class II antigen Cell surface 
protein 
Immune response antigen that function in T cell dependent immune response 
Tnfrsf18 Tumour necrosis factor receptor 
superfamily 18 
Cell surface 
recpetor 
Key role in regulating immunological self tolerance  
Cd40 CD40 molecule, TNF receptor 
superfamily 5 
Cell surface 
recpetor 
CD40 activates antigen presenting cells 
Cd40lg Cd40 ligand Cell surface 
ligand 
Primarily expressed on activated T cells and binds to CD40 on antigen 
presenting cells  
Sele E-selectin Cell adhesion Expressed only on activated endothelial cells and plays a role in leukocyte 
recruitment 
Selp P-selectin Cell adhesion Expressed on the surface of activated endothelial cells and functions in 
leukocyte recruitment 
Ptprc Protein tyrosine phosphatise receptor C Enzyme Signalling molecule with extracellular domain.  Regulates a variety of cellular 
processes including growth and differentiation. 
Hla-dra 
(Human) 
HLA class II histocompatability 
antigen, DR alpha chain 
Cell surface 
protein 
Plays a central role in the immune system by presenting peptides derived from 
extracellular proteins 
Hla-drb1 
(Human) 
HLA class II histocompatability 
antigen, DRB1-9 beta 
Cell surface 
protein 
Plays a central role in the immune system by presenting peptides derived from 
extracellular proteins 
Myh6 
(Human) 
Myosin-6 Motor protein Involvement in a wide range of motility processes 
Il2-RA 
(Human) 
Interleukin-2-receptor alpha chain Surface receptor High affinity IL-2 receptor 
Icam1 
(Human) 
Intercellular adhesion molecule 1 Surface 
glycoprotein 
Supports binding of leukocytes 
Table 6.8  List of human and murine cell surface proteins and adhesion molecules examined by TLDA.  Species specific genes are shown in bold
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